{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "toc_visible": true,
      "authorship_tag": "ABX9TyPtEMy1EDGBvpdYqd+obMke",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/xthomas/dataviz/blob/master/Convert_PDF_to_TXT.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# SETUP ANALYSIS"
      ],
      "metadata": {
        "id": "Fb5VsH6h12XC"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip3 install PyPDF2"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "9BsBLN1F2zLu",
        "outputId": "f8062eb3-88e4-4ebf-cafa-a41c7fccc2f0"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting PyPDF2\n",
            "  Downloading pypdf2-3.0.1-py3-none-any.whl (232 kB)\n",
            "\u001b[?25l     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m0.0/232.6 kB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K     \u001b[91m━━━━━━━━━━━━━━\u001b[0m\u001b[90m╺\u001b[0m\u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m81.9/232.6 kB\u001b[0m \u001b[31m2.4 MB/s\u001b[0m eta \u001b[36m0:00:01\u001b[0m\r\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m232.6/232.6 kB\u001b[0m \u001b[31m3.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: PyPDF2\n",
            "Successfully installed PyPDF2-3.0.1\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip3 install pdfminer.six"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "jaXTGJrgLIZK",
        "outputId": "ee365010-8a0d-4db0-81cd-edcfb2645594"
      },
      "execution_count": 44,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting pdfminer.six\n",
            "  Downloading pdfminer.six-20221105-py3-none-any.whl (5.6 MB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m5.6/5.6 MB\u001b[0m \u001b[31m30.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: charset-normalizer>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from pdfminer.six) (3.3.2)\n",
            "Requirement already satisfied: cryptography>=36.0.0 in /usr/local/lib/python3.10/dist-packages (from pdfminer.six) (41.0.7)\n",
            "Requirement already satisfied: cffi>=1.12 in /usr/local/lib/python3.10/dist-packages (from cryptography>=36.0.0->pdfminer.six) (1.16.0)\n",
            "Requirement already satisfied: pycparser in /usr/local/lib/python3.10/dist-packages (from cffi>=1.12->cryptography>=36.0.0->pdfminer.six) (2.21)\n",
            "Installing collected packages: pdfminer.six\n",
            "Successfully installed pdfminer.six-20221105\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 7,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GCOI16KG0Sqb",
        "outputId": "5f8a6480-89f4-4c48-a7a1-15de60e6fd5b"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Drive already mounted at /content/gdrive; to attempt to forcibly remount, call drive.mount(\"/content/gdrive\", force_remount=True).\n"
          ]
        }
      ],
      "source": [
        "# Basic python environment\n",
        "import pandas as pd\n",
        "import numpy as np\n",
        "import sys\n",
        "import os\n",
        "\n",
        "import re\n",
        "import glob\n",
        "\n",
        "# Mount your google drive in google colab\n",
        "from google.colab import drive\n",
        "drive.mount('/content/gdrive')"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# PDF-specific libraries\n",
        "import PyPDF2"
      ],
      "metadata": {
        "id": "T5Fe32P02pML"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "# READ PDFS FROM GOOGLE DRIVE"
      ],
      "metadata": {
        "id": "ZSeNl-0q12dR"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "print ('PDFs on my Drive:')\n",
        "!ls '/content/gdrive/MyDrive/5.Klick/Octapharma/pdf'\n",
        "\n",
        "print ('\\nOutput Dir Contents:')\n",
        "!ls '/content/gdrive/MyDrive/3.COda/summarizer/output'\n",
        "\n",
        "pdfPath = '/content/gdrive/MyDrive/5.Klick/Octapharma/pdf'\n",
        "outputPath = '/content/gdrive/MyDrive/3.COda/summarizer/output'"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-iHag0T31-Rx",
        "outputId": "c6ffb4d9-28e1-4ccb-9d93-300b451bc060"
      },
      "execution_count": 36,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "PDFs on my Drive:\n",
            "'Abrahamyan 2023 JAMA Surg - FIBRES cost-effectiveness.pdf'\n",
            "'JAMA_Callum_2019_Fibryga vs Cryo cardiac sx Canada.pdf'\n",
            "'JAMA_Hess_2019_editorial_Fibryga v Cryo cardiac sx Canada.pdf'\n",
            "'Karkouti-FIBRES-ASA Symposium 2019.pptx'\n",
            "'Roy et al 2019_JTH_Fib conc in major abdominal surgery-PMP.pdf'\n",
            "\n",
            "Output Dir Contents:\n",
            "example-pdf-output.txt\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Specify the pattern to match files (e.g., all PDF files in a directory)\n",
        "file_pattern = '*.pdf'\n",
        "\n",
        "# Use glob.glob to generate a list of file paths that match the pattern\n",
        "file_list = glob.glob(f\"{pdfPath}/{file_pattern}\")\n",
        "\n",
        "# Iterate over the list of file paths\n",
        "for file_path in file_list:\n",
        "    # Process each file\n",
        "    print(file_path)\n",
        "    # Add your code to perform actions on each file"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "w6sRFRsF2ZUP",
        "outputId": "cfd4b5b6-c46a-4745-858c-19a7da75638c"
      },
      "execution_count": 37,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "/content/gdrive/MyDrive/5.Klick/Octapharma/pdf/Abrahamyan 2023 JAMA Surg - FIBRES cost-effectiveness.pdf\n",
            "/content/gdrive/MyDrive/5.Klick/Octapharma/pdf/JAMA_Callum_2019_Fibryga vs Cryo cardiac sx Canada.pdf\n",
            "/content/gdrive/MyDrive/5.Klick/Octapharma/pdf/JAMA_Hess_2019_editorial_Fibryga v Cryo cardiac sx Canada.pdf\n",
            "/content/gdrive/MyDrive/5.Klick/Octapharma/pdf/Roy et al 2019_JTH_Fib conc in major abdominal surgery-PMP.pdf\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(file_list[1])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "XWc5FxnQ6IQr",
        "outputId": "bd5ce9cc-9ed2-4114-a7e8-49571990f753"
      },
      "execution_count": 38,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "/content/gdrive/MyDrive/5.Klick/Octapharma/pdf/JAMA_Callum_2019_Fibryga vs Cryo cardiac sx Canada.pdf\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#create file object variable, opening in binary mode\n",
        "pdffileobj=open(file_list[1],'rb')\n",
        "\n",
        "#create reader variable that will read the pdffileobj\n",
        "pdfreader=PyPDF2.PdfReader(pdffileobj)\n",
        "print (f\"There are {len(pdfreader.pages)} pages in this PDF\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mlxnGDua6UYe",
        "outputId": "cc4e5e91-49c1-4ce2-ed10-ca9b17d7a329"
      },
      "execution_count": 39,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "There are 11 pages in this PDF\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# TRY THE FUNCTION USING PYPDF2"
      ],
      "metadata": {
        "id": "CKiz5WJ_BcDf"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Write the basic extraction function\n",
        "# Extracting to a TXT file\n",
        "\n",
        "for page_number in range(len(pdfreader.pages)):\n",
        "  page = pdfreader.pages[page_number]\n",
        "  text = page.extract_text()\n",
        "  print (text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "WjwGBEDD7znD",
        "outputId": "03d87943-be8b-4f32-a73a-4fa1579b369e"
      },
      "execution_count": 40,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Effect of Fibrinogen Concentrate vs Cryoprecipitate\n",
            "on Blood Component Transfusion After Cardiac SurgeryThe FIBRES Randomized Clinical Trial\n",
            "Jeannie Callum, MD; Michael E. Farkouh, MD; Damon C. Scales, MD; Nancy M. Heddle, MSc; Mark Crowther, MD;\n",
            "Vivek Rao, MD; Hans-Peter Hucke, PhD; Jo Carroll, BHA; Deep Grewal, MD; Sukhpal Brar, MD; Jean Bussières, MD;Hilary Grocott, MD; Christopher Harle, MD; Katerina Pavenski, MD; Antoine Rochon, MD; Tarit Saha, MD;Lois Shepherd, MD; Summer Syed, MD; Diem Tran, MD; Daniel Wong, MD; Michelle Zeller, MD;Keyvan Karkouti, MD; for the FIBRES Research Group\n",
            "IMPORTANCE\n",
            "Excessive bleeding is a common complication of cardiac surgery. An important\n",
            "cause of bleeding is acquired hypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), for whichguidelines recommend fibrinogen replacement with cryoprecipitate or fibrinogen concentrate.The 2 products have important differences, but comparative clinical data are lacking.\n",
            "OBJECTIVE To determine if fibrinogen concentrate is noninferior to cryoprecipitate for\n",
            "treatment of bleeding related to hypofibrinogenemia after cardiac surgery.\n",
            "DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial at 11 Canadian hospitals\n",
            "enrolling adult patients experiencing clinically significant bleeding and hypofibrinogenemiaafter cardiac surgery (from February 10, 2017, to November 1, 2018). Final 28-day follow-upvisit was completed on November 28, 2018.\n",
            "INTERVENTIONS Fibrinogen concentrate (4 g; n = 415) or cryoprecipitate (10 units; n = 412)\n",
            "for each ordered dose within 24 hours after cardiopulmonary bypass.\n",
            "MAIN OUTCOMES AND MEASURES Primary outcome was blood components (red blood cells,\n",
            "platelets, plasma) administered during 24 hours post bypass. A 2-sample, 1-sided test for theratio of the mean number of units was conducted to evaluate noninferiority (threshold fornoninferiority ratio, <1.2).\n",
            "RESULTS Of 827 randomized patients, 735 (372 fibrinogen concentrate, 363 cryoprecipitate)\n",
            "were treated and included in the primary analysis (median age, 64 [interquartile range, 53-72]years; 30% women; 72% underwent complex operations; 95% moderate to severe bleeding;and pretreatment fibrinogen level, 1.6 [interquartile range, 1.3-1.9] g/L). The trial met the apriori stopping criterion for noninferiority at the interim analysis after 827 of planned 1200patients were randomized. Mean 24-hour postbypass allogeneic transfusions were 16.3 (95%CI, 14.9 to 17.8) units in the fibrinogen concentrate group and 17.0 (95% CI, 15.6 to 18.6) unitsin the cryoprecipitate group (ratio, 0.96 [1-sided 97.5% CI, − /H11009to 1.09; P< .001 for\n",
            "noninferiority] [2-sided 95% CI, 0.84 to 1.09; P= .50 for superiority]). Thromboembolic\n",
            "events occurred in 26 patients (7.0%) in the fibrinogen concentrate group and 35 patients(9.6%) in the cryoprecipitate group.\n",
            "CONCLUSIONS AND RELEVANCE In patients undergoing cardiac surgery who develop clinically\n",
            "significant bleeding and hypofibrinogenemia after cardiopulmonary bypass, fibrinogenconcentrate is noninferior to cryoprecipitate with regard to number of blood componentstransfused in a 24-hour period post bypass. Use of fibrinogen concentrate may be consideredfor management of bleeding in patients with acquired hypofibrinogenemia in cardiac surgery.\n",
            "TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03037424\n",
            "JAMA . doi: 10.1001/jama.2019.17312\n",
            "Published online October 21, 2019.Visual Abstract\n",
            "Editorial\n",
            "Supplemental content\n",
            "Author Affiliations: Author\n",
            "affiliations are listed at the end of thisarticle.\n",
            "Group Information: Members of the\n",
            "FIBRES Research Group are listed inSupplement 2.\n",
            "Corresponding Author: Keyvan\n",
            "Karkouti, MD, Department ofAnesthesia and Pain Managementand Peter Munk Cardiac Centre,Toronto General Hospital,200 Elizabeth St, 3EN-460,Toronto, ON M5G 2C4, Canada(keyvan.karkouti@uhn.ca ).Research\n",
            "JAMA | Original Investigation\n",
            "(Reprinted) E1\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n",
            "Excessivebleedingnecessitatingbloodcomponenttrans-\n",
            "fusion is common after cardiac surgery and is associ-atedwithincreasedriskofmorbidityandmortalityand\n",
            "associated costs.\n",
            "1The pathophysiology of cardiac surgery–\n",
            "relatedbleedingisoftenmultifactorialbutincludesacquiredhypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), which isassociatedwithexcessivebleedinginchildren\n",
            "2andadults.3In\n",
            "cases of excessive bleeding and acquired hypofibrinogen-emia,guidelinesrecommendtreatmentwitheithercryopre-cipitateorfibrinogenconcentrate.\n",
            "4,5\n",
            "Althoughbothproductsareplasma-derived,theyhavedis-\n",
            "tinctfeatures.Cryoprecipitateisanonpurifiedproduct;hence,inadditiontofibrinogenitcontainsfibronectinandplateletmi-croparticles, as well as coagulation factors VIII, XIII, andvon Willebrand factor.\n",
            "6Its fibrinogen content varies widely\n",
            "(from 3-30 g/L per unit); in most cases it must be maintainedandshippedinaf rozenstateand thenthawedandpooled(typi-\n",
            "cally 5-10 unit pools) before administration; and it has a lim-itedshelflifeafterthawing(<4-6hours),increasingwastage.\n",
            "7,8\n",
            "Fibrinogen concentrates are pathogen-reduced and purified;havestandardizedfibrinogencontent(20g/L);arelyophilized,allowingforeasystorage,reconstitution,andadministration;andhavelongershelflifeafterreconstitution(upto24hours),which reduces wastage. There is divergent practice regardingthe preferred product for fibrinogen replacement.\n",
            "9Cryopre-\n",
            "cipitateremainsthetherapyofchoiceinmanyareas(includingNorthAmerica).InmanyEuropeancountries,however,fibrino-gen concentrates have replaced cryoprecipitate, even thoughveryfewstudieshavedirectlycomparedtheseproducts.\n",
            "10,11\n",
            "Inthismulticenterrandomizedclinicaltrialinpatientsun-\n",
            "dergoing cardiac surgery and requiring fibrinogen replace-ment because of clinically significant bleeding related to ac-quiredhypofibrinogenemia,theobjectivewastodetermineiffibrinogen concentrate was noninferior to cryoprecipitate asmeasuredbytheamountofallogeneicbloodcomponents(redcells,platelets,andplasma)administered.\n",
            "Methods\n",
            "Trial Oversight\n",
            "Thiswasaninvestigator-initiated,multicenter,randomizedclini-caltrialconductedat11centersinCanada.Thetrialdesignandmethodologyhavebeenpreviouslypublished\n",
            "12;thestudypro-\n",
            "tocolandstatisticalanalysisplanareavailablein Supplement1 ,\n",
            "andaspectsofthetrialdesignandmethodologyareincludedintheeMethodsin Supplement2 .Thetrialcoordinatingcenterwas\n",
            "the Department of Anesthesia and Pain Management ClinicalTrialsUnitattheUniversityHealthNetwork(Toronto,Ontario,Canada). The trial was overseen by an independent data andsafetymonitoringcommittee,whichreviewedadverseeventsafterevery100patientsandreviewedapreplannedinterimanaly-sisperformedafterapproximately600evaluablepatientswereenrolled.Studymonitorsindependentlyreviewedallprimaryoutcomesandadverseevents.Thetrialwasperformedinaccor-dancewiththeprinciplesoftheDeclarationofHelsinkiandap-plicableregulatoryrequirements.Researchethicsboardapprovalwasobtainedateachsitebeforetrialinitiation,includingapprovalofadelayedwrittenconsentprocess.Consentwasdelayedun-\n",
            "tilaftertreatment(inaccordancewiththeCanadianTri-CouncilPolicyStatementsontheethicalconductofresearchinvolvinghumans),\n",
            "13inpartbecauseitisnotpossibletoreliablypredict\n",
            "beforesurgerywhichpatientswillrequirefibrinogenreplacementforbleedingcontrolduringoraftersurgery,atwhichtimethereisaneedforrapidaccesstotherapy.\n",
            "Patients\n",
            "Adultpatientsundergoingcardiacsurgerywithcardiopulmo-narybypassforwhomfibrinogenreplacementwasorderedinresponsetoclinicallysignificantpostbypassbleedingdeemedrelated to acquired hypofibrinogenemia (fibrinogen plasmalevel<2.0g/LbytheClaussmethodorFIBTEM[fibrin-basedthromboelastometrytestextrinsicallyactivatedwithtissuefac-tor and containing the platelet inhibitor cytochalasin D]–derivedclotamplitudeat10minutes<10mmbythromboelas-tometry)wereeligibleforenrollment.\n",
            "14,15Inlinewithclinical\n",
            "practice, patients with bleeding were also eligible if hypofi-brinogenemiawassuspectedbutplasmafibrinogenlevelswereunavailableatthetimeofdecision-making.\n",
            "Blood bank technologists screened and randomized eli-\n",
            "gible patients if they had none of the following exclusion cri-teria: receipt of fibrinogen concentrate or cryoprecipitatewithin 24 hours before surgery; history of severe allergicreaction to fibrinogen concentrate or cryoprecipitate; refusalof blood components for religious or other reasons; plasmafibrinogen level greater than 3.0 g/L within 30 minutes oftreatment order (to avoid increasing levels above the upperlimitofnormal[4.0g/L]);andknownpregnancy.\n",
            "Trial Procedures\n",
            "Participantswererandomlyassigned(1:1)tostudygroupsusingapseudorandomnumbergenerator(PROCPLANprocedureinSAS) in randomly permuted blocks of 4, stratified by center.Allocationwasblinded;randomizationschedulewaskeptatthebloodbanksinsequentiallynumberedopaquesealeden-velopes (prepared by Ergomed GmbH), which were openedwhentheorderforfibrinogenreplacementwasreceived.Pa-tientsinthefibrinogenconcentrategroupreceive d4goffibrino-\n",
            "genconcentrate(Fibryga;OctapharmaAG),tobeinfusedoverKey Points\n",
            "Question Is fibrinogen concentrate noninferior to cryoprecipitate\n",
            "for treatment of bleeding related to acquired hypofibrinogenemiain cardiac surgery?\n",
            "Findings In this randomized trial of 735 adult patients who\n",
            "underwent cardiac surgery and developed clinically significantbleeding and hypofibrinogenemia post cardiopulmonary bypass,the mean number of blood components transfused within 24hours post bypass was 16.3 units in the fibrinogen concentrategroup and 17.0 units in the cryoprecipitate group; ratio of the meannumber of units transfused was 0.96, which met the prespecifiednoninferiority margin ratio of less than 1.2.\n",
            "Meaning For management of cardiac surgery–associated bleeding\n",
            "related to acquired hypofibrinogenemia, fibrinogen concentratemay be considered for fibrinogen replacement.Research Original Investigation Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "E2 JAMA Published online October 21, 2019 (Reprinted) jama.com\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n",
            "approximately 10 minutes, and those in the cryoprecipitate\n",
            "groupreceived10unitsofcryoprecipitate,tobeinfusedaccord-ingtolocalpractice.Thedosagesforfibrinogenconcentrate\n",
            "16-18\n",
            "andcryoprecipitate19,20wereconsistentwithrecentlypublished\n",
            "trialsandguidelines.CryoprecipitatedoseinCanadaisstandard-izedat10unitsperdose,\n",
            "21andalthoughtheamountoffibrino-\n",
            "genineachunitofcryoprecipitateisvariable,onaverageeach10-unitpoolcontainsapproximatel y4goffibrinogen(Cana-\n",
            "dianBloodServicesdata;DanaDevine,PhD,CanadianBloodServices,emailcommunication,September2019).\n",
            "Patients were to only receive the allocated product for\n",
            "24hoursaftercardiopulmonarybypass,afterwhichonlycryo-precipitatewasusedforfibrinogenreplacement.Itwasnotfea-sibletoblindcliniciansinvolvedinproductadministration,butcliniciansnotinvolvedinproductadministration,patients,datacollectors, and outcome assessors were blinded. To maintainblinding,chartlabelsforbothproductsstated“FibrinogenStudyProduct4grams.”Dataonracewerecollectedfordescriptivepur-posesasreportedbypatientsbasedonpredefinedcategories.\n",
            "Therewerenootheralterationstopatientcare.Eachhos-\n",
            "pitalhadanestablishedprotocolforbleedingmanagementthatwasnotalteredforthepurposesofthisstudy.Tranexamicaciduse was routine at all centers. Administration of blood com-ponentsandhemostaticagents(otherthancryoprecipitateandfibrinogen concentrate), use of cell salvage, and viscoelastictestingwerebasedonlocalhospitalprotocols.\n",
            "Outcomes\n",
            "Theprimaryefficacyoutcomewascumulativeallogeneicbloodcomponentunits(redbloodcells,platelets,andplasma)admin-isteredfor24hoursafterterminationofcardiopulmonarybypass.Since2typesofplateletsareissuedinCanada(75%standardbuffy-coatpoolsfrom4allogeneicdonorsand25%apheresisunitsfromasingleallogeneicdonor),bothtypeswerecountedasa4-unittransfusion.Secondaryoutcomesincludedindividualbloodcom-ponentunitsadministeredfor24hoursafterterminationofcar-diopulmonarybypass,alltransfusionsfrombeginningofsurgerytopostoperativeday7,bleedingseverity(accordingtotheuniver-saldefinitionofperioperativebleeding[UDPB])\n",
            "22duringthe24\n",
            "hoursaftercardiopulmonarybypass,andpretreatmentandpost-treatment fibrinogen levels. The UDPB components “delay inchestclosure”and“cryoprecipitateorfibrinogenconcentratead-ministration”werenotused.Postoperativefollow-upwas28days.Adverse events were classified using the Medical Dictionary\n",
            "for Regulatory Activities (version21.1)systemofnomenclature.\n",
            "Adverseeventsthatstartedorworsenedonorafterthefirstdoseof the investigational product were classified as treatment-emergent.Dataondurationofmechanicalventilation,intensivecareunitstay,andhospitalizationaftersurgerywerealsocollected.\n",
            "Statistical Analysis\n",
            "Sample size was based on demonstrating noninferiority of fi-brinogenconcentraterelativetocryoprecipitatewithrespecttothe primary efficacy outcome. Determination of noninferior-itywasbasedona1-sidedtypeIerrorprobabilityof.025andanoninferioritymarginof20%fortheratioofmeannumberofunits transfused per group. A 20% margin was deemed by anexpertpaneltobeaplausibletrade-offinefficacyinexchangeforthepotentialadvantagesoffibrinogenconcentraterelative\n",
            "tothoseofcryoprecipitate.Anempiricaldistributionfunctionwascalculatedbasedonameanof16unitsandastandardde-viationof14units(derivedfromarecentstudyonbleedingman-agementincardiacsurgery)\n",
            "23andwasusedtoestimatepower\n",
            "by performing 10000 simulations for each of the possiblesamplesizes.Calculationsshowedthat1200patientswouldpro-videanempiricalpowergreaterthan90%(assuminga10%drop-outrateandequalmeanunitstransfusedpergroup).\n",
            "Theprimaryanalysissetcomprisedallrandomizedpatients\n",
            "whohadundergonecardiacsurgerywithcardiopulmonaryby-pass,receivedatleast1(partialorcomplete)doseofeithertreat-ment,andforwhominformedconsentwasobtained.Theper-protocolanalysisexcludedpatientswhodidnotundergocardiacsurgery with cardiopulmonary bypass, received the incorrecttreatment,receivedlessthan80%oftheplanneddose,orre-ceivedthefirsttreatmentmorethan24hoursaftercardiopul-monarybypass.Theprespecifiedsubgroupsforanalysiswereelectivevsnonelectivesurgery,simplevscomplexsurgery,andasubgroupexcludingpatientswhowereincriticalstatebeforesurgery(blindedadjudicationbasedonpredefinedconditionssuchasacuteaorticdissectionorcardiacarrestimmediatelybe-foresurgery).Posthocsubgroupsanalyzedwerepatientsunder-goingnonelectivesurgeryandnotincriticalstatebeforesurgery,patientswhohadafibrinogenmeasurementbeforeproductad-ministration, patients with confirmed hypofibrinogenemia(withClaussmethod)beforeproductadministration,andpatientswithatleastmoderatebloodlossaccordingtotheUDPB.\n",
            "22\n",
            "A 2-sample, 1-sided test of the null hypothesis that the\n",
            "treatmentgroupfibrinogenconcentratetocryoprecipitatera-tio of the mean number of allogenic blood components was1.2orgreater(ie,20%noninferioritymargin)wasusedtoevalu-atenoninferiorityusingPoissonregressionmodelingforcountdata.Noninferioritywouldbedemonstratediftheupperlimitofthemodel-derived1-sided97.5%CIwaslessthan1.2.Ifnon-inferioritywasdemonstrated,ananalogoustestforsuperior-itywastobeperformed,testingthehypothesisthatthetreat-ment group ratio of the mean number of allogenic bloodcomponents was 1.0 or greater against the alternative thatit was less than 1.0, at a 1-sided type I error level of α = .025.Noαadjustmentwasmadebecauseofthehierarchicalorder-ingofthetests.Thisanalysiswasrepeatedforthesecondaryallogeneicbloodcomponenttransfusionoutcomes.\n",
            "There was 1 prespecified interim analysis after approxi-\n",
            "mately50%oftheplanned1200evaluablepatientswereen-rolled,whichusedanadjustedtypeIerrorrateof.00258ac-cordingtotheO’Brien-Flemingmethod\n",
            "24foranoninferiority\n",
            "stop.Thetrialwasalsotobestoppedforfutilityifthepredic-tivepowerforthetestofnoninferioritywaslessthan0.25.\n",
            "Secondaryoutcomeswereexaminedusingdescriptivesta-\n",
            "tistics, the Wilcoxon rank-sum test, point estimates and riskratios with 2-sided 95% CIs, and the Hodges-Lehmann esti-mator of median differences with 95% CIs, where appropri-ate.Kaplan-Meierestimatesfortime-to-deathdistributionwerecalculatedandgraphicallypresented.Comparisonswerepre-specifiedassuperiorityanalyseswithα = .05.\n",
            "Severalposthocanalyseswereperformed:(1)noninferi-\n",
            "ority was assessed for the outcome of cumulative allogeneicEffect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery Original Investigation Research\n",
            "jama.com (Reprinted) JAMA Published online October 21, 2019 E3\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n",
            "bloodcomponentunitsadministeredfrominvestigationalprod-\n",
            "uctadministrationto24hoursaftercardiopulmonarybypass;(2)treatment × siteinteractionwasaccountedforbyincludingsiteinthemodelfortheprimaryoutcomeasafixed-effectvari-able(as3categoriesbasedonnumberofpatientsenrolled:<40;40-99;>99);and(3)therelationshipofcriticalstatebeforesur-gerywasexploredbyadjustingforitinthecomparisonsfortheprimaryoutcomeandmortality.Theresultsofsecondaryout-comesandposthocanalysesshouldbeinterpretedasexplor-atory,asnocorrectionfortypeIerrorwasmade.\n",
            "Variableswithmissingvaluesarenotedwhereapplicable\n",
            "andpatientswithmissingvalueswereexcludedfromtherel-evant analyses. All analyses were performed using SAS ver-sion9.4(SASInstituteInc).\n",
            "Results\n",
            "Patient recruitment continued from February 10, 2017, toNovember1,2018,withthefinalfollow-upvisitonNovember28, 2018. The trial was stopped based on the recommenda-tionoftheindependentdataandsafetymonitoringcommit-teeformeetingthecriterionfornoninferiorityattheinterim\n",
            "analysis. Of the 15412 patients who underwent cardiac sur-geryatthe11participatingsites,827(5.3%)werescreenedandrandomized( Figure1).Sixty-onerandomizedpatientswerenot\n",
            "treated because of cessation of bleeding. Informed consentcouldnotbeobtainedfor31treatedpatients,leaving735pa-tients in the primary analysis set (n = 372 for fibrinogenconcentrate, n = 363 for cryoprecipitate). After excluding 10patientswithmajorprotocoldeviations,725patientswerein-cluded in the per-protocol analysis (Figure 1). No patientsin the primary analysis set had missing transfusion or ad-verse event information; thus, they were all included in therelevantanalyses.\n",
            "Baselinedemographicsandsurgicalcharacteristicswere\n",
            "wellbalancedexceptforcriticalstatebeforesurgery( Table1).\n",
            "Patientsreceivedamedianof4(interquartilerange[IQR],4-4)goffibrinogenconcentrateand10(IQR,10-10)unitsofcryo-precipitate( Table2;eT able1in Supplement2 ).\n",
            "Transfusions\n",
            "In the primary analysis set, mean allogeneic blood compo-\n",
            "nent units administered were 16.7 (SD, 16.4) units withinFigure 1. Patient Flow in the FIBRES Study of the Effect of Fibrinogen Concentrate vs Cryoprecipitate\n",
            "on Blood Component Transfusion After Cardiac Surgery\n",
            "890 Patients assessed for eligibility\n",
            "63Excluded\n",
            "27Physician refusal\n",
            "10Did not meet inclusion criteria\n",
            "7Fibrinogen level >3 g/L within 30 min\n",
            "of IMP order\n",
            "3Enrolled in another trial\n",
            "3Received either fibrinogen concentrate or\n",
            "cryoprecipitate within 24 h before surgery\n",
            "2Blood bank technologist unable to randomize\n",
            "because of workload\n",
            "11Unknown reason\n",
            "827 Randomized\n",
            "412 Randomized to receive cryoprecipitate\n",
            "383 Received intervention as randomized\n",
            "29Did not receive intervention (cessation of bleeding)\n",
            "363 Included in primary analysis\n",
            "361 Included in per-protocol analysis\n",
            "2Excluded\n",
            "1Did not undergo primary cardiac surgery\n",
            "1Administered IMP different from assigned IMP20Lost to follow-up\n",
            "5Patient refused to provide consent\n",
            "4Surrogate decision maker refused to provide consent\n",
            "2Family could not be reached to obtain consent\n",
            "5Discharged or transferred to another facility\n",
            "before consent obtained\n",
            "1Refused (already enrolled in another trial)\n",
            "1Age <16 y (hospital did not allow surrogate decision\n",
            "maker consent)\n",
            "1Consent not obtained (patient did not meet inclusion\n",
            "criteria [off pump])\n",
            "1Unknown reason415 Randomized to receive fibrinogen concentrate\n",
            "383 Received intervention as randomized\n",
            "32Did not receive intervention (cessation of bleeding)\n",
            "372 Included in primary analysis\n",
            "364 Included in per-protocol analysis\n",
            "8Excluded\n",
            "4Received <80% of planned first dose\n",
            "2Start of IMP not within 24 h after CPB\n",
            "2Administered IMP different from assigned IMP11Lost to follow-up\n",
            "3Patient refused to provide consent\n",
            "3Surrogate decision maker refused to provide consent\n",
            "1Surrogate decision maker and patient did not speak\n",
            "English and no translator available\n",
            "1Family could not be reached to obtain consent\n",
            "1Discharged or transferred to another facility\n",
            "before consent obtained\n",
            "1Patient unable to provide consent (hospital did\n",
            "not allow surrogate decision maker consent)\n",
            "1Consent not obtained (patient did not meet inclusion\n",
            "criteria [off pump])\n",
            "CPB indicates cardiopulmonary\n",
            "bypass; IMP, investigationalmedicinal product.Research Original Investigation Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "E4 JAMA Published online October 21, 2019 (Reprinted) jama.com\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n",
            "24hoursafterterminationofcardiopulmonarybypassand22.4\n",
            "(SD,23.1)unitsfrombeginningofsurgerytopostoperativeday7.Themean24-hourpostbypasscumulativeallogeneicbloodcomponenttransfusionswere16.3(95%CI,14.9to17.8)unitsinthefibrinogenconcentrategroupand17.0(95%CI,15.6to18.6)unitsinthecryoprecipitategroup,andthemeanratiowas0.96 (1-sided 97.5% CI, − /H11009to 1.09; P< .001 for nonferiority;\n",
            "2-sided95%CI,0.84to1.09; P= .50forsuperiority])( Table3\n",
            "andFigure2 ).Table 1. Characteristics of the Study Population at Baseline\n",
            "CharacteristicNo. (%)\n",
            "Fibrinogen\n",
            "Concentrate(n = 372)Cryoprecipitate\n",
            "(n = 363)\n",
            "Age, median (IQR), y 65 (54-72) 64 (53-72)\n",
            "Sex\n",
            "Women 113 (30.4) 105 (28.9)\n",
            "Men 259 (69.6) 258 (71.1)\n",
            "Race\n",
            "White 287 (77.2) 273 (75.2)\n",
            "Asian 51(13.7) 58 (16.0)\n",
            "Black 3 (0.81) 6 (1.6)\n",
            "Aboriginal 5 (1.3) 2 (0.55)\n",
            "Othera26 (7.0) 24 (6.6)\n",
            "Body mass index,\n",
            "median (IQR)b22.2(19.6-25.4)22.8\n",
            "(19.6-25.6)\n",
            "NYHA classc\n",
            "I (least severe) 104 (27.9) 112 (30.8)\n",
            "II 110 (29.6) 108 (29.8)\n",
            "III 110 (29.6) 103 (28.4)\n",
            "IV (most severe) 48 (12.9) 40 (11.0)\n",
            "Myocardial infarction, d\n",
            "No. 367 358\n",
            "None 294 (80.1) 299 (83.5)\n",
            "0-90 39 (10.6) 30 (8.4)\n",
            ">90 34 (9.3) 29 (8.1)\n",
            "Ejection fraction, %\n",
            "No. 357 347\n",
            ">50 256 (71.7) 263 (75.8)\n",
            "31-50 51 (14.3) 57 (16.4)\n",
            "21-30 28 (7.8) 12 (3.5)\n",
            "<21 22 (6.2) 15 (4.3)\n",
            "Pulmonary pressure,\n",
            "mm Hg\n",
            "No. 308 303\n",
            "≤30 225 (73.1) 215 (71.0)\n",
            "31-55 58 (18.8) 68 (22.4)\n",
            ">55 25 (8.1) 20 (6.6)\n",
            "Hypertension 234 (62.9) 240 (66.1)Dyslipidemia 185 (49.7) 185 (51.0)Congestive heart\n",
            "failure113 (30.4) 91 (25.1)\n",
            "Atrial fibrillation 81 (21.8) 80 (22.0)\n",
            "Diabetes mellitus 80 (21.5) 74 (20.4)Chronic lung disease 53 (14.3) 37 (10.2)Stroke/TIA 46 (12.4) 49 (13.5)Peripheral vascular\n",
            "disease37 (10.0) 34 (9.4)\n",
            "Active endocarditis 19 (5.1) 18 (5.0)\n",
            "CCS class IV angina 15 (4.0) 13 (3.6)Dialysis (preoperative) 9 (2.4) 14 (3.9)Intra-aortic balloon pump 10 (2.7) 3 (0.8)VAD/ECMO 9 (2.4) 9 (2.5)Critical state before\n",
            "surgery\n",
            "d63 (16.9) 38 (10.5)\n",
            "(continued)Table 1. Characteristics of the Study Population at Baseline (continued)\n",
            "CharacteristicNo. (%)\n",
            "Fibrinogen\n",
            "Concentrate(n = 372)Cryoprecipitate\n",
            "(n = 363)\n",
            "Preoperative laboratory values,\n",
            "median (IQR)\n",
            "Creatinine, μmol/L 88 (72-107)\n",
            "[n = 359]86 (72-106)\n",
            "[n = 352]\n",
            "Hemoglobin, g/dL 13.4 (11.6-14.6)\n",
            "[n = 366]13.5 (11.7-14.8)\n",
            "[n = 356]\n",
            "Platelet count, ×103/μL 189 (154-235)\n",
            "[n = 365]185 (152-230)\n",
            "[n = 356]\n",
            "Internationalnormalized ratio1.02 (0.98-1.20)\n",
            "[n = 335]1.03 (0.98-1.15)\n",
            "[n = 334]\n",
            "Surgical factors\n",
            "Nonelective surgery 141 (37.9) 128 (35.3)\n",
            "Complex surgerye267 (71.8) 260 (71.6)\n",
            "Procedure (% of procedures)f653 (100.0) 612 (100.0)\n",
            "Aortic valve procedure 165 (25.3) 146 (23.9)\n",
            "Surgery on aorta 161 (24.7) 177 (28.9)\n",
            "CABG surgery 153 (23.4) 146 (23.9)\n",
            "Mitral valve procedure 68 (10.4) 70 (11.4)\n",
            "Tricuspid valve procedure 31 (4.7) 35 (5.7)\n",
            "ASD/VSD repair 20 (3.1) 8 (1.3)\n",
            "Heart transplant 18 (2.8) 10 (1.6)\n",
            "Complex congenital 11 (1.7) 11 (1.8)\n",
            "Otherg26 (4.0) 9 (1.5)\n",
            "Cardiopulmonary bypass\n",
            "duration, median (IQR), min143 (102-209) 134 (99-200)\n",
            "Abbreviations: ASD, atrial septal defect; CABG, coronary artery bypass graft;\n",
            "CCS, Canadian Cardiovascular Society; ECMO, extracorporeal membraneoxygenation; IQR, interquartile range; NYHA, New York Heart Association;TIA, transient ischemic attack; VAD, ventricular assist device; VSD, ventricularseptal defect.\n",
            "aOther races marked as unknown or not applicable.\n",
            "bCalculated as weight in kilograms divided by height in meters squared.\n",
            "cNYHA functional classification: I = no limitation of physical activity and no\n",
            "symptoms; II = slight limitation of physical activity (ordinary physical activityresults in fatigue, palpitation, dyspnea); III = marked limitation of physicalactivity (less than ordinary activity causes fatigue, palpitation, or dyspnea);IV = unable to carry on any physical activity without discomfort (symptoms ofheart failure at rest).\n",
            "dDetermined by blinded adjudication for patients who underwent emergencysurgery deemed to be in a critical state, based on criteria outlined inSupplement 2 .\n",
            "eProcedures other than CABG surgery only, single valve only, or repair of atrial\n",
            "septal defect only.\n",
            "fTotals exceed 100% because some patients underwent more than 1 procedure.\n",
            "gExamples of other procedures included aortic root enlargement, left\n",
            "ventricular aneurysmectomy, and left atrial appendage resection.Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery Original Investigation Research\n",
            "jama.com (Reprinted) JAMA Published online October 21, 2019 E5\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n",
            "Noninferiority was also observed for the secondary out-\n",
            "comesofindividual24-hourandcumulative7-daybloodcom-ponent transfusions (Table 3), as well as in the post hoc out-come of cumulative transfusions measured from productadministrationto24hoursafterterminationofcardiopulmo-narybypass(meanunits,8.6[95%CI,7.5to9.9]inthefibrino-genconcentrategroupvs8.9[95%CI,7.8to10.2]inthecryo-precipitategroup;meanratio,0.97[1-sided97.5%CI,− /H11009to1.18;\n",
            "P= .02 for noninferiority) and after accounting for treat-\n",
            "ment × siteinteraction( P< .001)(eFigure1in Supplement2 )\n",
            "ontheprimaryoutcome(meanratio,1.00[1-sided97.5%CI,−/H11009to1.13; P= .003fornoninferiority).Noninferioritywasalso\n",
            "observedforalldefinedsubgroupsexceptforthenonelectivegroup,whichincludedallpatientsincriticalstatebeforesur-gery(Figure2;eTable2in Supplement2 ).\n",
            "Fibrinogen Levels\n",
            "Timingandnumberofdosesofinvestigationalproductwere\n",
            "similar between groups. Fibrinogen response was slightlygreater in the fibrinogen concentrate group (median in-crease,0.9[IQR,0.6-1.2]g/Lvs0.7[IQR,0.5–1.0]g/L; P< .001)\n",
            "(Table2;eTable1in Supplement2 ).Table 2. Details of Intervention, Perioperative Laboratory Values, Fibrinogen Levels, and Bleeding\n",
            "VariableMedian (IQR)\n",
            "Fibrinogen Concentrate\n",
            "(n = 372)Cryoprecipitate\n",
            "(n = 363)\n",
            "Dosage of investigational product\n",
            "Mean (SD) 4.8 (2.1) g 12.9 (8.5) units\n",
            "Median (IQR) 4 (4-4) g 10 (10-10) units\n",
            "Doses of investigational product, No. (%)\n",
            "1 309 (83.1) 296 (81.5)\n",
            "2 49 (13.2) 49 (13.5)\n",
            "3 10 (2.7) 10 (2.8)\n",
            "≥4 4 (1.1) 8 (2.2)\n",
            "Time from start of surgery to order of first dose, h 5.8 (4.5-7.3) 5.8 (4.6-7.1)Time from order of first dose to administration, min 45 (32-62) 47 (37-60)Time from end of CPB to administration\n",
            "of first dose, min97 (52-159) 104 (59-160)\n",
            "Plasma fibrinogen level, g/L\n",
            "Pretransfusion 1.6 (1.3-1.9) [n = 352] 1.6 (1.3-1.9) [n = 346]\n",
            "Posttransfusion 2.5 (2.1-2.9) [n = 324] 2.3 (2.0-2.6) [n = 296]\n",
            "Change from pretransfusion 0.90 (0.6-1.2) [n = 306] 0.70 (0.5-1.0) [n = 280]\n",
            "Blood components transfused\n",
            "before randomization, mean (SD), units4.3 (6.1) 4.5 (6.0)\n",
            "Cell salvage blood, mL 373 (0-918) 400 (0-876)\n",
            "Nadir hematocrit during cardiopulmonary bypass, % 26 (23-30) 25 (23-30)Hemoglobin, g/dL\n",
            "Intraoperative post-CPB 9.1 (8.3-9.9) [n = 348] 8.9 (8.2-9.7) [n = 342]\n",
            "Day of surgery (last recorded value) 9.6 (8.6-10.9) [n = 365] 9.5 (8.7-10.7) [n = 356]\n",
            "Postoperative day 1 (last recorded value) 9.0 (8.3-9.9) [n = 367] 9.0 (8.3-10.0) [n = 361]\n",
            "Platelet count, ×103/μL\n",
            "Intraoperative post-CPB 107 (84-136) [n = 280] 103 (81-129) [n = 278]\n",
            "Day of surgery (last recorded value) 132 (107-165) [n = 362] 133 (107-163) [n = 353]\n",
            "Postoperative day 1 (last recorded value) 117 (91-145) [n = 366] 115 (92-143) [n = 359]\n",
            "International normalized ratio\n",
            "Intraoperative post-CPB 1.6 (1.4-1.8) [n = 295] 1.6 (1.5-1.8) [n = 277]\n",
            "Day of surgery (last recorded value) 1.3 (1.2-1.4) [n = 355] 1.3 (1.2-1.4) [n = 340]\n",
            "Postoperative day 1 (last recorded value) 1.2 (1.1-1.4) [n = 342] 1.2 (1.1-1.3) [n = 335]\n",
            "Bleeding categories according to\n",
            "modified UDPB classification, No. (%)a\n",
            "≥2 (moderate to massive) 349 (93.8) 347 (95.6)\n",
            "<2 (insignificant to mild) 23 (6.2) 16 (4.4)\n",
            "24-h chest tube drainage, mL 800 (500-1350) 830 (540-1350)Reexploration, No. (%) 53 (14.2) 44 (12.1)Prothrombin complex concentrate, No. (%) 110 (29.6) 98 (27.0)Recombinant factor VII, No. (%) 35 (9.4) 28 (7.7)Abbreviations: CPB, cardiopulmonary\n",
            "bypass; IQR, interquartile range;UDPB, universal definition ofperioperative bleeding.\n",
            "aUDPB determinants used in this\n",
            "study include postoperative chesttube output; units of red blood cells,plasma, and platelets transfused;use of factor concentrates; andsurgical reexploration (classificationscheme included in the eAppendixinSupplement 2 ).\n",
            "22For this study\n",
            "the following components of theUDPB score were not used: delay inchest closure and use ofcryoprecipitate or fibrinogenconcentrate. One intraoperativedeath was included in the severe ormassive category in the fibrinogenconcentrate group.Research Original Investigation Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "E6 JAMA Published online October 21, 2019 (Reprinted) jama.com\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n",
            "Adverse Events and Other Outcomes\n",
            "Treatment-emergent adverse event profiles were similar\n",
            "(Table 4;e T a b l e3i n Supplement 2 ), as were the duration of\n",
            "intubation,intensivecareunitstay,andhospitalstay(Table4).There were 35 deaths (9.4%) in the fibrinogen concentrategroupand27(7.4%)inthecryoprecipitategroup(unadjustedhazard ratio, 1.28 [95% CI, 0.77 to 2.12]; P= .35) (Kaplan-\n",
            "MeiercurvesshownineFigures2and3in Supplement2 ).Death\n",
            "rates were also not significantly different when stratified bycritical state before surgery (fibrinogen concentrate vs cryo-precipitate:19/63[30.2%]vs12/38[31.6%]incriticalstatepa-tients;16/309[5.2%]vs15/325[4.6%]inremainingpatients)and after risk adjustment for critical state (post hoc analysishazardratio,1.03[95%CI,0.62to1.70]; P= .92)(resultsfrom\n",
            "post hoc analyses reported in eTables 4 and 5 in Supple-\n",
            "ment2).Thromboembolicadverseeventswereobservedin26\n",
            "patients(7.0%)inthefibrinogengroupand35patients(9.6%)inthecryoprecipitategroup(unadjustedoddsratio,0.70[95%CI,0.42to1.20])(Table4).Discussion\n",
            "Inthisstudyofpatientswhoexperiencedbleedingaftercar-diacsurgeryandrequiredfibrinogenreplacementaspartofrou-tineclinicalpractice,theprimaryfindingwasthatfibrinogenconcentratewasnoninferiortocryoprecipitateasmeasuredbythenumberofbloodcomponentstransfused.\n",
            "The study protocol, which did not modify clinical prac-\n",
            "tice and used a delayed (postintervention) consent process,successfully randomized the small proportion of patientswith bleeding who were ordered fibrinogen replacement(comprising approximately 5% of patients who underwentcardiac surgery at participating centers during the studyperiod). The groups were well balanced for baseline vari-ables except for critical state before surgery, an importantprognostic variable that was more prevalent in the fibrino-gen concentrate group. The occurrence of adverse eventswas comparable between the groups, although there wasTable 3. Primary and Secondary Outcomes: Allogeneic Blood Component Transfusions\n",
            "PopulationFibrinogen Concentrate Cryoprecipitate\n",
            "Mean Difference\n",
            "(95% CI)Unadjusted Ratio\n",
            "of LS Means(1-Sided 97.5% CI)Noninferiority\n",
            "PValue No.Median\n",
            "(IQR)LS Mean\n",
            "(95% CI) No.Median\n",
            "(IQR)LS Mean\n",
            "(95% CI)\n",
            "Primary Outcome: Cumulative Allogeneic Blood Components Transfused Within 24 h After Cardiopulmonary Bypassa\n",
            "Primary analysis set 372 12.0\n",
            "(5.5 to 22.0)16.3\n",
            "(14.9 to 17.8)363 14.0\n",
            "(7.0 to 23.0)17.0\n",
            "(15.6 to 18.6)−0.73\n",
            "(−3.10 to 1.64)Unadjusted 0.96\n",
            "(−/H11009to 1.09)<.001\n",
            "Adjusted 0.91\n",
            "(−/H11009to 1.03)c<.001\n",
            "Per-protocol setb364 12.0\n",
            "(6.0 to 22.0)16.4\n",
            "(15.0 to 18.0)361 14.0\n",
            "(7.0 to 22.0)16.9\n",
            "(15.5 to 18.5)−0.50\n",
            "(−2.90 to 1.89)Unadjusted 0.97\n",
            "(−/H11009to 1.10)<.001\n",
            "Adjusted 0.92\n",
            "(−/H11009to 1.05)c<.001\n",
            "Secondary Outcome: Red Blood Cell Transfusions Within 24 h After Cardiopulmonary Bypass\n",
            "Primary analysis set 372 2.0\n",
            "(0.0 to 5.0)3.3\n",
            "(3.0 to 3.7)363 2.0\n",
            "(1.0 to 5.0)3.3\n",
            "(2.9 to 3.7)0.23\n",
            "(−0.55 to 1.00)1.00\n",
            "(0 to 1.18).02\n",
            "Per-protocol set 364 2.0\n",
            "(0.0 to 5.0)3.3\n",
            "(3.0 to 3.7)361 2.0\n",
            "(1.0 to 5.0)3.3\n",
            "(2.9 to 3.7)0.25\n",
            "(−0.53 to 1.03)1.01\n",
            "(0 to 1.18).02\n",
            "Secondary Outcome: Platelet Transfusions Within 24 h After Cardiopulmonary Bypass\n",
            "Primary analysis set 372 8.0\n",
            "(4.0 to 12.0)9.1\n",
            "(8.3 to 9.9)363 8.0\n",
            "(4.0 to 12.0)9.7\n",
            "(8.9 to 10.5)−0.46\n",
            "(−1.70 to 0.78)0.94\n",
            "(−/H11009to 1.06)<.001\n",
            "Per-protocol set 364 8.0\n",
            "(4.0 to 12.0)9.1\n",
            "(8.3 to 10.0)361 8.0\n",
            "(4.0 to 12.0)9.6\n",
            "(8.8 to 10.5)−0.31\n",
            "(−1.56 to 0.93)0.95\n",
            "(−/H11009to 1.08)<.001\n",
            "Secondary Outcome: Plasma Transfusions Within 24 h After Cardiopulmonary Bypass\n",
            "Primary analysis set 372 2.0\n",
            "(0.0 to 6.0)3.9\n",
            "(3.5 to 4.4)363 3.0\n",
            "(0.0 to 6.0)4.1\n",
            "(3.6 to 4.6)−0.04\n",
            "(−0.97 to 0.89)0.96\n",
            "(−/H11009to 1.15).008\n",
            "Per-protocol set 364 2.0\n",
            "(0.0 to 6.0)4.0\n",
            "(3.5 to 4.5)361 3.0\n",
            "(0.0 to 6.0)4.0\n",
            "(3.6 to 4.6)0.04\n",
            "(−0.91 to 0.98)0.98\n",
            "(−/H11009to 1.17).01\n",
            "Secondary Outcome: Cumulative Allogeneic Blood Components Transfused Withi n7dA f t e r Start of Surgery\n",
            "Primary analysis set 372 15.5\n",
            "(6.0 to 29.5)22.5\n",
            "(20.5 to 24.7)363 17.0\n",
            "(9.0 to 28.0)22.3\n",
            "(20.3 to 24.5)0.21(−3.14 to 3.55)Unadjusted 1.01\n",
            "(0 to 1.15).005\n",
            "Adjusted 0.96\n",
            "(−/H11009to 1.09)c<.001\n",
            "Per-protocol set 364 15.5\n",
            "(6.0 to 29.0)22.5\n",
            "(20.5 to 24.8)361 17.0\n",
            "(9.0 to 28.0)22.2\n",
            "(20.2 to 24.5)0.31\n",
            "(−3.07 to 3.70)Unadjusted 1.01\n",
            "(0 to 1.16).007\n",
            "Adjusted 0.96\n",
            "(−/H11009to 1.09)c<.001\n",
            "Abbreviation: LS, least-squares.\n",
            "aUnits of allogenic blood components counted as follows: each red blood cell\n",
            "unit = 1 unit, each 250-mL plasma unit = 1 unit, each 500-mL plasma unit = 2units, each platelet dose = 4 units.\n",
            "bPer-protocol set excluded patients who did not undergo cardiac surgery withcardiopulmonary bypass, received the incorrect treatment, received less than\n",
            "80% of the planned dose, or received the first treatment more than 24 hoursafter cardiopulmonary bypass.\n",
            "cAdjusted for critical state before surgery (post hoc analysis).Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery Original Investigation Research\n",
            "jama.com (Reprinted) JAMA Published online October 21, 2019 E7\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n",
            "a nonsignificant difference of 2.0% in mortality. This\n",
            "seemedtoberelatedtothebetween-groupimbalanceinthenumber of patients in critical state before surgery.\n",
            "The study objective was to compare the 2 currently rec-\n",
            "ommended therapies for fibrinogen replacement\n",
            "4,5under\n",
            "usual conditions of clinical care. Thus, it did not include aplacebo group to determine the efficacy of fibrinogenreplacement per se, nor did it attempt to identify the appro-priate threshold for fibrinogen replacement.\n",
            "16A recent sys-\n",
            "tematic review comparing fibrinogen concentrates withcryoprecipitate in patients with bleeding\n",
            "10identified 1 ran-\n",
            "domized trial (with high risk for bias)19and 3 observational\n",
            "studies25-27and concluded that there was insufficient evi-\n",
            "dence to recommend one product over the other. Anotherreview of trauma, obstetric, and gastrointestinal bleeding\n",
            "populations reached similar conclusions.9This study pro-\n",
            "vides further data regarding the comparative efficacy andadverse event profile of these 2 products.\n",
            "The noninferiority finding can inform the choice of cryo-\n",
            "precipitate or fibrinogen concentrate for treatment of bleed-ing related to acquired hypofibrinogenemia. A core tenet andmajor regulatory driver in transfusion medicine is the pre-cautionary principle that requires risk-mitigation strategiesto be instituted even if there is only a theoretical risk ofharm.\n",
            "28Consistent with this principle, the US Food and Drug\n",
            "Administration blood safety strategy recommends the use ofpathogen-reduced blood products when feasible.\n",
            "28Cur-\n",
            "rently, there are no known impending infectious threats forFigure 2. Ratio of Mean Number of Allogeneic Blood Components Transfused in the 24 Hours\n",
            "After Cardiopulmonary Bypass for the Primary Analysis Set, Per-Protocol Analysis Set,and A Priori–Defined Subgroups\n",
            "Group/Subgroup Ratio (97.5% CI)\n",
            "Primary analysis set 0.96 (– ∞ to 1.09)\n",
            "Per-protocol analysis set 0.97 (– ∞ to 1.10)\n",
            "Excluding patients in critical state 0.84 (– ∞ to 0.96)\n",
            "Elective surgery 0.81 (– ∞ to 0.96)\n",
            "Nonelective surgery 1.09 (0 to 1.31)\n",
            "Complex surgery 0.98 (– ∞ to 1.13)\n",
            "Noncomplex surgery 0.86 (– ∞ to 1.12)\n",
            "0.7 2 1\n",
            "Ratio of Mean No. of Units (97.5% CI)Favors\n",
            "Fibrinogen\n",
            "ConcentrateFavors\n",
            "Cryoprecipitate\n",
            "1.2All patients in critical state were in the\n",
            "nonelective subgroup. Blue dashedline at x = 1.2 indicates thenoninferiority margin.\n",
            "Table 4. Treatment-Emergent Adverse Events and Other Measured Outcomes at 28-Day Follow-up\n",
            "OutcomeNo. (%)\n",
            "Fibrinogen Concentrate\n",
            "(n = 372)Cryoprecipitate\n",
            "(n = 363)\n",
            "Any adverse event 248 (66.7) 264 (72.7)\n",
            "No. of events 623 673\n",
            "Any serious adverse event 117 (31.5) 126 (34.7)\n",
            "No. of events 224 264\n",
            "Thromboembolic adverse eventsa26 (7.0) 35 (9.6)\n",
            "No. of events 27 39\n",
            "Stroke/TIA 17 (4.6) 18 (5.0)\n",
            "DVT/PE 5 (1.3) 9 (2.5)\n",
            "Myocardial infarction 3 (0.8) 4 (1.1)\n",
            "Other vessel thrombosis 0 7 (1.9)\n",
            "Amaurosis fugax 0 1 (0.3)\n",
            "Disseminated intravascular coagulation 1 (0.3) 0\n",
            "Thrombophlebitis 1 (0.3) 0\n",
            "Acute kidney injuryb48 (12.9) 48 (13.2)\n",
            "Hepatobiliary disordersc32 (8.6) 37 (10.2)\n",
            "Duration of mechanical ventilation,\n",
            "median (IQR), d1.3 (0.7-5.0) [n = 337] 1.3 (0.7-4.2) [n = 342]\n",
            "Duration of intensive care unit stay,\n",
            "median (IQR), d2.9 (1.4-5.7) [n = 352] 2.8 (1.2-5.6) [n = 345]\n",
            "Duration of hospitalization,\n",
            "median (IQR), d8.2 (6.3-13.0) [n = 314] 9.0 (6.3-13.3) [n = 308]Abbreviations: DVT, deep vein\n",
            "thrombosis; PE, pulmonaryembolism; TIA, transient ischemicattack.\n",
            "aPatients who experienced more\n",
            "than 1 event are counted only oncein the total.\n",
            "bAcute kidney injury was definedas greater than a 2-fold increasein creatinine or kidney failurerequiring hemodialysis within28 days of surgery.\n",
            "cHepatobiliary disorders were\n",
            "defined by the Medical Dictionary\n",
            "for Regulatory Activities (version\n",
            "21.1) system of nomenclature.Research Original Investigation Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "E8 JAMA Published online October 21, 2019 (Reprinted) jama.com\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n",
            "recipients of cryoprecipitate; however, the history of blood\n",
            "pathogens suggests that plasma-derived products havetransmitted pathogens in the past and may do so in thefuture.\n",
            "29In addition, mathematical models of emerging\n",
            "pathogens suggest that the association of plasma-derivedproducts (such as cryoprecipitate) with outcomes and costsmay be substantial.\n",
            "30In this regard, fibrinogen concentrate\n",
            "may be preferred to cryoprecipitate because it is pathogen-reduced. Another advantage of fibrinogen concentrate isthatinmostsituationsitcanbelogisticallysimplertodeliverto the bedside of a patient with bleeding. One importantconsideration is the cost differential that currently favorscryoprecipitate, but this varies across regions, and the mostrecenteconomicanalysisfailedtoincludethecostsoffutureemerging pathogens and did not include comprehensiveactivity-based costing.\n",
            "31\n",
            "Limitations\n",
            "Thisstudyhasseverallimitations.First,sincetheaimwastocomparethe2productswhenusedunderusualconditionsofcare, it was not logistically possible to institute a standard-ized transfusion protocol across the sites or to blind clini-cians to treatment assignment. Although a post hoc analysisshowedthatthereweretreatment × siteinteractions,account-ing for the interactions did not have a material effect on theprimaryoutcome.Moreover,postoperativehemoglobin,plate-let count, and coagulation measures were similar betweengroups (Table 2), suggesting that transfusion practice wasconsistent in both groups. In addition, the results were con-sistent when transfusions were measured from beginning ofsurgery to postoperative day 7 (a priori analysis) or after ad-ministration of investigational product (post hoc analysis),whichsuggeststhatlackofblindingdidnotinfluencethetim-ingoftransfusionsrelativetoproductadministration.Ofnote,to ensure that all transfusions and adverse events were col-lected without bias, patients and outcome assessors wereblindedtotreatmentallocationandindependentmonitorsre-viewedalltransfusionandadverseevents.Second,whilethe\n",
            "studyhadfewexclusioncriteria,itincludedonlypatientsun-dergoingcardiacsurgerywithbleeding,anditsfindingsmaythereforenotbegeneralizabletoothersettingswherefibrino-gen replacement is required. This would primarily be othertypesofsurgery,trauma,andpostpartumhemorrhage,\n",
            "32but\n",
            "most evidence suggests that the role of fibrinogen is similarinthesesettings.\n",
            "33,34Third,becauseofthepragmaticdesign\n",
            "ofthestudy,stricttimingoflaboratoryassessmentscouldnotbe enforced. However, only less than 5% of patients had no\n",
            "measuredfibrinogenlevelsbeforeproductadministration.Re-latedtothis,asmallproportionofpatientshadfibrinogenval-uesaboverecommendedthresholdswhentreatmentorderwasreceived. However, this is consistent with recent experience\n",
            "in major bleeding,\n",
            "32and ongoing bleeding from sample col-\n",
            "lection to therapy means that actual fibrinogen levels at thetime of therapy were likely lower than measured values.Fourth,fibrinogencontentisstandardizedinfibrinogencon-centratebutishighlyvariableincryoprecipitate.Asaresult,somepatientsinthecryoprecipitategrouplikelyreceivedmuchlessormuchmoretha n4goffibrinogen.Whilethisisoneof\n",
            "the inherent limitations of cryoprecipitate, observed differ-encesinpretreatmentandposttreatmentfibrinogenlevelssug-gest that on average both groups received clinically similaramountsoffibrinogen.\n",
            "Conclusions\n",
            "In patients undergoing cardiac surgery who develop clini-cally significant bleeding and hypofibrinogenemia after car-diopulmonary bypass, fibrinogen concentrate is noninferiorto cryoprecipitate with regard to number of blood compo-nents transfused in a 24-hour period post bypass. Use of fi-brinogenconcentratemaybeconsideredformanagementofbleedinginpatientswithacquiredhypofibrinogenemiaincar-diacsurgery.\n",
            "ARTICLE INFORMATION\n",
            "Accepted for Publication: October 2, 2019.\n",
            "Published Online: October 21, 2019.\n",
            "doi:10.1001/jama.2019.17312\n",
            "Author Affiliations: Department of Laboratory\n",
            "Medicine and Molecular Diagnostics, SunnybrookHealth Sciences Centre, Toronto, Ontario, Canada(Callum); Laboratory Medicine Program, UniversityHealth Network, Toronto, Ontario, Canada(Callum); Department of Laboratory Medicine andPathobiology, University of Toronto, Toronto,Ontario, Canada (Callum); Peter Munk CardiacCentre, University Health Network, Toronto,Ontario, Canada (Farkouh, Rao, Carroll, Grewal,Karkouti); Heart and Stroke Richard Lewar Centre,University of Toronto, Toronto, Ontario, Canada(Farkouh); Interdepartmental Division of CriticalCare, Department of Medicine, University ofToronto, Toronto, Ontario, Canada (Scales,Karkouti); Sunnybrook Research Institute,Department of Critical Care Medicine, SunnybrookHealth Sciences Centre, Toronto, Ontario, Canada(Scales); Faculty of Health Sciences, McMasterUniversity, Hamilton, Ontario, Canada (Heddle);\n",
            "Department of Medicine, McMaster University,Hamilton, Ontario, Canada (Heddle, Crowther);University Health Network, Division ofCardiovascular Surgery, Toronto General Hospital,Toronto, Ontario, Canada (Rao); University ofToronto, Toronto, Ontario, Canada (Rao, Carroll,Grewal); Department of Biostatistics, ERGOMEDCDS GmbH, Cologne, Germany (Hucke);Department of Anesthesia and Pain Management,Sinai Health System, Women’s College Hospital,University Health Network, Toronto, Ontario,Canada (Carroll, Grewal, Karkouti); Department ofAnesthesiology, Pharmacology and Therapeutics;University of British Columbia, Vancouver, Canada(Brar); Royal Columbian Hospital, Vancouver, BritishColumbia, Canada (Brar); AnesthesiologyDepartment, Institut universitaire de cardiologie etde pneumologie de Québec-Université Laval,Québec City, Québec, Canada (Bussières);Departments of Anesthesiology, Perioperative andPain Medicine, and Surgery, University of Manitoba,Winnipeg, Canada (Grocott); Department ofAnesthesia and Perioperative Medicine, WesternUniversity, London, Ontario, Canada (Harle);\n",
            "St Michael’s Hospital, Division of TransfusionMedicine, Department of Laboratory Medicine andPathobiology, University of Toronto, Toronto,Ontario, Canada (Pavenski); Department ofAnesthesiology, Montréal Heart Institute,Université de Montréal, Montréal, Québec, Canada(Rochon); Department of Anesthesiology andPerioperative Medicine; Kingston General Hospital,Queen’s University, Kingston, Ontario, Canada(Saha); Department of Pathology and MolecularMedicine, Kingston Health Science Center, Queen’sUniversity, Kingston, Ontario, Canada (Shepherd);Department of Anesthesiology; Hamilton HealthSciences Corporation, McMaster University,Hamilton, Ontario, Canada (Syed); University ofOttawa Heart Institute, Division of CardiacAnesthesiology and Critical Care, Department ofAnesthesia and Pain Medicine, University of OttawaSchool of Epidemiology and Public Health, Ottawa,Ontario, Canada (Tran); Cardiac Surgery, RoyalColumbian Hospital, University of British Columbia,Vancouver, Canada (Wong); McMaster Centre forTransfusion Research, Department of Medicine,Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery Original Investigation Research\n",
            "jama.com (Reprinted) JAMA Published online October 21, 2019 E9\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n",
            "McMaster University, Hamilton, Ontario, Canada\n",
            "(Zeller); Department of Anesthesia and Institute ofHealth Policy, Management, and Evaluation,University of Toronto, Toronto, Ontario, Canada(Karkouti).\n",
            "Author Contributions: Drs Hucke and Karkouti had\n",
            "full access to all of the data in the study and takeresponsibility for the integrity of the data and theaccuracy of the data analysis.Concept and design: Callum, Farkouh, Scales,\n",
            "Heddle, Crowther, Rao, Hucke, Grocott, Karkouti.Acquisition, analysis, or interpretation of data:Callum, Farkouh, Scales, Heddle, Rao, Hucke,Carroll, Grewal, Brar, Bussières, Grocott, Harle,Pavenski, Rochon, Saha, Shepherd, Syed, Tran,Wong, Zeller, Karkouti.Drafting of the manuscript: Callum, Grocott, Tran,\n",
            "Karkouti.Critical revision of the manuscript for importantintellectual content: All authors.\n",
            "Statistical analysis: Callum, Hucke, Karkouti.\n",
            "Obtained funding: Karkouti.\n",
            "Administrative, technical, or material support:Callum, Farkouh, Crowther, Rao, Carroll, Grewal,Brar, Grocott, Harle, Pavenski, Rochon, Saha,Shepherd, Syed, Tran, Wong, Karkouti.Supervision: Callum, Carroll, Brar, Bussières,\n",
            "Grocott, Harle, Pavenski, Rochon, Saha, Shepherd,Tran, Wong, Zeller, Karkouti.\n",
            "Conflict of Interest Disclosures: Dr Callum\n",
            "reported receiving grants from Canadian BloodServices, Octapharma, and CSL Behring during theconduct of the study. Dr Farkouh reported receivinggrants from Amgen and Novo Nordisk. Dr Scalesreported receiving grants from Canadian Institutefor Health Research. Dr Heddle reported receivingnonfinancial support from Octapharma during theconduct of the study and receiving grants fromCanadian Blood Services. Dr Crowther reportedreceiving grants or personal fees from Bayer, Pfizer,BMS Canada, CSL Behring, Servier Canada, andDiagnostica Stago. Dr Rao reported receiving grantsfrom Octapharma during the conduct of the studyand receiving personal fees from Medtronic andAbbott. Dr Hucke reported receiving grants fromOctapharma during the conduct of the study.Dr Pavenski reported serving as a member of theNational Advisory Committee on Blood and BloodProducts (Canada) and the Ontario Blood AdvisoryCommittee (Ontario). Dr Tran reported receivinggrants from Octapharma during the conduct of thestudy. Dr Zeller reported receiving grants fromCanadian Blood Services and receiving personalfees from Pfizer. Dr Karkouti reported receivinggrants and personal fees from Octapharma andInstrumentation Laboratory during the conduct ofthe study. No other disclosures were reported.\n",
            "Funding/Support: The trial was supported by an\n",
            "unrestricted grant from Octapharma AG (Lachen,Switzerland), which also provided the fibrinogenconcentrate. Cryoprecipitate was provided by theCanadian Blood Services (Ottawa, Ontario) andHéma-Québec (Ville de Québec, Québec, Canada).\n",
            "Role of the Funders/Sponsors: Octapharma,\n",
            "Canadian Blood Services, and Héma-Québec had norole in the design and conduct of the study;collection, management, analysis, andinterpretation of the data; preparation, review, orapproval of the manuscript; and decision to submitthe manuscript for publication.Meeting Presentation: Presented at the\n",
            "AABB Annual Meeting; October 21, 2019;San Antonio, Texas.\n",
            "Data Sharing Statement: SeeSupplement 3 .\n",
            "Additional Contributions: We thank all the\n",
            "patients and clinicians who participated in thisstudy, all members of the study teams at theparticipating centers, members of studycommittees and monitoring team, the Octapharmateam (Sri Adapa, MBA [Octapharma Canada Inc];Oliver Hegener, PhD, Sigurd Knaub, PhD, andCristina Solomon, MD [Octapharma AG,Switzerland]; and Bruce Schwartz, PhD[Octapharma USA Inc]), and Dr Kathryn Webert,MD (Canadian Blood Services) for their support.None of these individuals received compensationfor their roles in the study; h owever, the\n",
            "Octapharma team members were employees ofOctapharma at time of study. Editorial assistancefor revisions of the manuscript was provided byAbigail Baines, PhD, of Portland MedicalCommunications (Manchester, United Kingdom),who received compensation for her contributions.\n",
            "REFERENCES\n",
            "1. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI,\n",
            "Culliford L, Angelini GD. Increased mortality,postoperative morbidity, and cost after red bloodcell transfusion in patients having cardiac surgery.Circulation . 2007;116(22):2544-2552. doi: 10.1161/\n",
            "CIRCULATIONAHA.107.698977\n",
            "2. Faraoni D, Willems A, Savan V, Demanet H,\n",
            "De Ville A, Van der Linden P. Plasma fibrinogenconcentration is correlated with postoperativeblood loss in children undergoing cardiac surgery:a retrospective review. Eur J Anaesthesiol . 2014;31\n",
            "(6):317-326. doi: 10.1097/EJA.\n",
            "0000000000000043\n",
            "3. Karkouti K, Callum J, Crowther MA, et al. The\n",
            "relationship between fibrinogen levels aftercardiopulmonary bypass and large volume red celltransfusion in cardiac surgery: an observationalstudy. Anesth Analg . 2013;117(1):14-22. doi: 10.1213/\n",
            "ANE.0b013e318292efa4\n",
            "4. Spahn DR, Bouillon B, Cerny V, et al. The\n",
            "European guideline on management of majorbleeding and coagulopathy following trauma: fifthedition. Crit Care . 2019;23(1):98. doi: 10.1186/\n",
            "s13054-019-2347-3\n",
            "5. Boer C, Meesters MI, Milojevic M, et al; Task\n",
            "Force on Patient Blood Management for AdultCardiac Surgery of the European Association forCardio-Thoracic Surgery (EACTS) and the EuropeanAssociation of Cardiothoracic Anaesthesiology(EACTA). 2017 EACTS/EACTA Guidelines on patientblood management for adult cardiac surgery.J Cardiothorac Vasc Anesth . 2018;32(1):88-120. doi:\n",
            "10.1053/j.jvca.2017.06.026\n",
            "6. Callum JL, Karkouti K, Lin Y. Cryoprecipitate:\n",
            "the current state of knowledge. Transfus Med Rev .\n",
            "2009;23(3):177-188. doi: 10.1016/j.tmrv.2009.03.001\n",
            "7. Dunbar NM, Olson NJ, Szczepiorkowski ZM,\n",
            "et al. Blood component transfusion and wastagerates in the setting of massive transfusion in threeregional trauma centers. Transfusion . 2017;57(1):45-\n",
            "52. doi: 10.1111/trf.13880\n",
            "8. Yazer MH, Dunbar NM, Cohn C, et al; Biomedical\n",
            "Excellence for Safer Transfusion (BEST)Collaborative. Blood product transfusion andwastage rates in obstetric hemorrhage. Transfusion .\n",
            "2018;58(6):1408-1413. doi: 10.1111/trf.14571\n",
            "9. Novak A, Stanworth SJ, Curry N. Do we still need\n",
            "cryoprecipitate? cryoprecipitate and fibrinogenconcentrate as treatments for majorhemorrhage—how do they compare? Expert Rev\n",
            "Hematol . 2018;11(5):351-360. doi: 10.1080/17474086.\n",
            "2018.1458610\n",
            "10. Jensen NH, Stensballe J, Afshari A. Comparing\n",
            "efficacy and safety of fibrinogen concentrate tocryoprecipitate in bleeding patients: a systematicreview. Acta Anaesthesiol Scand . 2016;60(8):1033-\n",
            "1042. doi: 10.1111/aas.12734\n",
            "11. Li JY, Gong J, Zhu F, et al. Fibrinogen\n",
            "concentrate in cardiovascular surgery:a meta-analysis of randomized controlled trials.Anesth Analg . 2018;127(3):612-621. doi: 10.1213/\n",
            "ANE.0000000000003508\n",
            "12. Karkouti K, Callum J, Rao V, et al. Protocol for\n",
            "a phase III, non-inferiority, randomised comparisonof a new fibrinogen concentrate versuscryoprecipitate for treating acquiredhypofibrinogenaemia in bleeding cardiac surgicalpatients: the FIBRES trial. BMJ Open . 2018;8(4):\n",
            "e020741. doi: 10.1136/bmjopen-2017-020741\n",
            "13. Canadian Institutes of Health Research.\n",
            "Introducing TCPS 2 (2018)—Tri-Council PolicyStatement: Ethical Conduct for Research InvolvingHumans. Government of Canada website.http://www.pre.ethics.gc.ca/eng/nr-cp_2019-06-05.html . Published August 15, 2019. Accessed\n",
            "October 8, 2019.\n",
            "14. Erdoes G, Gerster G, Colucci G, Kaiser H, Alberio\n",
            "L, Eberle B. Prediction of post-weaning fibrinogenstatus during cardiopulmonary bypass: anobservational study in 110 patients. PLoS One . 2015;\n",
            "10(5):e0126692. doi: 10.1371/journal.pone.0126692\n",
            "15. Mace H, Lightfoot N, McCluskey S, et al. Validity\n",
            "of thromboelastometry for rapid assessment offibrinogen levels in heparinized samples duringcardiac surgery: a retrospective, single-center,observational study. J Cardiothorac Vasc Anesth .\n",
            "2016;30(1):90-95. doi: 10.1053/j.jvca.2015.04.030\n",
            "16. Bilecen S, de Groot JA, Kalkman CJ, et al. Effect\n",
            "of fibrinogen concentrate on intraoperative bloodloss among patients with intraoperative bleedingduring high-risk cardiac surgery: a randomizedclinical trial. JAMA . 2017;317(7):738-747. doi: 10.\n",
            "1001/jama.2016.21037\n",
            "17. Nascimento B, Callum J, Tien H, et al.\n",
            "Fibrinogen in the initial Resuscitation of SevereTrauma (FiiRST): a randomized feasibility trial. Br J\n",
            "Anaesth . 2016;117(6):775-782. doi: 10.1093/bja/\n",
            "aew343\n",
            "18. Winearls J, Wullschleger M, Wake E, et al.\n",
            "Fibrinogen Early In Severe Trauma studY (FEISTY):study protocol for a randomised controlled trial. Trials .\n",
            "2017;18(1):241. doi: 10.1186/s13063-017-1980-x\n",
            "19. Galas FR, de Almeida JP, Fukushima JT, et al.\n",
            "Hemostatic effects of fibrinogen concentratecompared with cryoprecipitate in children aftercardiac surgery: a randomized pilot trial. J Thorac\n",
            "Cardiovasc Surg . 2014;148(4):1647-1655. doi: 10.\n",
            "1016/j.jtcvs.2014.04.029\n",
            "20. Green L, Bolton-Maggs P, Beattie C, et al.\n",
            "British Society of Haematology Guidelines on thespectrum of fresh frozen plasma andcryoprecipitate products: their handling and use invarious patient groups in the absence of majorResearch Original Investigation Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "E10 JAMA Published online October 21, 2019 (Reprinted) jama.com\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n",
            "bleeding. Br J Haematol . 2018;181(1):54-67. doi: 10.\n",
            "1111/bjh.15167\n",
            "21. Callum JL, Pinkerton PH, Lima A, et al. Bloody\n",
            "Easy 4: Blood Transfusions, Blood Alternatives andTransfusion Reaction . 4th ed. Toronto, Ontario,\n",
            "Canada: Ontario Regional Blood CoordinatingNetwork; 2016.\n",
            "22. Dyke C, Aronson S, Dietrich W, et al. Universal\n",
            "definition of perioperative bleeding in adult cardiacsurgery. J Thorac Cardiovasc Surg . 2014;147(5):\n",
            "1458-1463. doi: 10.1016/j.jtcvs.2013.10.070\n",
            "23. Karkouti K, Callum J, Wijeysundera DN, et al;\n",
            "TACS Investigators. Point-of-care hemostatictesting in cardiac surgery: a stepped-wedgeclustered randomized controlled trial. Circulation .\n",
            "2016;134(16):1152-1162. doi: 10.1161/\n",
            "CIRCULATIONAHA.116.023956\n",
            "24. Fleming TR, Harrington DP, O’Brien PC. Designs\n",
            "for group sequential tests. Control Clin Trials . 1984;\n",
            "5(4):348-361. doi: 10.1016/S0197-2456(84)80014-8\n",
            "25. Ahmed S, Harrity C, Johnson S, et al.\n",
            "The efficacy of fibrinogen concentrate comparedwith cryoprecipitate in major obstetrichaemorrhage—an observational study. Transfus Med .2012;22(5):344-349. doi: 10.1111/j.1365-3148.2012.\n",
            "01178.x\n",
            "26. Theodoulou A, Berryman J, Nathwani A, Scully\n",
            "M. Comparison of cryoprecipitate with fibrinogenconcentrate for acquired hypofibrinogenaemia.Transfus Apher Sci . 2012;46(2):159-162. doi: 10.\n",
            "1016/j.transci.2011.11.005\n",
            "27. Yang L, Vuylsteke A, Gerrard C, Besser M,\n",
            "Baglin T. Postoperative fibrinogen level isassociated with postoperative bleeding followingcardiothoracic surgery and the effect of fibrinogenreplacement therapy remains uncertain. J Thromb\n",
            "Haemost . 2013;11(8):1519-1526. doi: 10.1111/jth.12304\n",
            "28. Leach Bennett J, Blajchman MA, Delage G,\n",
            "Fearon M, Devine D. Proceedings of a consensusconference: risk-based decision making for bloodsafety. Transfus Med Rev . 2011;25(4):267-292. doi:\n",
            "10.1016/j.tmrv.2011.05.002\n",
            "29. Stramer SL, Hollinger FB, Katz LM, et al.\n",
            "Emerging infectious disease agents and theirpotential threat to transfusion safety. Transfusion .\n",
            "2009;49(suppl 2):1S-29S. doi: 10.1111/j.1537-2995.\n",
            "2009.02279.x\n",
            "30. Kleinman S, Cameron C, Custer B, et al.\n",
            "Modeling the risk of an emerging pathogenentering the Canadian blood supply. Transfusion .\n",
            "2010;50(12):2592-2606. doi: 10.1111/j.1537-2995.2010.\n",
            "02724.x\n",
            "31. Okerberg CK, Williams LA III, Kilgore ML, et al.\n",
            "Cryoprecipitate AHF vs. fibrinogen concentrates forfibrinogen replacement in acquired bleedingpatients—an economic evaluation. Vox Sang . 2016;\n",
            "111(3):292-298. doi: 10.1111/vox.12417\n",
            "32. McQuilten ZK, Bailey M, Cameron PA, et al.\n",
            "Fibrinogen concentration and use of fibrinogensupplementation with cryoprecipitate in patientswith critical bleeding receiving massive transfusion:a bi-national cohort study. Br J Haematol . 2017;179\n",
            "(1):131-141. doi: 10.1111/bjh.14804\n",
            "33. McQuilten ZK, Wood EM, Bailey M, Cameron\n",
            "PA, Cooper DJ. Fibrinogen is an independentpredictor of mortality in major trauma patients:a five-year statewide cohort study. Injury . 2017;48\n",
            "(5):1074-1081. doi: 10.1016/j.injury.2016.11.021\n",
            "34. Gillissen A, van den Akker T, Caram-Deelder C,\n",
            "et al; TeMpOH-1 Study Group. Coagulation\n",
            "parameters during the course of severe postpartumhemorrhage: a nationwide retrospective cohortstudy. Blood Adv . 2018;2(19):2433-2442 .Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery Original Investigation Research\n",
            "jama.com (Reprinted) JAMA Published online October 21, 2019 E11\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# \"Formal Function\"\n",
        "pdf_file_path = file_list[1]\n",
        "txt_file_path = f\"{outputPath}/pypdf-output.txt\"\n",
        "\n",
        "def pdf_to_txt(pdf_path, txt_path):\n",
        "    # Open the PDF file in binary mode\n",
        "    with open(pdf_path, 'rb') as pdf_file:\n",
        "        # Create a PDF reader object\n",
        "        pdf_reader = PyPDF2.PdfReader(pdf_file)\n",
        "\n",
        "        # Get the total number of pages in the PDF\n",
        "        total_pages = len(pdf_reader.pages)\n",
        "\n",
        "        # Create a text file to write the extracted text\n",
        "        with open(txt_path, 'w', encoding='utf-8') as txt_file:\n",
        "            # Iterate over all pages\n",
        "            for page_number in range(total_pages):\n",
        "                # Get a specific page\n",
        "                page = pdf_reader.pages[page_number]\n",
        "\n",
        "                # Extract text from the page and write it to the text file\n",
        "                page_text = page.extract_text()\n",
        "                txt_file.write(page_text)\n",
        "\n",
        "# Example usage\n",
        "\n",
        "pdf_to_txt(pdf_file_path, txt_file_path)"
      ],
      "metadata": {
        "id": "-cAL4jYdCNQb"
      },
      "execution_count": 42,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## That worked, but the resulting text was not that great. Trying PDFMINER instead"
      ],
      "metadata": {
        "id": "yeKMQYUWJhSO"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "# TRY THE FUNCTION USING PDFMINER"
      ],
      "metadata": {
        "id": "GrtrLzSFBopv"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from io import BytesIO, StringIO\n",
        "from pdfminer.high_level import extract_text_to_fp\n",
        "\n",
        "def extract_text_from_pdf(pdf_path):\n",
        "    pdf_buffer = open(pdf_path, 'rb')\n",
        "    text_buffer = StringIO()\n",
        "    extract_text_to_fp(pdf_buffer, text_buffer)\n",
        "    return text_buffer.getvalue()\n",
        "\n",
        "extract_text_from_pdf(pdf_file_path)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 256
        },
        "id": "pbE-40FI--bU",
        "outputId": "b5c62f27-433e-407e-d8cc-abaf2d326baa"
      },
      "execution_count": 45,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'EffectofFibrinogenConcentratevsCryoprecipitateonBloodComponentTransfusionAfterCardiacSurgeryTheFIBRESRandomizedClinicalTrialJeannieCallum,MD;MichaelE.Farkouh,MD;DamonC.Scales,MD;NancyM.Heddle,MSc;MarkCrowther,MD;VivekRao,MD;Hans-PeterHucke,PhD;JoCarroll,BHA;DeepGrewal,MD;SukhpalBrar,MD;JeanBussières,MD;HilaryGrocott,MD;ChristopherHarle,MD;KaterinaPavenski,MD;AntoineRochon,MD;TaritSaha,MD;LoisShepherd,MD;SummerSyed,MD;DiemTran,MD;DanielWong,MD;MichelleZeller,MD;KeyvanKarkouti,MD;fortheFIBRESResearchGroupIMPORTANCEExcessivebleedingisacommoncomplicationofcardiacsurgery.Animportantcauseofbleedingisacquiredhypofibrinogenemia(fibrinogenlevel<1.5-2.0g/L),forwhichguidelinesrecommendfibrinogenreplacementwithcryoprecipitateorfibrinogenconcentrate.The2productshaveimportantdifferences,butcomparativeclinicaldataarelacking.OBJECTIVETodetermineiffibrinogenconcentrateisnoninferiortocryoprecipitatefortreatmentofbleedingrelatedtohypofibrinogenemiaaftercardiacsurgery.DESIGN,SETTING,ANDPARTICIPANTSRandomizedclinicaltrialat11Canadianhospitalsenrollingadultpatientsexperiencingclinicallysignificantbleedingandhypofibrinogenemiaaftercardiacsurgery(fromFebruary10,2017,toNovember1,2018).Final28-dayfollow-upvisitwascompletedonNovember28,2018.INTERVENTIONSFibrinogenconcentrate(4g;n=415)orcryoprecipitate(10units;n=412)foreachordereddosewithin24hoursaftercardiopulmonarybypass.MAINOUTCOMESANDMEASURESPrimaryoutcomewasbloodcomponents(redbloodcells,platelets,plasma)administeredduring24hourspostbypass.A2-sample,1-sidedtestfortheratioofthemeannumberofunitswasconductedtoevaluatenoninferiority(thresholdfornoninferiorityratio,<1.2).RESULTSOf827randomizedpatients,735(372fibrinogenconcentrate,363cryoprecipitate)weretreatedandincludedintheprimaryanalysis(medianage,64[interquartilerange,53-72]years;30%women;72%underwentcomplexoperations;95%moderatetoseverebleeding;andpretreatmentfibrinogenlevel,1.6[interquartilerange,1.3-1.9]g/L).Thetrialmettheaprioristoppingcriterionfornoninferiorityattheinterimanalysisafter827ofplanned1200patientswererandomized.Mean24-hourpostbypassallogeneictransfusionswere16.3(95%CI,14.9to17.8)unitsinthefibrinogenconcentrategroupand17.0(95%CI,15.6to18.6)unitsinthecryoprecipitategroup(ratio,0.96[1-sided97.5%CI,−(cid:2)to1.09;P<.001fornoninferiority][2-sided95%CI,0.84to1.09;P=.50forsuperiority]).Thromboemboliceventsoccurredin26patients(7.0%)inthefibrinogenconcentrategroupand35patients(9.6%)inthecryoprecipitategroup.CONCLUSIONSANDRELEVANCEInpatientsundergoingcardiacsurgerywhodevelopclinicallysignificantbleedingandhypofibrinogenemiaaftercardiopulmonarybypass,fibrinogenconcentrateisnoninferiortocryoprecipitatewithregardtonumberofbloodcomponentstransfusedina24-hourperiodpostbypass.Useoffibrinogenconcentratemaybeconsideredformanagementofbleedinginpatientswithacquiredhypofibrinogenemiaincardiacsurgery.TRIALREGISTRATIONClinicalTrials.govIdentifier:NCT03037424JAMA.doi:10.1001/jama.2019.17312PublishedonlineOctober21,2019.VisualAbstractEditorialSupplementalcontentAuthorAffiliations:Authoraffiliationsarelistedattheendofthisarticle.GroupInformation:MembersoftheFIBRESResearchGrouparelistedinSupplement2.CorrespondingAuthor:KeyvanKarkouti,MD,DepartmentofAnesthesiaandPainManagementandPeterMunkCardiacCentre,TorontoGeneralHospital,200ElizabethSt,3EN-460,Toronto,ONM5G2C4,Canada(keyvan.karkouti@uhn.ca).ResearchJAMA|OriginalInvestigation(Reprinted)E1©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0cExcessivebleedingnecessitatingbloodcomponenttrans-fusioniscommonaftercardiacsurgeryandisassoci-atedwithincreasedriskofmorbidityandmortalityandassociatedcosts.1Thepathophysiologyofcardiacsurgery–relatedbleedingisoftenmultifactorialbutincludesacquiredhypofibrinogenemia(fibrinogenlevel<1.5-2.0g/L),whichisassociatedwithexcessivebleedinginchildren2andadults.3Incasesofexcessivebleedingandacquiredhypofibrinogen-emia,guidelinesrecommendtreatmentwitheithercryopre-cipitateorfibrinogenconcentrate.4,5Althoughbothproductsareplasma-derived,theyhavedis-tinctfeatures.Cryoprecipitateisanonpurifiedproduct;hence,inadditiontofibrinogenitcontainsfibronectinandplateletmi-croparticles,aswellascoagulationfactorsVIII,XIII,andvonWillebrandfactor.6Itsfibrinogencontentvarieswidely(from3-30g/Lperunit);inmostcasesitmustbemaintainedandshippedinafrozenstateandthenthawedandpooled(typi-cally5-10unitpools)beforeadministration;andithasalim-itedshelflifeafterthawing(<4-6hours),increasingwastage.7,8Fibrinogenconcentratesarepathogen-reducedandpurified;havestandardizedfibrinogencontent(20g/L);arelyophilized,allowingforeasystorage,reconstitution,andadministration;andhavelongershelflifeafterreconstitution(upto24hours),whichreduceswastage.Thereisdivergentpracticeregardingthepreferredproductforfibrinogenreplacement.9Cryopre-cipitateremainsthetherapyofchoiceinmanyareas(includingNorthAmerica).InmanyEuropeancountries,however,fibrino-genconcentrateshavereplacedcryoprecipitate,eventhoughveryfewstudieshavedirectlycomparedtheseproducts.10,11Inthismulticenterrandomizedclinicaltrialinpatientsun-dergoingcardiacsurgeryandrequiringfibrinogenreplace-mentbecauseofclinicallysignificantbleedingrelatedtoac-quiredhypofibrinogenemia,theobjectivewastodetermineiffibrinogenconcentratewasnoninferiortocryoprecipitateasmeasuredbytheamountofallogeneicbloodcomponents(redcells,platelets,andplasma)administered.MethodsTrialOversightThiswasaninvestigator-initiated,multicenter,randomizedclini-caltrialconductedat11centersinCanada.Thetrialdesignandmethodologyhavebeenpreviouslypublished12;thestudypro-tocolandstatisticalanalysisplanareavailableinSupplement1,andaspectsofthetrialdesignandmethodologyareincludedintheeMethodsinSupplement2.ThetrialcoordinatingcenterwastheDepartmentofAnesthesiaandPainManagementClinicalTrialsUnitattheUniversityHealthNetwork(Toronto,Ontario,Canada).Thetrialwasoverseenbyanindependentdataandsafetymonitoringcommittee,whichreviewedadverseeventsafterevery100patientsandreviewedapreplannedinterimanaly-sisperformedafterapproximately600evaluablepatientswereenrolled.Studymonitorsindependentlyreviewedallprimaryoutcomesandadverseevents.Thetrialwasperformedinaccor-dancewiththeprinciplesoftheDeclarationofHelsinkiandap-plicableregulatoryrequirements.Researchethicsboardapprovalwasobtainedateachsitebeforetrialinitiation,includingapprovalofadelayedwrittenconsentprocess.Consentwasdelayedun-tilaftertreatment(inaccordancewiththeCanadianTri-CouncilPolicyStatementsontheethicalconductofresearchinvolvinghumans),13inpartbecauseitisnotpossibletoreliablypredictbeforesurgerywhichpatientswillrequirefibrinogenreplacementforbleedingcontrolduringoraftersurgery,atwhichtimethereisaneedforrapidaccesstotherapy.PatientsAdultpatientsundergoingcardiacsurgerywithcardiopulmo-narybypassforwhomfibrinogenreplacementwasorderedinresponsetoclinicallysignificantpostbypassbleedingdeemedrelatedtoacquiredhypofibrinogenemia(fibrinogenplasmalevel<2.0g/LbytheClaussmethodorFIBTEM[fibrin-basedthromboelastometrytestextrinsicallyactivatedwithtissuefac-torandcontainingtheplateletinhibitorcytochalasinD]–derivedclotamplitudeat10minutes<10mmbythromboelas-tometry)wereeligibleforenrollment.14,15Inlinewithclinicalpractice,patientswithbleedingwerealsoeligibleifhypofi-brinogenemiawassuspectedbutplasmafibrinogenlevelswereunavailableatthetimeofdecision-making.Bloodbanktechnologistsscreenedandrandomizedeli-giblepatientsiftheyhadnoneofthefollowingexclusioncri-teria:receiptoffibrinogenconcentrateorcryoprecipitatewithin24hoursbeforesurgery;historyofsevereallergicreactiontofibrinogenconcentrateorcryoprecipitate;refusalofbloodcomponentsforreligiousorotherreasons;plasmafibrinogenlevelgreaterthan3.0g/Lwithin30minutesoftreatmentorder(toavoidincreasinglevelsabovetheupperlimitofnormal[4.0g/L]);andknownpregnancy.TrialProceduresParticipantswererandomlyassigned(1:1)tostudygroupsusingapseudorandomnumbergenerator(PROCPLANprocedureinSAS)inrandomlypermutedblocksof4,stratifiedbycenter.Allocationwasblinded;randomizationschedulewaskeptatthebloodbanksinsequentiallynumberedopaquesealeden-velopes(preparedbyErgomedGmbH),whichwereopenedwhentheorderforfibrinogenreplacementwasreceived.Pa-tientsinthefibrinogenconcentrategroupreceived4goffibrino-genconcentrate(Fibryga;OctapharmaAG),tobeinfusedoverKeyPointsQuestionIsfibrinogenconcentratenoninferiortocryoprecipitatefortreatmentofbleedingrelatedtoacquiredhypofibrinogenemiaincardiacsurgery?FindingsInthisrandomizedtrialof735adultpatientswhounderwentcardiacsurgeryanddevelopedclinicallysignificantbleedingandhypofibrinogenemiapostcardiopulmonarybypass,themeannumberofbloodcomponentstransfusedwithin24hourspostbypasswas16.3unitsinthefibrinogenconcentrategroupand17.0unitsinthecryoprecipitategroup;ratioofthemeannumberofunitstransfusedwas0.96,whichmettheprespecifiednoninferioritymarginratiooflessthan1.2.MeaningFormanagementofcardiacsurgery–associatedbleedingrelatedtoacquiredhypofibrinogenemia,fibrinogenconcentratemaybeconsideredforfibrinogenreplacement.ResearchOriginalInvestigationEffectofFibrinogenConcentratevsCryoprecipitateonTransfusionVolumeAfterCardiacSurgeryE2JAMAPublishedonlineOctober21,2019(Reprinted)jama.com©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0capproximately10minutes,andthoseinthecryoprecipitategroupreceived10unitsofcryoprecipitate,tobeinfusedaccord-ingtolocalpractice.Thedosagesforfibrinogenconcentrate16-18andcryoprecipitate19,20wereconsistentwithrecentlypublishedtrialsandguidelines.CryoprecipitatedoseinCanadaisstandard-izedat10unitsperdose,21andalthoughtheamountoffibrino-genineachunitofcryoprecipitateisvariable,onaverageeach10-unitpoolcontainsapproximately4goffibrinogen(Cana-dianBloodServicesdata;DanaDevine,PhD,CanadianBloodServices,emailcommunication,September2019).Patientsweretoonlyreceivetheallocatedproductfor24hoursaftercardiopulmonarybypass,afterwhichonlycryo-precipitatewasusedforfibrinogenreplacement.Itwasnotfea-sibletoblindcliniciansinvolvedinproductadministration,butcliniciansnotinvolvedinproductadministration,patients,datacollectors,andoutcomeassessorswereblinded.Tomaintainblinding,chartlabelsforbothproductsstated“FibrinogenStudyProduct4grams.”Dataonracewerecollectedfordescriptivepur-posesasreportedbypatientsbasedonpredefinedcategories.Therewerenootheralterationstopatientcare.Eachhos-pitalhadanestablishedprotocolforbleedingmanagementthatwasnotalteredforthepurposesofthisstudy.Tranexamicacidusewasroutineatallcenters.Administrationofbloodcom-ponentsandhemostaticagents(otherthancryoprecipitateandfibrinogenconcentrate),useofcellsalvage,andviscoelastictestingwerebasedonlocalhospitalprotocols.OutcomesTheprimaryefficacyoutcomewascumulativeallogeneicbloodcomponentunits(redbloodcells,platelets,andplasma)admin-isteredfor24hoursafterterminationofcardiopulmonarybypass.Since2typesofplateletsareissuedinCanada(75%standardbuffy-coatpoolsfrom4allogeneicdonorsand25%apheresisunitsfromasingleallogeneicdonor),bothtypeswerecountedasa4-unittransfusion.Secondaryoutcomesincludedindividualbloodcom-ponentunitsadministeredfor24hoursafterterminationofcar-diopulmonarybypass,alltransfusionsfrombeginningofsurgerytopostoperativeday7,bleedingseverity(accordingtotheuniver-saldefinitionofperioperativebleeding[UDPB])22duringthe24hoursaftercardiopulmonarybypass,andpretreatmentandpost-treatmentfibrinogenlevels.TheUDPBcomponents“delayinchestclosure”and“cryoprecipitateorfibrinogenconcentratead-ministration”werenotused.Postoperativefollow-upwas28days.AdverseeventswereclassifiedusingtheMedicalDictionaryforRegulatoryActivities(version21.1)systemofnomenclature.Adverseeventsthatstartedorworsenedonorafterthefirstdoseoftheinvestigationalproductwereclassifiedastreatment-emergent.Dataondurationofmechanicalventilation,intensivecareunitstay,andhospitalizationaftersurgerywerealsocollected.StatisticalAnalysisSamplesizewasbasedondemonstratingnoninferiorityoffi-brinogenconcentraterelativetocryoprecipitatewithrespecttotheprimaryefficacyoutcome.Determinationofnoninferior-itywasbasedona1-sidedtypeIerrorprobabilityof.025andanoninferioritymarginof20%fortheratioofmeannumberofunitstransfusedpergroup.A20%marginwasdeemedbyanexpertpaneltobeaplausibletrade-offinefficacyinexchangeforthepotentialadvantagesoffibrinogenconcentraterelativetothoseofcryoprecipitate.Anempiricaldistributionfunctionwascalculatedbasedonameanof16unitsandastandardde-viationof14units(derivedfromarecentstudyonbleedingman-agementincardiacsurgery)23andwasusedtoestimatepowerbyperforming10000simulationsforeachofthepossiblesamplesizes.Calculationsshowedthat1200patientswouldpro-videanempiricalpowergreaterthan90%(assuminga10%drop-outrateandequalmeanunitstransfusedpergroup).Theprimaryanalysissetcomprisedallrandomizedpatientswhohadundergonecardiacsurgerywithcardiopulmonaryby-pass,receivedatleast1(partialorcomplete)doseofeithertreat-ment,andforwhominformedconsentwasobtained.Theper-protocolanalysisexcludedpatientswhodidnotundergocardiacsurgerywithcardiopulmonarybypass,receivedtheincorrecttreatment,receivedlessthan80%oftheplanneddose,orre-ceivedthefirsttreatmentmorethan24hoursaftercardiopul-monarybypass.Theprespecifiedsubgroupsforanalysiswereelectivevsnonelectivesurgery,simplevscomplexsurgery,andasubgroupexcludingpatientswhowereincriticalstatebeforesurgery(blindedadjudicationbasedonpredefinedconditionssuchasacuteaorticdissectionorcardiacarrestimmediatelybe-foresurgery).Posthocsubgroupsanalyzedwerepatientsunder-goingnonelectivesurgeryandnotincriticalstatebeforesurgery,patientswhohadafibrinogenmeasurementbeforeproductad-ministration,patientswithconfirmedhypofibrinogenemia(withClaussmethod)beforeproductadministration,andpatientswithatleastmoderatebloodlossaccordingtotheUDPB.22A2-sample,1-sidedtestofthenullhypothesisthatthetreatmentgroupfibrinogenconcentratetocryoprecipitatera-tioofthemeannumberofallogenicbloodcomponentswas1.2orgreater(ie,20%noninferioritymargin)wasusedtoevalu-atenoninferiorityusingPoissonregressionmodelingforcountdata.Noninferioritywouldbedemonstratediftheupperlimitofthemodel-derived1-sided97.5%CIwaslessthan1.2.Ifnon-inferioritywasdemonstrated,ananalogoustestforsuperior-itywastobeperformed,testingthehypothesisthatthetreat-mentgroupratioofthemeannumberofallogenicbloodcomponentswas1.0orgreateragainstthealternativethatitwaslessthan1.0,ata1-sidedtypeIerrorlevelofα=.025.Noαadjustmentwasmadebecauseofthehierarchicalorder-ingofthetests.Thisanalysiswasrepeatedforthesecondaryallogeneicbloodcomponenttransfusionoutcomes.Therewas1prespecifiedinterimanalysisafterapproxi-mately50%oftheplanned1200evaluablepatientswereen-rolled,whichusedanadjustedtypeIerrorrateof.00258ac-cordingtotheO’Brien-Flemingmethod24foranoninferioritystop.Thetrialwasalsotobestoppedforfutilityifthepredic-tivepowerforthetestofnoninferioritywaslessthan0.25.Secondaryoutcomeswereexaminedusingdescriptivesta-tistics,theWilcoxonrank-sumtest,pointestimatesandriskratioswith2-sided95%CIs,andtheHodges-Lehmannesti-matorofmediandifferenceswith95%CIs,whereappropri-ate.Kaplan-Meierestimatesfortime-to-deathdistributionwerecalculatedandgraphicallypresented.Comparisonswerepre-specifiedassuperiorityanalyseswithα=.05.Severalposthocanalyseswereperformed:(1)noninferi-oritywasassessedfortheoutcomeofcumulativeallogeneicEffectofFibrinogenConcentratevsCryoprecipitateonTransfusionVolumeAfterCardiacSurgeryOriginalInvestigationResearchjama.com(Reprinted)JAMAPublishedonlineOctober21,2019E3©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0cbloodcomponentunitsadministeredfrominvestigationalprod-uctadministrationto24hoursaftercardiopulmonarybypass;(2)treatment×siteinteractionwasaccountedforbyincludingsiteinthemodelfortheprimaryoutcomeasafixed-effectvari-able(as3categoriesbasedonnumberofpatientsenrolled:<40;40-99;>99);and(3)therelationshipofcriticalstatebeforesur-gerywasexploredbyadjustingforitinthecomparisonsfortheprimaryoutcomeandmortality.Theresultsofsecondaryout-comesandposthocanalysesshouldbeinterpretedasexplor-atory,asnocorrectionfortypeIerrorwasmade.Variableswithmissingvaluesarenotedwhereapplicableandpatientswithmissingvalueswereexcludedfromtherel-evantanalyses.AllanalyseswereperformedusingSASver-sion9.4(SASInstituteInc).ResultsPatientrecruitmentcontinuedfromFebruary10,2017,toNovember1,2018,withthefinalfollow-upvisitonNovember28,2018.Thetrialwasstoppedbasedontherecommenda-tionoftheindependentdataandsafetymonitoringcommit-teeformeetingthecriterionfornoninferiorityattheinterimanalysis.Ofthe15412patientswhounderwentcardiacsur-geryatthe11participatingsites,827(5.3%)werescreenedandrandomized(Figure1).Sixty-onerandomizedpatientswerenottreatedbecauseofcessationofbleeding.Informedconsentcouldnotbeobtainedfor31treatedpatients,leaving735pa-tientsintheprimaryanalysisset(n=372forfibrinogenconcentrate,n=363forcryoprecipitate).Afterexcluding10patientswithmajorprotocoldeviations,725patientswerein-cludedintheper-protocolanalysis(Figure1).Nopatientsintheprimaryanalysissethadmissingtransfusionorad-verseeventinformation;thus,theywereallincludedintherelevantanalyses.Baselinedemographicsandsurgicalcharacteristicswerewellbalancedexceptforcriticalstatebeforesurgery(Table1).Patientsreceivedamedianof4(interquartilerange[IQR],4-4)goffibrinogenconcentrateand10(IQR,10-10)unitsofcryo-precipitate(Table2;eTable1inSupplement2).TransfusionsIntheprimaryanalysisset,meanallogeneicbloodcompo-nentunitsadministeredwere16.7(SD,16.4)unitswithinFigure1.PatientFlowintheFIBRESStudyoftheEffectofFibrinogenConcentratevsCryoprecipitateonBloodComponentTransfusionAfterCardiacSurgery890Patients assessed for eligibility63Excluded27Physician refusal10Did not meet inclusion criteria7Fibrinogen level >3 g/L within 30 minof IMP order3Enrolled in another trial3Received either fibrinogen concentrate orcryoprecipitate within 24 h before surgery2Blood bank technologist unable to randomizebecause of workload11Unknown reason827Randomized412Randomized to receive cryoprecipitate383Received intervention as randomized29Did not receive intervention (cessation of bleeding)363Included in primary analysis361Included in per-protocol analysis2Excluded1Did not undergo primary cardiac surgery1Administered IMP different from assigned IMP20Lost to follow-up5Patient refused to provide consent4Surrogate decision maker refused to provide consent2Family could not be reached to obtain consent5Discharged or transferred to another facilitybefore consent obtained1Refused (already enrolled in another trial)1Age <16 y (hospital did not allow surrogate decisionmaker consent)1Consent not obtained (patient did not meet inclusioncriteria [off pump])1Unknown reason415Randomized to receive fibrinogen concentrate383Received intervention as randomized32Did not receive intervention (cessation of bleeding)372Included in primary analysis364Included in per-protocol analysis8Excluded4Received <80% of planned first dose2Start of IMP not within 24 h after CPB2Administered IMP different from assigned IMP11Lost to follow-up3Patient refused to provide consent3Surrogate decision maker refused to provide consent1Surrogate decision maker and patient did not speakEnglish and no translator available1Family could not be reached to obtain consent1Discharged or transferred to another facilitybefore consent obtained1Patient unable to provide consent (hospital didnot allow surrogate decision maker consent)1Consent not obtained (patient did not meet inclusioncriteria [off pump])CPBindicatescardiopulmonarybypass;IMP,investigationalmedicinalproduct.ResearchOriginalInvestigationEffectofFibrinogenConcentratevsCryoprecipitateonTransfusionVolumeAfterCardiacSurgeryE4JAMAPublishedonlineOctober21,2019(Reprinted)jama.com©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0c24hoursafterterminationofcardiopulmonarybypassand22.4(SD,23.1)unitsfrombeginningofsurgerytopostoperativeday7.Themean24-hourpostbypasscumulativeallogeneicbloodcomponenttransfusionswere16.3(95%CI,14.9to17.8)unitsinthefibrinogenconcentrategroupand17.0(95%CI,15.6to18.6)unitsinthecryoprecipitategroup,andthemeanratiowas0.96(1-sided97.5%CI,−(cid:2)to1.09;P<.001fornonferiority;2-sided95%CI,0.84to1.09;P=.50forsuperiority])(Table3andFigure2).Table1.CharacteristicsoftheStudyPopulationatBaselineCharacteristicNo.(%)FibrinogenConcentrate(n=372)Cryoprecipitate(n=363)Age,median(IQR),y65(54-72)64(53-72)SexWomen113(30.4)105(28.9)Men259(69.6)258(71.1)RaceWhite287(77.2)273(75.2)Asian51(13.7)58(16.0)Black3(0.81)6(1.6)Aboriginal5(1.3)2(0.55)Othera26(7.0)24(6.6)Bodymassindex,median(IQR)b22.2(19.6-25.4)22.8(19.6-25.6)NYHAclasscI(leastsevere)104(27.9)112(30.8)II110(29.6)108(29.8)III110(29.6)103(28.4)IV(mostsevere)48(12.9)40(11.0)Myocardialinfarction,dNo.367358None294(80.1)299(83.5)0-9039(10.6)30(8.4)>9034(9.3)29(8.1)Ejectionfraction,%No.357347>50256(71.7)263(75.8)31-5051(14.3)57(16.4)21-3028(7.8)12(3.5)<2122(6.2)15(4.3)Pulmonarypressure,mmHgNo.308303≤30225(73.1)215(71.0)31-5558(18.8)68(22.4)>5525(8.1)20(6.6)Hypertension234(62.9)240(66.1)Dyslipidemia185(49.7)185(51.0)Congestiveheartfailure113(30.4)91(25.1)Atrialfibrillation81(21.8)80(22.0)Diabetesmellitus80(21.5)74(20.4)Chroniclungdisease53(14.3)37(10.2)Stroke/TIA46(12.4)49(13.5)Peripheralvasculardisease37(10.0)34(9.4)Activeendocarditis19(5.1)18(5.0)CCSclassIVangina15(4.0)13(3.6)Dialysis(preoperative)9(2.4)14(3.9)Intra-aorticballoonpump10(2.7)3(0.8)VAD/ECMO9(2.4)9(2.5)Criticalstatebeforesurgeryd63(16.9)38(10.5)(continued)Table1.CharacteristicsoftheStudyPopulationatBaseline(continued)CharacteristicNo.(%)FibrinogenConcentrate(n=372)Cryoprecipitate(n=363)Preoperativelaboratoryvalues,median(IQR)Creatinine,μmol/L88(72-107)[n=359]86(72-106)[n=352]Hemoglobin,g/dL13.4(11.6-14.6)[n=366]13.5(11.7-14.8)[n=356]Plateletcount,×103/μL189(154-235)[n=365]185(152-230)[n=356]Internationalnormalizedratio1.02(0.98-1.20)[n=335]1.03(0.98-1.15)[n=334]SurgicalfactorsNonelectivesurgery141(37.9)128(35.3)Complexsurgerye267(71.8)260(71.6)Procedure(%ofprocedures)f653(100.0)612(100.0)Aorticvalveprocedure165(25.3)146(23.9)Surgeryonaorta161(24.7)177(28.9)CABGsurgery153(23.4)146(23.9)Mitralvalveprocedure68(10.4)70(11.4)Tricuspidvalveprocedure31(4.7)35(5.7)ASD/VSDrepair20(3.1)8(1.3)Hearttransplant18(2.8)10(1.6)Complexcongenital11(1.7)11(1.8)Otherg26(4.0)9(1.5)Cardiopulmonarybypassduration,median(IQR),min143(102-209)134(99-200)Abbreviations:ASD,atrialseptaldefect;CABG,coronaryarterybypassgraft;CCS,CanadianCardiovascularSociety;ECMO,extracorporealmembraneoxygenation;IQR,interquartilerange;NYHA,NewYorkHeartAssociation;TIA,transientischemicattack;VAD,ventricularassistdevice;VSD,ventricularseptaldefect.aOtherracesmarkedasunknownornotapplicable.bCalculatedasweightinkilogramsdividedbyheightinmeterssquared.cNYHAfunctionalclassification:I=nolimitationofphysicalactivityandnosymptoms;II=slightlimitationofphysicalactivity(ordinaryphysicalactivityresultsinfatigue,palpitation,dyspnea);III=markedlimitationofphysicalactivity(lessthanordinaryactivitycausesfatigue,palpitation,ordyspnea);IV=unabletocarryonanyphysicalactivitywithoutdiscomfort(symptomsofheartfailureatrest).dDeterminedbyblindedadjudicationforpatientswhounderwentemergencysurgerydeemedtobeinacriticalstate,basedoncriteriaoutlinedinSupplement2.eProceduresotherthanCABGsurgeryonly,singlevalveonly,orrepairofatrialseptaldefectonly.fTotalsexceed100%becausesomepatientsunderwentmorethan1procedure.gExamplesofotherproceduresincludedaorticrootenlargement,leftventricularaneurysmectomy,andleftatrialappendageresection.EffectofFibrinogenConcentratevsCryoprecipitateonTransfusionVolumeAfterCardiacSurgeryOriginalInvestigationResearchjama.com(Reprinted)JAMAPublishedonlineOctober21,2019E5©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0cNoninferioritywasalsoobservedforthesecondaryout-comesofindividual24-hourandcumulative7-daybloodcom-ponenttransfusions(Table3),aswellasintheposthocout-comeofcumulativetransfusionsmeasuredfromproductadministrationto24hoursafterterminationofcardiopulmo-narybypass(meanunits,8.6[95%CI,7.5to9.9]inthefibrino-genconcentrategroupvs8.9[95%CI,7.8to10.2]inthecryo-precipitategroup;meanratio,0.97[1-sided97.5%CI,−(cid:2)to1.18;P=.02fornoninferiority)andafteraccountingfortreat-ment×siteinteraction(P<.001)(eFigure1inSupplement2)ontheprimaryoutcome(meanratio,1.00[1-sided97.5%CI,−(cid:2)to1.13;P=.003fornoninferiority).Noninferioritywasalsoobservedforalldefinedsubgroupsexceptforthenonelectivegroup,whichincludedallpatientsincriticalstatebeforesur-gery(Figure2;eTable2inSupplement2).FibrinogenLevelsTimingandnumberofdosesofinvestigationalproductweresimilarbetweengroups.Fibrinogenresponsewasslightlygreaterinthefibrinogenconcentrategroup(medianin-crease,0.9[IQR,0.6-1.2]g/Lvs0.7[IQR,0.5–1.0]g/L;P<.001)(Table2;eTable1inSupplement2).Table2.DetailsofIntervention,PerioperativeLaboratoryValues,FibrinogenLevels,andBleedingVariableMedian(IQR)FibrinogenConcentrate(n=372)Cryoprecipitate(n=363)DosageofinvestigationalproductMean(SD)4.8(2.1)g12.9(8.5)unitsMedian(IQR)4(4-4)g10(10-10)unitsDosesofinvestigationalproduct,No.(%)1309(83.1)296(81.5)249(13.2)49(13.5)310(2.7)10(2.8)≥44(1.1)8(2.2)Timefromstartofsurgerytoorderoffirstdose,h5.8(4.5-7.3)5.8(4.6-7.1)Timefromorderoffirstdosetoadministration,min45(32-62)47(37-60)TimefromendofCPBtoadministrationoffirstdose,min97(52-159)104(59-160)Plasmafibrinogenlevel,g/LPretransfusion1.6(1.3-1.9)[n=352]1.6(1.3-1.9)[n=346]Posttransfusion2.5(2.1-2.9)[n=324]2.3(2.0-2.6)[n=296]Changefrompretransfusion0.90(0.6-1.2)[n=306]0.70(0.5-1.0)[n=280]Bloodcomponentstransfusedbeforerandomization,mean(SD),units4.3(6.1)4.5(6.0)Cellsalvageblood,mL373(0-918)400(0-876)Nadirhematocritduringcardiopulmonarybypass,%26(23-30)25(23-30)Hemoglobin,g/dLIntraoperativepost-CPB9.1(8.3-9.9)[n=348]8.9(8.2-9.7)[n=342]Dayofsurgery(lastrecordedvalue)9.6(8.6-10.9)[n=365]9.5(8.7-10.7)[n=356]Postoperativeday1(lastrecordedvalue)9.0(8.3-9.9)[n=367]9.0(8.3-10.0)[n=361]Plateletcount,×103/μLIntraoperativepost-CPB107(84-136)[n=280]103(81-129)[n=278]Dayofsurgery(lastrecordedvalue)132(107-165)[n=362]133(107-163)[n=353]Postoperativeday1(lastrecordedvalue)117(91-145)[n=366]115(92-143)[n=359]InternationalnormalizedratioIntraoperativepost-CPB1.6(1.4-1.8)[n=295]1.6(1.5-1.8)[n=277]Dayofsurgery(lastrecordedvalue)1.3(1.2-1.4)[n=355]1.3(1.2-1.4)[n=340]Postoperativeday1(lastrecordedvalue)1.2(1.1-1.4)[n=342]1.2(1.1-1.3)[n=335]BleedingcategoriesaccordingtomodifiedUDPBclassification,No.(%)a≥2(moderatetomassive)349(93.8)347(95.6)<2(insignificanttomild)23(6.2)16(4.4)24-hchesttubedrainage,mL800(500-1350)830(540-1350)Reexploration,No.(%)53(14.2)44(12.1)Prothrombincomplexconcentrate,No.(%)110(29.6)98(27.0)RecombinantfactorVII,No.(%)35(9.4)28(7.7)Abbreviations:CPB,cardiopulmonarybypass;IQR,interquartilerange;UDPB,universaldefinitionofperioperativebleeding.aUDPBdeterminantsusedinthisstudyincludepostoperativechesttubeoutput;unitsofredbloodcells,plasma,andplateletstransfused;useoffactorconcentrates;andsurgicalreexploration(classificationschemeincludedintheeAppendixinSupplement2).22ForthisstudythefollowingcomponentsoftheUDPBscorewerenotused:delayinchestclosureanduseofcryoprecipitateorfibrinogenconcentrate.Oneintraoperativedeathwasincludedinthesevereormassivecategoryinthefibrinogenconcentrategroup.ResearchOriginalInvestigationEffectofFibrinogenConcentratevsCryoprecipitateonTransfusionVolumeAfterCardiacSurgeryE6JAMAPublishedonlineOctober21,2019(Reprinted)jama.com©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0cAdverseEventsandOtherOutcomesTreatment-emergentadverseeventprofilesweresimilar(Table4;eTable3inSupplement2),aswerethedurationofintubation,intensivecareunitstay,andhospitalstay(Table4).Therewere35deaths(9.4%)inthefibrinogenconcentrategroupand27(7.4%)inthecryoprecipitategroup(unadjustedhazardratio,1.28[95%CI,0.77to2.12];P=.35)(Kaplan-MeiercurvesshownineFigures2and3inSupplement2).Deathrateswerealsonotsignificantlydifferentwhenstratifiedbycriticalstatebeforesurgery(fibrinogenconcentratevscryo-precipitate:19/63[30.2%]vs12/38[31.6%]incriticalstatepa-tients;16/309[5.2%]vs15/325[4.6%]inremainingpatients)andafterriskadjustmentforcriticalstate(posthocanalysishazardratio,1.03[95%CI,0.62to1.70];P=.92)(resultsfromposthocanalysesreportedineTables4and5inSupple-ment2).Thromboembolicadverseeventswereobservedin26patients(7.0%)inthefibrinogengroupand35patients(9.6%)inthecryoprecipitategroup(unadjustedoddsratio,0.70[95%CI,0.42to1.20])(Table4).DiscussionInthisstudyofpatientswhoexperiencedbleedingaftercar-diacsurgeryandrequiredfibrinogenreplacementaspartofrou-tineclinicalpractice,theprimaryfindingwasthatfibrinogenconcentratewasnoninferiortocryoprecipitateasmeasuredbythenumberofbloodcomponentstransfused.Thestudyprotocol,whichdidnotmodifyclinicalprac-ticeandusedadelayed(postintervention)consentprocess,successfullyrandomizedthesmallproportionofpatientswithbleedingwhowereorderedfibrinogenreplacement(comprisingapproximately5%ofpatientswhounderwentcardiacsurgeryatparticipatingcentersduringthestudyperiod).Thegroupswerewellbalancedforbaselinevari-ablesexceptforcriticalstatebeforesurgery,animportantprognosticvariablethatwasmoreprevalentinthefibrino-genconcentrategroup.Theoccurrenceofadverseeventswascomparablebetweenthegroups,althoughtherewasTable3.PrimaryandSecondaryOutcomes:AllogeneicBloodComponentTransfusionsPopulationFibrinogenConcentrateCryoprecipitateMeanDifference(95%CI)UnadjustedRatioofLSMeans(1-Sided97.5%CI)NoninferiorityPValueNo.Median(IQR)LSMean(95%CI)No.Median(IQR)LSMean(95%CI)PrimaryOutcome:CumulativeAllogeneicBloodComponentsTransfusedWithin24hAfterCardiopulmonaryBypassaPrimaryanalysisset37212.0(5.5to22.0)16.3(14.9to17.8)36314.0(7.0to23.0)17.0(15.6to18.6)−0.73(−3.10to1.64)Unadjusted0.96(−(cid:2)to1.09)<.001Adjusted0.91(−(cid:2)to1.03)c<.001Per-protocolsetb36412.0(6.0to22.0)16.4(15.0to18.0)36114.0(7.0to22.0)16.9(15.5to18.5)−0.50(−2.90to1.89)Unadjusted0.97(−(cid:2)to1.10)<.001Adjusted0.92(−(cid:2)to1.05)c<.001SecondaryOutcome:RedBloodCellTransfusionsWithin24hAfterCardiopulmonaryBypassPrimaryanalysisset3722.0(0.0to5.0)3.3(3.0to3.7)3632.0(1.0to5.0)3.3(2.9to3.7)0.23(−0.55to1.00)1.00(0to1.18).02Per-protocolset3642.0(0.0to5.0)3.3(3.0to3.7)3612.0(1.0to5.0)3.3(2.9to3.7)0.25(−0.53to1.03)1.01(0to1.18).02SecondaryOutcome:PlateletTransfusionsWithin24hAfterCardiopulmonaryBypassPrimaryanalysisset3728.0(4.0to12.0)9.1(8.3to9.9)3638.0(4.0to12.0)9.7(8.9to10.5)−0.46(−1.70to0.78)0.94(−(cid:2)to1.06)<.001Per-protocolset3648.0(4.0to12.0)9.1(8.3to10.0)3618.0(4.0to12.0)9.6(8.8to10.5)−0.31(−1.56to0.93)0.95(−(cid:2)to1.08)<.001SecondaryOutcome:PlasmaTransfusionsWithin24hAfterCardiopulmonaryBypassPrimaryanalysisset3722.0(0.0to6.0)3.9(3.5to4.4)3633.0(0.0to6.0)4.1(3.6to4.6)−0.04(−0.97to0.89)0.96(−(cid:2)to1.15).008Per-protocolset3642.0(0.0to6.0)4.0(3.5to4.5)3613.0(0.0to6.0)4.0(3.6to4.6)0.04(−0.91to0.98)0.98(−(cid:2)to1.17).01SecondaryOutcome:CumulativeAllogeneicBloodComponentsTransfusedWithin7dAfterStartofSurgeryPrimaryanalysisset37215.5(6.0to29.5)22.5(20.5to24.7)36317.0(9.0to28.0)22.3(20.3to24.5)0.21(−3.14to3.55)Unadjusted1.01(0to1.15).005Adjusted0.96(−(cid:2)to1.09)c<.001Per-protocolset36415.5(6.0to29.0)22.5(20.5to24.8)36117.0(9.0to28.0)22.2(20.2to24.5)0.31(−3.07to3.70)Unadjusted1.01(0to1.16).007Adjusted0.96(−(cid:2)to1.09)c<.001Abbreviation:LS,least-squares.aUnitsofallogenicbloodcomponentscountedasfollows:eachredbloodcellunit=1unit,each250-mLplasmaunit=1unit,each500-mLplasmaunit=2units,eachplateletdose=4units.bPer-protocolsetexcludedpatientswhodidnotundergocardiacsurgerywithcardiopulmonarybypass,receivedtheincorrecttreatment,receivedlessthan80%oftheplanneddose,orreceivedthefirsttreatmentmorethan24hoursaftercardiopulmonarybypass.cAdjustedforcriticalstatebeforesurgery(posthocanalysis).EffectofFibrinogenConcentratevsCryoprecipitateonTransfusionVolumeAfterCardiacSurgeryOriginalInvestigationResearchjama.com(Reprinted)JAMAPublishedonlineOctober21,2019E7©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0canonsignificantdifferenceof2.0%inmortality.Thisseemedtoberelatedtothebetween-groupimbalanceinthenumberofpatientsincriticalstatebeforesurgery.Thestudyobjectivewastocomparethe2currentlyrec-ommendedtherapiesforfibrinogenreplacement4,5underusualconditionsofclinicalcare.Thus,itdidnotincludeaplacebogrouptodeterminetheefficacyoffibrinogenreplacementperse,nordiditattempttoidentifytheappro-priatethresholdforfibrinogenreplacement.16Arecentsys-tematicreviewcomparingfibrinogenconcentrateswithcryoprecipitateinpatientswithbleeding10identified1ran-domizedtrial(withhighriskforbias)19and3observationalstudies25-27andconcludedthattherewasinsufficientevi-dencetorecommendoneproductovertheother.Anotherreviewoftrauma,obstetric,andgastrointestinalbleedingpopulationsreachedsimilarconclusions.9Thisstudypro-videsfurtherdataregardingthecomparativeefficacyandadverseeventprofileofthese2products.Thenoninferiorityfindingcaninformthechoiceofcryo-precipitateorfibrinogenconcentratefortreatmentofbleed-ingrelatedtoacquiredhypofibrinogenemia.Acoretenetandmajorregulatorydriverintransfusionmedicineisthepre-cautionaryprinciplethatrequiresrisk-mitigationstrategiestobeinstitutedevenifthereisonlyatheoreticalriskofharm.28Consistentwiththisprinciple,theUSFoodandDrugAdministrationbloodsafetystrategyrecommendstheuseofpathogen-reducedbloodproductswhenfeasible.28Cur-rently,therearenoknownimpendinginfectiousthreatsforFigure2.RatioofMeanNumberofAllogeneicBloodComponentsTransfusedinthe24HoursAfterCardiopulmonaryBypassforthePrimaryAnalysisSet,Per-ProtocolAnalysisSet,andAPriori–DefinedSubgroupsGroup/SubgroupRatio (97.5% CI)Primary analysis set0.96 (–∞ to 1.09)Per-protocol analysis set0.97 (–∞ to 1.10)Excluding patients in critical state0.84 (–∞ to 0.96)Elective surgery0.81 (–∞ to 0.96)Nonelective surgery1.09 (0 to 1.31)Complex surgery0.98 (–∞ to 1.13)Noncomplex surgery0.86 (–∞ to 1.12)0.721Ratio of Mean No. of Units (97.5% CI)FavorsFibrinogenConcentrateFavorsCryoprecipitate1.2Allpatientsincriticalstatewereinthenonelectivesubgroup.Bluedashedlineatx=1.2indicatesthenoninferioritymargin.Table4.Treatment-EmergentAdverseEventsandOtherMeasuredOutcomesat28-DayFollow-upOutcomeNo.(%)FibrinogenConcentrate(n=372)Cryoprecipitate(n=363)Anyadverseevent248(66.7)264(72.7)No.ofevents623673Anyseriousadverseevent117(31.5)126(34.7)No.ofevents224264Thromboembolicadverseeventsa26(7.0)35(9.6)No.ofevents2739Stroke/TIA17(4.6)18(5.0)DVT/PE5(1.3)9(2.5)Myocardialinfarction3(0.8)4(1.1)Othervesselthrombosis07(1.9)Amaurosisfugax01(0.3)Disseminatedintravascularcoagulation1(0.3)0Thrombophlebitis1(0.3)0Acutekidneyinjuryb48(12.9)48(13.2)Hepatobiliarydisordersc32(8.6)37(10.2)Durationofmechanicalventilation,median(IQR),d1.3(0.7-5.0)[n=337]1.3(0.7-4.2)[n=342]Durationofintensivecareunitstay,median(IQR),d2.9(1.4-5.7)[n=352]2.8(1.2-5.6)[n=345]Durationofhospitalization,median(IQR),d8.2(6.3-13.0)[n=314]9.0(6.3-13.3)[n=308]Abbreviations:DVT,deepveinthrombosis;PE,pulmonaryembolism;TIA,transientischemicattack.aPatientswhoexperiencedmorethan1eventarecountedonlyonceinthetotal.bAcutekidneyinjurywasdefinedasgreaterthana2-foldincreaseincreatinineorkidneyfailurerequiringhemodialysiswithin28daysofsurgery.cHepatobiliarydisordersweredefinedbytheMedicalDictionaryforRegulatoryActivities(version21.1)systemofnomenclature.ResearchOriginalInvestigationEffectofFibrinogenConcentratevsCryoprecipitateonTransfusionVolumeAfterCardiacSurgeryE8JAMAPublishedonlineOctober21,2019(Reprinted)jama.com©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0crecipientsofcryoprecipitate;however,thehistoryofbloodpathogenssuggeststhatplasma-derivedproductshavetransmittedpathogensinthepastandmaydosointhefuture.29Inaddition,mathematicalmodelsofemergingpathogenssuggestthattheassociationofplasma-derivedproducts(suchascryoprecipitate)withoutcomesandcostsmaybesubstantial.30Inthisregard,fibrinogenconcentratemaybepreferredtocryoprecipitatebecauseitispathogen-reduced.Anotheradvantageoffibrinogenconcentrateisthatinmostsituationsitcanbelogisticallysimplertodelivertothebedsideofapatientwithbleeding.Oneimportantconsiderationisthecostdifferentialthatcurrentlyfavorscryoprecipitate,butthisvariesacrossregions,andthemostrecenteconomicanalysisfailedtoincludethecostsoffutureemergingpathogensanddidnotincludecomprehensiveactivity-basedcosting.31LimitationsThisstudyhasseverallimitations.First,sincetheaimwastocomparethe2productswhenusedunderusualconditionsofcare,itwasnotlogisticallypossibletoinstituteastandard-izedtransfusionprotocolacrossthesitesortoblindclini-cianstotreatmentassignment.Althoughaposthocanalysisshowedthatthereweretreatment×siteinteractions,account-ingfortheinteractionsdidnothaveamaterialeffectontheprimaryoutcome.Moreover,postoperativehemoglobin,plate-letcount,andcoagulationmeasuresweresimilarbetweengroups(Table2),suggestingthattransfusionpracticewasconsistentinbothgroups.Inaddition,theresultswerecon-sistentwhentransfusionsweremeasuredfrombeginningofsurgerytopostoperativeday7(apriorianalysis)orafterad-ministrationofinvestigationalproduct(posthocanalysis),whichsuggeststhatlackofblindingdidnotinfluencethetim-ingoftransfusionsrelativetoproductadministration.Ofnote,toensurethatalltransfusionsandadverseeventswerecol-lectedwithoutbias,patientsandoutcomeassessorswereblindedtotreatmentallocationandindependentmonitorsre-viewedalltransfusionandadverseevents.Second,whilethestudyhadfewexclusioncriteria,itincludedonlypatientsun-dergoingcardiacsurgerywithbleeding,anditsfindingsmaythereforenotbegeneralizabletoothersettingswherefibrino-genreplacementisrequired.Thiswouldprimarilybeothertypesofsurgery,trauma,andpostpartumhemorrhage,32butmostevidencesuggeststhattheroleoffibrinogenissimilarinthesesettings.33,34Third,becauseofthepragmaticdesignofthestudy,stricttimingoflaboratoryassessmentscouldnotbeenforced.However,onlylessthan5%ofpatientshadnomeasuredfibrinogenlevelsbeforeproductadministration.Re-latedtothis,asmallproportionofpatientshadfibrinogenval-uesaboverecommendedthresholdswhentreatmentorderwasreceived.However,thisisconsistentwithrecentexperienceinmajorbleeding,32andongoingbleedingfromsamplecol-lectiontotherapymeansthatactualfibrinogenlevelsatthetimeoftherapywerelikelylowerthanmeasuredvalues.Fourth,fibrinogencontentisstandardizedinfibrinogencon-centratebutishighlyvariableincryoprecipitate.Asaresult,somepatientsinthecryoprecipitategrouplikelyreceivedmuchlessormuchmorethan4goffibrinogen.Whilethisisoneoftheinherentlimitationsofcryoprecipitate,observeddiffer-encesinpretreatmentandposttreatmentfibrinogenlevelssug-gestthatonaveragebothgroupsreceivedclinicallysimilaramountsoffibrinogen.ConclusionsInpatientsundergoingcardiacsurgerywhodevelopclini-callysignificantbleedingandhypofibrinogenemiaaftercar-diopulmonarybypass,fibrinogenconcentrateisnoninferiortocryoprecipitatewithregardtonumberofbloodcompo-nentstransfusedina24-hourperiodpostbypass.Useoffi-brinogenconcentratemaybeconsideredformanagementofbleedinginpatientswithacquiredhypofibrinogenemiaincar-diacsurgery.ARTICLEINFORMATIONAcceptedforPublication:October2,2019.PublishedOnline:October21,2019.doi:10.1001/jama.2019.17312AuthorAffiliations:DepartmentofLaboratoryMedicineandMolecularDiagnostics,SunnybrookHealthSciencesCentre,Toronto,Ontario,Canada(Callum);LaboratoryMedicineProgram,UniversityHealthNetwork,Toronto,Ontario,Canada(Callum);DepartmentofLaboratoryMedicineandPathobiology,UniversityofToronto,Toronto,Ontario,Canada(Callum);PeterMunkCardiacCentre,UniversityHealthNetwork,Toronto,Ontario,Canada(Farkouh,Rao,Carroll,Grewal,Karkouti);HeartandStrokeRichardLewarCentre,UniversityofToronto,Toronto,Ontario,Canada(Farkouh);InterdepartmentalDivisionofCriticalCare,DepartmentofMedicine,UniversityofToronto,Toronto,Ontario,Canada(Scales,Karkouti);SunnybrookResearchInstitute,DepartmentofCriticalCareMedicine,SunnybrookHealthSciencesCentre,Toronto,Ontario,Canada(Scales);FacultyofHealthSciences,McMasterUniversity,Hamilton,Ontario,Canada(Heddle);DepartmentofMedicine,McMasterUniversity,Hamilton,Ontario,Canada(Heddle,Crowther);UniversityHealthNetwork,DivisionofCardiovascularSurgery,TorontoGeneralHospital,Toronto,Ontario,Canada(Rao);UniversityofToronto,Toronto,Ontario,Canada(Rao,Carroll,Grewal);DepartmentofBiostatistics,ERGOMEDCDSGmbH,Cologne,Germany(Hucke);DepartmentofAnesthesiaandPainManagement,SinaiHealthSystem,Women’sCollegeHospital,UniversityHealthNetwork,Toronto,Ontario,Canada(Carroll,Grewal,Karkouti);DepartmentofAnesthesiology,PharmacologyandTherapeutics;UniversityofBritishColumbia,Vancouver,Canada(Brar);RoyalColumbianHospital,Vancouver,BritishColumbia,Canada(Brar);AnesthesiologyDepartment,InstitutuniversitairedecardiologieetdepneumologiedeQuébec-UniversitéLaval,QuébecCity,Québec,Canada(Bussières);DepartmentsofAnesthesiology,PerioperativeandPainMedicine,andSurgery,UniversityofManitoba,Winnipeg,Canada(Grocott);DepartmentofAnesthesiaandPerioperativeMedicine,WesternUniversity,London,Ontario,Canada(Harle);StMichael’sHospital,DivisionofTransfusionMedicine,DepartmentofLaboratoryMedicineandPathobiology,UniversityofToronto,Toronto,Ontario,Canada(Pavenski);DepartmentofAnesthesiology,MontréalHeartInstitute,UniversitédeMontréal,Montréal,Québec,Canada(Rochon);DepartmentofAnesthesiologyandPerioperativeMedicine;KingstonGeneralHospital,Queen’sUniversity,Kingston,Ontario,Canada(Saha);DepartmentofPathologyandMolecularMedicine,KingstonHealthScienceCenter,Queen’sUniversity,Kingston,Ontario,Canada(Shepherd);DepartmentofAnesthesiology;HamiltonHealthSciencesCorporation,McMasterUniversity,Hamilton,Ontario,Canada(Syed);UniversityofOttawaHeartInstitute,DivisionofCardiacAnesthesiologyandCriticalCare,DepartmentofAnesthesiaandPainMedicine,UniversityofOttawaSchoolofEpidemiologyandPublicHealth,Ottawa,Ontario,Canada(Tran);CardiacSurgery,RoyalColumbianHospital,UniversityofBritishColumbia,Vancouver,Canada(Wong);McMasterCentreforTransfusionResearch,DepartmentofMedicine,EffectofFibrinogenConcentratevsCryoprecipitateonTransfusionVolumeAfterCardiacSurgeryOriginalInvestigationResearchjama.com(Reprinted)JAMAPublishedonlineOctober21,2019E9©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0cMcMasterUniversity,Hamilton,Ontario,Canada(Zeller);DepartmentofAnesthesiaandInstituteofHealthPolicy,Management,andEvaluation,UniversityofToronto,Toronto,Ontario,Canada(Karkouti).AuthorContributions:DrsHuckeandKarkoutihadfullaccesstoallofthedatainthestudyandtakeresponsibilityfortheintegrityofthedataandtheaccuracyofthedataanalysis.Conceptanddesign:Callum,Farkouh,Scales,Heddle,Crowther,Rao,Hucke,Grocott,Karkouti.Acquisition,analysis,orinterpretationofdata:Callum,Farkouh,Scales,Heddle,Rao,Hucke,Carroll,Grewal,Brar,Bussières,Grocott,Harle,Pavenski,Rochon,Saha,Shepherd,Syed,Tran,Wong,Zeller,Karkouti.Draftingofthemanuscript:Callum,Grocott,Tran,Karkouti.Criticalrevisionofthemanuscriptforimportantintellectualcontent:Allauthors.Statisticalanalysis:Callum,Hucke,Karkouti.Obtainedfunding:Karkouti.Administrative,technical,ormaterialsupport:Callum,Farkouh,Crowther,Rao,Carroll,Grewal,Brar,Grocott,Harle,Pavenski,Rochon,Saha,Shepherd,Syed,Tran,Wong,Karkouti.Supervision:Callum,Carroll,Brar,Bussières,Grocott,Harle,Pavenski,Rochon,Saha,Shepherd,Tran,Wong,Zeller,Karkouti.ConflictofInterestDisclosures:DrCallumreportedreceivinggrantsfromCanadianBloodServices,Octapharma,andCSLBehringduringtheconductofthestudy.DrFarkouhreportedreceivinggrantsfromAmgenandNovoNordisk.DrScalesreportedreceivinggrantsfromCanadianInstituteforHealthResearch.DrHeddlereportedreceivingnonfinancialsupportfromOctapharmaduringtheconductofthestudyandreceivinggrantsfromCanadianBloodServices.DrCrowtherreportedreceivinggrantsorpersonalfeesfromBayer,Pfizer,BMSCanada,CSLBehring,ServierCanada,andDiagnosticaStago.DrRaoreportedreceivinggrantsfromOctapharmaduringtheconductofthestudyandreceivingpersonalfeesfromMedtronicandAbbott.DrHuckereportedreceivinggrantsfromOctapharmaduringtheconductofthestudy.DrPavenskireportedservingasamemberoftheNationalAdvisoryCommitteeonBloodandBloodProducts(Canada)andtheOntarioBloodAdvisoryCommittee(Ontario).DrTranreportedreceivinggrantsfromOctapharmaduringtheconductofthestudy.DrZellerreportedreceivinggrantsfromCanadianBloodServicesandreceivingpersonalfeesfromPfizer.DrKarkoutireportedreceivinggrantsandpersonalfeesfromOctapharmaandInstrumentationLaboratoryduringtheconductofthestudy.Nootherdisclosureswerereported.Funding/Support:ThetrialwassupportedbyanunrestrictedgrantfromOctapharmaAG(Lachen,Switzerland),whichalsoprovidedthefibrinogenconcentrate.CryoprecipitatewasprovidedbytheCanadianBloodServices(Ottawa,Ontario)andHéma-Québec(VilledeQuébec,Québec,Canada).RoleoftheFunders/Sponsors:Octapharma,CanadianBloodServices,andHéma-Québechadnoroleinthedesignandconductofthestudy;collection,management,analysis,andinterpretationofthedata;preparation,review,orapprovalofthemanuscript;anddecisiontosubmitthemanuscriptforpublication.MeetingPresentation:PresentedattheAABBAnnualMeeting;October21,2019;SanAntonio,Texas.DataSharingStatement:SeeSupplement3.AdditionalContributions:Wethankallthepatientsandclinicianswhoparticipatedinthisstudy,allmembersofthestudyteamsattheparticipatingcenters,membersofstudycommitteesandmonitoringteam,theOctapharmateam(SriAdapa,MBA[OctapharmaCanadaInc];OliverHegener,PhD,SigurdKnaub,PhD,andCristinaSolomon,MD[OctapharmaAG,Switzerland];andBruceSchwartz,PhD[OctapharmaUSAInc]),andDrKathrynWebert,MD(CanadianBloodServices)fortheirsupport.Noneoftheseindividualsreceivedcompensationfortheirrolesinthestudy;however,theOctapharmateammemberswereemployeesofOctapharmaattimeofstudy.EditorialassistanceforrevisionsofthemanuscriptwasprovidedbyAbigailBaines,PhD,ofPortlandMedicalCommunications(Manchester,UnitedKingdom),whoreceivedcompensationforhercontributions.REFERENCES1.MurphyGJ,ReevesBC,RogersCA,RizviSI,CullifordL,AngeliniGD.Increasedmortality,postoperativemorbidity,andcostafterredbloodcelltransfusioninpatientshavingcardiacsurgery.Circulation.2007;116(22):2544-2552.doi:10.1161/CIRCULATIONAHA.107.6989772.FaraoniD,WillemsA,SavanV,DemanetH,DeVilleA,VanderLindenP.Plasmafibrinogenconcentrationiscorrelatedwithpostoperativebloodlossinchildrenundergoingcardiacsurgery:aretrospectivereview.EurJAnaesthesiol.2014;31(6):317-326.doi:10.1097/EJA.00000000000000433.KarkoutiK,CallumJ,CrowtherMA,etal.Therelationshipbetweenfibrinogenlevelsaftercardiopulmonarybypassandlargevolumeredcelltransfusionincardiacsurgery:anobservationalstudy.AnesthAnalg.2013;117(1):14-22.doi:10.1213/ANE.0b013e318292efa44.SpahnDR,BouillonB,CernyV,etal.TheEuropeanguidelineonmanagementofmajorbleedingandcoagulopathyfollowingtrauma:fifthedition.CritCare.2019;23(1):98.doi:10.1186/s13054-019-2347-35.BoerC,MeestersMI,MilojevicM,etal;TaskForceonPatientBloodManagementforAdultCardiacSurgeryoftheEuropeanAssociationforCardio-ThoracicSurgery(EACTS)andtheEuropeanAssociationofCardiothoracicAnaesthesiology(EACTA).2017EACTS/EACTAGuidelinesonpatientbloodmanagementforadultcardiacsurgery.JCardiothoracVascAnesth.2018;32(1):88-120.doi:10.1053/j.jvca.2017.06.0266.CallumJL,KarkoutiK,LinY.Cryoprecipitate:thecurrentstateofknowledge.TransfusMedRev.2009;23(3):177-188.doi:10.1016/j.tmrv.2009.03.0017.DunbarNM,OlsonNJ,SzczepiorkowskiZM,etal.Bloodcomponenttransfusionandwastageratesinthesettingofmassivetransfusioninthreeregionaltraumacenters.Transfusion.2017;57(1):45-52.doi:10.1111/trf.138808.YazerMH,DunbarNM,CohnC,etal;BiomedicalExcellenceforSaferTransfusion(BEST)Collaborative.Bloodproducttransfusionandwastageratesinobstetrichemorrhage.Transfusion.2018;58(6):1408-1413.doi:10.1111/trf.145719.NovakA,StanworthSJ,CurryN.Dowestillneedcryoprecipitate?cryoprecipitateandfibrinogenconcentrateastreatmentsformajorhemorrhage—howdotheycompare?ExpertRevHematol.2018;11(5):351-360.doi:10.1080/17474086.2018.145861010.JensenNH,StensballeJ,AfshariA.Comparingefficacyandsafetyoffibrinogenconcentratetocryoprecipitateinbleedingpatients:asystematicreview.ActaAnaesthesiolScand.2016;60(8):1033-1042.doi:10.1111/aas.1273411.LiJY,GongJ,ZhuF,etal.Fibrinogenconcentrateincardiovascularsurgery:ameta-analysisofrandomizedcontrolledtrials.AnesthAnalg.2018;127(3):612-621.doi:10.1213/ANE.000000000000350812.KarkoutiK,CallumJ,RaoV,etal.ProtocolforaphaseIII,non-inferiority,randomisedcomparisonofanewfibrinogenconcentrateversuscryoprecipitatefortreatingacquiredhypofibrinogenaemiainbleedingcardiacsurgicalpatients:theFIBREStrial.BMJOpen.2018;8(4):e020741.doi:10.1136/bmjopen-2017-02074113.CanadianInstitutesofHealthResearch.IntroducingTCPS2(2018)—Tri-CouncilPolicyStatement:EthicalConductforResearchInvolvingHumans.GovernmentofCanadawebsite.http://www.pre.ethics.gc.ca/eng/nr-cp_2019-06-05.html.PublishedAugust15,2019.AccessedOctober8,2019.14.ErdoesG,GersterG,ColucciG,KaiserH,AlberioL,EberleB.Predictionofpost-weaningfibrinogenstatusduringcardiopulmonarybypass:anobservationalstudyin110patients.PLoSOne.2015;10(5):e0126692.doi:10.1371/journal.pone.012669215.MaceH,LightfootN,McCluskeyS,etal.Validityofthromboelastometryforrapidassessmentoffibrinogenlevelsinheparinizedsamplesduringcardiacsurgery:aretrospective,single-center,observationalstudy.JCardiothoracVascAnesth.2016;30(1):90-95.doi:10.1053/j.jvca.2015.04.03016.BilecenS,deGrootJA,KalkmanCJ,etal.Effectoffibrinogenconcentrateonintraoperativebloodlossamongpatientswithintraoperativebleedingduringhigh-riskcardiacsurgery:arandomizedclinicaltrial.JAMA.2017;317(7):738-747.doi:10.1001/jama.2016.2103717.NascimentoB,CallumJ,TienH,etal.FibrinogenintheinitialResuscitationofSevereTrauma(FiiRST):arandomizedfeasibilitytrial.BrJAnaesth.2016;117(6):775-782.doi:10.1093/bja/aew34318.WinearlsJ,WullschlegerM,WakeE,etal.FibrinogenEarlyInSevereTraumastudY(FEISTY):studyprotocolforarandomisedcontrolledtrial.Trials.2017;18(1):241.doi:10.1186/s13063-017-1980-x19.GalasFR,deAlmeidaJP,FukushimaJT,etal.Hemostaticeffectsoffibrinogenconcentratecomparedwithcryoprecipitateinchildrenaftercardiacsurgery:arandomizedpilottrial.JThoracCardiovascSurg.2014;148(4):1647-1655.doi:10.1016/j.jtcvs.2014.04.02920.GreenL,Bolton-MaggsP,BeattieC,etal.BritishSocietyofHaematologyGuidelinesonthespectrumoffreshfrozenplasmaandcryoprecipitateproducts:theirhandlinganduseinvariouspatientgroupsintheabsenceofmajorResearchOriginalInvestigationEffectofFibrinogenConcentratevsCryoprecipitateonTransfusionVolumeAfterCardiacSurgeryE10JAMAPublishedonlineOctober21,2019(Reprinted)jama.com©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0cbleeding.BrJHaematol.2018;181(1):54-67.doi:10.1111/bjh.1516721.CallumJL,PinkertonPH,LimaA,etal.BloodyEasy4:BloodTransfusions,BloodAlternativesandTransfusionReaction.4thed.Toronto,Ontario,Canada:OntarioRegionalBloodCoordinatingNetwork;2016.22.DykeC,AronsonS,DietrichW,etal.Universaldefinitionofperioperativebleedinginadultcardiacsurgery.JThoracCardiovascSurg.2014;147(5):1458-1463.doi:10.1016/j.jtcvs.2013.10.07023.KarkoutiK,CallumJ,WijeysunderaDN,etal;TACSInvestigators.Point-of-carehemostatictestingincardiacsurgery:astepped-wedgeclusteredrandomizedcontrolledtrial.Circulation.2016;134(16):1152-1162.doi:10.1161/CIRCULATIONAHA.116.02395624.FlemingTR,HarringtonDP,O’BrienPC.Designsforgroupsequentialtests.ControlClinTrials.1984;5(4):348-361.doi:10.1016/S0197-2456(84)80014-825.AhmedS,HarrityC,JohnsonS,etal.Theefficacyoffibrinogenconcentratecomparedwithcryoprecipitateinmajorobstetrichaemorrhage—anobservationalstudy.TransfusMed.2012;22(5):344-349.doi:10.1111/j.1365-3148.2012.01178.x26.TheodoulouA,BerrymanJ,NathwaniA,ScullyM.Comparisonofcryoprecipitatewithfibrinogenconcentrateforacquiredhypofibrinogenaemia.TransfusApherSci.2012;46(2):159-162.doi:10.1016/j.transci.2011.11.00527.YangL,VuylstekeA,GerrardC,BesserM,BaglinT.Postoperativefibrinogenlevelisassociatedwithpostoperativebleedingfollowingcardiothoracicsurgeryandtheeffectoffibrinogenreplacementtherapyremainsuncertain.JThrombHaemost.2013;11(8):1519-1526.doi:10.1111/jth.1230428.LeachBennettJ,BlajchmanMA,DelageG,FearonM,DevineD.Proceedingsofaconsensusconference:risk-baseddecisionmakingforbloodsafety.TransfusMedRev.2011;25(4):267-292.doi:10.1016/j.tmrv.2011.05.00229.StramerSL,HollingerFB,KatzLM,etal.Emerginginfectiousdiseaseagentsandtheirpotentialthreattotransfusionsafety.Transfusion.2009;49(suppl2):1S-29S.doi:10.1111/j.1537-2995.2009.02279.x30.KleinmanS,CameronC,CusterB,etal.ModelingtheriskofanemergingpathogenenteringtheCanadianbloodsupply.Transfusion.2010;50(12):2592-2606.doi:10.1111/j.1537-2995.2010.02724.x31.OkerbergCK,WilliamsLAIII,KilgoreML,etal.CryoprecipitateAHFvs.fibrinogenconcentratesforfibrinogenreplacementinacquiredbleedingpatients—aneconomicevaluation.VoxSang.2016;111(3):292-298.doi:10.1111/vox.1241732.McQuiltenZK,BaileyM,CameronPA,etal.Fibrinogenconcentrationanduseoffibrinogensupplementationwithcryoprecipitateinpatientswithcriticalbleedingreceivingmassivetransfusion:abi-nationalcohortstudy.BrJHaematol.2017;179(1):131-141.doi:10.1111/bjh.1480433.McQuiltenZK,WoodEM,BaileyM,CameronPA,CooperDJ.Fibrinogenisanindependentpredictorofmortalityinmajortraumapatients:afive-yearstatewidecohortstudy.Injury.2017;48(5):1074-1081.doi:10.1016/j.injury.2016.11.02134.GillissenA,vandenAkkerT,Caram-DeelderC,etal;TeMpOH-1StudyGroup.Coagulationparametersduringthecourseofseverepostpartumhemorrhage:anationwideretrospectivecohortstudy.BloodAdv.2018;2(19):2433-2442.EffectofFibrinogenConcentratevsCryoprecipitateonTransfusionVolumeAfterCardiacSurgeryOriginalInvestigationResearchjama.com(Reprinted)JAMAPublishedonlineOctober21,2019E11©2019AmericanMedicalAssociation.Allrightsreserved.Downloaded From: https://jamanetwork.com/ on 10/22/2019\\x0c'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 45
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## ☝ ok, also no spaces between words"
      ],
      "metadata": {
        "id": "AK2-fIn0NO5w"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from pdfminer.converter import TextConverter\n",
        "from pdfminer.layout import LAParams\n",
        "from pdfminer.pdfdocument import PDFDocument\n",
        "from pdfminer.pdfinterp import PDFResourceManager, PDFPageInterpreter\n",
        "from pdfminer.pdfpage import PDFPage\n",
        "from pdfminer.pdfparser import PDFParser\n",
        "\n",
        "output_string = StringIO()\n",
        "\n",
        "with open(pdf_file_path, 'rb') as in_file:\n",
        "  parser = PDFParser(in_file)\n",
        "  doc = PDFDocument(parser)\n",
        "  rsrcmgr = PDFResourceManager()\n",
        "  device = TextConverter(rsrcmgr, output_string, laparams=LAParams())\n",
        "  interpreter = PDFPageInterpreter(rsrcmgr, device)\n",
        "  for page in PDFPage.create_pages(doc):\n",
        "    interpreter.process_page(page)\n",
        "\n",
        "print(output_string.getvalue())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "oLQa3jenD1m0",
        "outputId": "dad07fde-ac8f-4d6a-c22b-17883d409488"
      },
      "execution_count": 46,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Research\n",
            "\n",
            "JAMA | Original Investigation\n",
            "Effect of Fibrinogen Concentrate vs Cryoprecipitate\n",
            "on Blood Component Transfusion After Cardiac Surgery\n",
            "The FIBRES Randomized Clinical Trial\n",
            "\n",
            "Jeannie Callum, MD; Michael E. Farkouh, MD; Damon C. Scales, MD; Nancy M. Heddle, MSc; Mark Crowther, MD;\n",
            "Vivek Rao, MD; Hans-Peter Hucke, PhD; Jo Carroll, BHA; Deep Grewal, MD; Sukhpal Brar, MD; Jean Bussières, MD;\n",
            "Hilary Grocott, MD; Christopher Harle, MD; Katerina Pavenski, MD; Antoine Rochon, MD; Tarit Saha, MD;\n",
            "Lois Shepherd, MD; Summer Syed, MD; Diem Tran, MD; Daniel Wong, MD; Michelle Zeller, MD;\n",
            "Keyvan Karkouti, MD; for the FIBRES Research Group\n",
            "\n",
            "IMPORTANCE Excessive bleeding is a common complication of cardiac surgery. An important\n",
            "cause of bleeding is acquired hypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), for which\n",
            "guidelines recommend fibrinogen replacement with cryoprecipitate or fibrinogen concentrate.\n",
            "The 2 products have important differences, but comparative clinical data are lacking.\n",
            "\n",
            "OBJECTIVE To determine if fibrinogen concentrate is noninferior to cryoprecipitate for\n",
            "treatment of bleeding related to hypofibrinogenemia after cardiac surgery.\n",
            "\n",
            "DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial at 11 Canadian hospitals\n",
            "enrolling adult patients experiencing clinically significant bleeding and hypofibrinogenemia\n",
            "after cardiac surgery (from February 10, 2017, to November 1, 2018). Final 28-day follow-up\n",
            "visit was completed on November 28, 2018.\n",
            "\n",
            "INTERVENTIONS Fibrinogen concentrate (4 g; n = 415) or cryoprecipitate (10 units; n = 412)\n",
            "for each ordered dose within 24 hours after cardiopulmonary bypass.\n",
            "\n",
            "MAIN OUTCOMES AND MEASURES Primary outcome was blood components (red blood cells,\n",
            "platelets, plasma) administered during 24 hours post bypass. A 2-sample, 1-sided test for the\n",
            "ratio of the mean number of units was conducted to evaluate noninferiority (threshold for\n",
            "noninferiority ratio, <1.2).\n",
            "\n",
            "RESULTS Of 827 randomized patients, 735 (372 fibrinogen concentrate, 363 cryoprecipitate)\n",
            "were treated and included in the primary analysis (median age, 64 [interquartile range, 53-72]\n",
            "years; 30% women; 72% underwent complex operations; 95% moderate to severe bleeding;\n",
            "and pretreatment fibrinogen level, 1.6 [interquartile range, 1.3-1.9] g/L). The trial met the a\n",
            "priori stopping criterion for noninferiority at the interim analysis after 827 of planned 1200\n",
            "patients were randomized. Mean 24-hour postbypass allogeneic transfusions were 16.3 (95%\n",
            "CI, 14.9 to 17.8) units in the fibrinogen concentrate group and 17.0 (95% CI, 15.6 to 18.6) units\n",
            "in the cryoprecipitate group (ratio, 0.96 [1-sided 97.5% CI, −(cid:2) to 1.09; P < .001 for\n",
            "noninferiority] [2-sided 95% CI, 0.84 to 1.09; P = .50 for superiority]). Thromboembolic\n",
            "events occurred in 26 patients (7.0%) in the fibrinogen concentrate group and 35 patients\n",
            "(9.6%) in the cryoprecipitate group.\n",
            "\n",
            "CONCLUSIONS AND RELEVANCE In patients undergoing cardiac surgery who develop clinically\n",
            "significant bleeding and hypofibrinogenemia after cardiopulmonary bypass, fibrinogen\n",
            "concentrate is noninferior to cryoprecipitate with regard to number of blood components\n",
            "transfused in a 24-hour period post bypass. Use of fibrinogen concentrate may be considered\n",
            "for management of bleeding in patients with acquired hypofibrinogenemia in cardiac surgery.\n",
            "\n",
            "TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03037424\n",
            "\n",
            "JAMA. doi:10.1001/jama.2019.17312\n",
            "Published online October 21, 2019.\n",
            "\n",
            "Visual Abstract\n",
            "\n",
            "Editorial\n",
            "\n",
            "Supplemental content\n",
            "\n",
            "Author Affiliations: Author\n",
            "affiliations are listed at the end of this\n",
            "article.\n",
            "\n",
            "Group Information: Members of the\n",
            "FIBRES Research Group are listed in\n",
            "Supplement 2.\n",
            "\n",
            "Corresponding Author: Keyvan\n",
            "Karkouti, MD, Department of\n",
            "Anesthesia and Pain Management\n",
            "and Peter Munk Cardiac Centre,\n",
            "Toronto General Hospital,\n",
            "200 Elizabeth St, 3EN-460,\n",
            "Toronto, ON M5G 2C4, Canada\n",
            "(keyvan.karkouti@uhn.ca).\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "(Reprinted) E1\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\fResearch Original Investigation\n",
            "\n",
            "Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "\n",
            "E xcessive bleeding necessitating blood component trans-\n",
            "\n",
            "fusion is common after cardiac surgery and is associ-\n",
            "ated with increased risk of morbidity and mortality and\n",
            "associated costs.1 The pathophysiology of cardiac surgery–\n",
            "related bleeding is often multifactorial but includes acquired\n",
            "hypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), which is\n",
            "associated with excessive bleeding in children2 and adults.3 In\n",
            "cases of excessive bleeding and acquired hypofibrinogen-\n",
            "emia, guidelines recommend treatment with either cryopre-\n",
            "cipitate or fibrinogen concentrate.4,5\n",
            "\n",
            "Although both products are plasma-derived, they have dis-\n",
            "tinct features. Cryoprecipitate is a nonpurified product; hence,\n",
            "in addition to fibrinogen it contains fibronectin and platelet mi-\n",
            "croparticles, as well as coagulation factors VIII, XIII, and\n",
            "von Willebrand factor.6 Its fibrinogen content varies widely\n",
            "(from 3-30 g/L per unit); in most cases it must be maintained\n",
            "and shipped in a frozen state and then thawed and pooled (typi-\n",
            "cally 5-10 unit pools) before administration; and it has a lim-\n",
            "ited shelf life after thawing (<4-6 hours), increasing wastage.7,8\n",
            "Fibrinogen concentrates are pathogen-reduced and purified;\n",
            "have standardized fibrinogen content (20 g/L); are lyophilized,\n",
            "allowing for easy storage, reconstitution, and administration;\n",
            "and have longer shelf life after reconstitution (up to 24 hours),\n",
            "which reduces wastage. There is divergent practice regarding\n",
            "the preferred product for fibrinogen replacement.9 Cryopre-\n",
            "cipitate remains the therapy of choice in many areas (including\n",
            "North America). In many European countries, however, fibrino-\n",
            "gen concentrates have replaced cryoprecipitate, even though\n",
            "very few studies have directly compared these products.10,11\n",
            "\n",
            "In this multicenter randomized clinical trial in patients un-\n",
            "dergoing cardiac surgery and requiring fibrinogen replace-\n",
            "ment because of clinically significant bleeding related to ac-\n",
            "quired hypofibrinogenemia, the objective was to determine if\n",
            "fibrinogen concentrate was noninferior to cryoprecipitate as\n",
            "measured by the amount of allogeneic blood components (red\n",
            "cells, platelets, and plasma) administered.\n",
            "\n",
            "Methods\n",
            "\n",
            "Trial Oversight\n",
            "This was an investigator-initiated, multicenter, randomized clini-\n",
            "cal trial conducted at 11 centers in Canada. The trial design and\n",
            "methodology have been previously published12; the study pro-\n",
            "tocol and statistical analysis plan are available in Supplement 1,\n",
            "and aspects of the trial design and methodology are included in\n",
            "the eMethods in Supplement 2. The trial coordinating center was\n",
            "the Department of Anesthesia and Pain Management Clinical\n",
            "Trials Unit at the University Health Network (Toronto, Ontario,\n",
            "Canada). The trial was overseen by an independent data and\n",
            "safety monitoring committee, which reviewed adverse events\n",
            "after every 100 patients and reviewed a preplanned interim analy-\n",
            "sis performed after approximately 600 evaluable patients were\n",
            "enrolled. Study monitors independently reviewed all primary\n",
            "outcomes and adverse events. The trial was performed in accor-\n",
            "dance with the principles of the Declaration of Helsinki and ap-\n",
            "plicable regulatory requirements. Research ethics board approval\n",
            "was obtained at each site before trial initiation, including approval\n",
            "\n",
            "Key Points\n",
            "\n",
            "Question Is fibrinogen concentrate noninferior to cryoprecipitate\n",
            "for treatment of bleeding related to acquired hypofibrinogenemia\n",
            "in cardiac surgery?\n",
            "\n",
            "Findings In this randomized trial of 735 adult patients who\n",
            "underwent cardiac surgery and developed clinically significant\n",
            "bleeding and hypofibrinogenemia post cardiopulmonary bypass,\n",
            "the mean number of blood components transfused within 24\n",
            "hours post bypass was 16.3 units in the fibrinogen concentrate\n",
            "group and 17.0 units in the cryoprecipitate group; ratio of the mean\n",
            "number of units transfused was 0.96, which met the prespecified\n",
            "noninferiority margin ratio of less than 1.2.\n",
            "\n",
            "Meaning For management of cardiac surgery–associated bleeding\n",
            "related to acquired hypofibrinogenemia, fibrinogen concentrate\n",
            "may be considered for fibrinogen replacement.\n",
            "\n",
            "of a delayed written consent process. Consent was delayed un-\n",
            "til after treatment (in accordance with the Canadian Tri-Council\n",
            "Policy Statements on the ethical conduct of research involving\n",
            "humans),13 in part because it is not possible to reliably predict\n",
            "before surgery which patients will require fibrinogen replacement\n",
            "for bleeding control during or after surgery, at which time there\n",
            "is a need for rapid access to therapy.\n",
            "\n",
            "Patients\n",
            "Adult patients undergoing cardiac surgery with cardiopulmo-\n",
            "nary bypass for whom fibrinogen replacement was ordered in\n",
            "response to clinically significant postbypass bleeding deemed\n",
            "related to acquired hypofibrinogenemia (fibrinogen plasma\n",
            "level <2.0 g/L by the Clauss method or FIBTEM [fibrin-based\n",
            "thromboelastometry test extrinsically activated with tissue fac-\n",
            "tor and containing the platelet inhibitor cytochalasin D]–\n",
            "derived clot amplitude at 10 minutes <10 mm by thromboelas-\n",
            "tometry) were eligible for enrollment.14,15 In line with clinical\n",
            "practice, patients with bleeding were also eligible if hypofi-\n",
            "brinogenemia was suspected but plasma fibrinogen levels were\n",
            "unavailable at the time of decision-making.\n",
            "\n",
            "Blood bank technologists screened and randomized eli-\n",
            "gible patients if they had none of the following exclusion cri-\n",
            "teria: receipt of fibrinogen concentrate or cryoprecipitate\n",
            "within 24 hours before surgery; history of severe allergic\n",
            "reaction to fibrinogen concentrate or cryoprecipitate; refusal\n",
            "of blood components for religious or other reasons; plasma\n",
            "fibrinogen level greater than 3.0 g/L within 30 minutes of\n",
            "treatment order (to avoid increasing levels above the upper\n",
            "limit of normal [4.0 g/L]); and known pregnancy.\n",
            "\n",
            "Trial Procedures\n",
            "Participants were randomly assigned (1:1) to study groups using\n",
            "a pseudorandom number generator (PROC PLAN procedure in\n",
            "SAS) in randomly permuted blocks of 4, stratified by center.\n",
            "Allocation was blinded; randomization schedule was kept at\n",
            "the blood banks in sequentially numbered opaque sealed en-\n",
            "velopes (prepared by Ergomed GmbH), which were opened\n",
            "when the order for fibrinogen replacement was received. Pa-\n",
            "tients in the fibrinogen concentrate group received 4 g of fibrino-\n",
            "gen concentrate (Fibryga; Octapharma AG), to be infused over\n",
            "\n",
            "E2\n",
            "\n",
            "JAMA Published online October 21, 2019 (Reprinted)\n",
            "\n",
            "jama.com\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\fEffect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "\n",
            "Original Investigation Research\n",
            "\n",
            "approximately 10 minutes, and those in the cryoprecipitate\n",
            "group received 10 units of cryoprecipitate, to be infused accord-\n",
            "ing to local practice. The dosages for fibrinogen concentrate16-18\n",
            "and cryoprecipitate19,20 were consistent with recently published\n",
            "trials and guidelines. Cryoprecipitate dose in Canada is standard-\n",
            "ized at 10 units per dose,21 and although the amount of fibrino-\n",
            "gen in each unit of cryoprecipitate is variable, on average each\n",
            "10-unit pool contains approximately 4 g of fibrinogen (Cana-\n",
            "dian Blood Services data; Dana Devine, PhD, Canadian Blood\n",
            "Services, email communication, September 2019).\n",
            "\n",
            "Patients were to only receive the allocated product for\n",
            "24 hours after cardiopulmonary bypass, after which only cryo-\n",
            "precipitate was used for fibrinogen replacement. It was not fea-\n",
            "sible to blind clinicians involved in product administration, but\n",
            "clinicians not involved in product administration, patients, data\n",
            "collectors, and outcome assessors were blinded. To maintain\n",
            "blinding, chart labels for both products stated “Fibrinogen Study\n",
            "Product 4 grams.” Data on race were collected for descriptive pur-\n",
            "poses as reported by patients based on predefined categories.\n",
            "\n",
            "There were no other alterations to patient care. Each hos-\n",
            "pital had an established protocol for bleeding management that\n",
            "was not altered for the purposes of this study. Tranexamic acid\n",
            "use was routine at all centers. Administration of blood com-\n",
            "ponents and hemostatic agents (other than cryoprecipitate and\n",
            "fibrinogen concentrate), use of cell salvage, and viscoelastic\n",
            "testing were based on local hospital protocols.\n",
            "\n",
            "Outcomes\n",
            "The primary efficacy outcome was cumulative allogeneic blood\n",
            "component units (red blood cells, platelets, and plasma) admin-\n",
            "istered for 24 hours after termination of cardiopulmonary bypass.\n",
            "Since2typesofplateletsareissuedinCanada(75%standardbuffy-\n",
            "coat pools from 4 allogeneic donors and 25% apheresis units from\n",
            "a single allogeneic donor), both types were counted as a 4-unit\n",
            "transfusion. Secondary outcomes included individual blood com-\n",
            "ponent units administered for 24 hours after termination of car-\n",
            "diopulmonary bypass, all transfusions from beginning of surgery\n",
            "to postoperative day 7, bleeding severity (according to the univer-\n",
            "sal definition of perioperative bleeding [UDPB])22 during the 24\n",
            "hours after cardiopulmonary bypass, and pretreatment and post-\n",
            "treatment fibrinogen levels. The UDPB components “delay in\n",
            "chest closure” and “cryoprecipitate or fibrinogen concentrate ad-\n",
            "ministration” were not used. Postoperative follow-up was 28 days.\n",
            "Adverse events were classified using the Medical Dictionary\n",
            "for Regulatory Activities (version 21.1) system of nomenclature.\n",
            "Adverse events that started or worsened on or after the first dose\n",
            "of the investigational product were classified as treatment-\n",
            "emergent. Data on duration of mechanical ventilation, intensive\n",
            "careunitstay,andhospitalizationaftersurgerywerealsocollected.\n",
            "\n",
            "Statistical Analysis\n",
            "Sample size was based on demonstrating noninferiority of fi-\n",
            "brinogen concentrate relative to cryoprecipitate with respect to\n",
            "the primary efficacy outcome. Determination of noninferior-\n",
            "ity was based on a 1-sided type I error probability of .025 and a\n",
            "noninferiority margin of 20% for the ratio of mean number of\n",
            "units transfused per group. A 20% margin was deemed by an\n",
            "expert panel to be a plausible trade-off in efficacy in exchange\n",
            "\n",
            "for the potential advantages of fibrinogen concentrate relative\n",
            "to those of cryoprecipitate. An empirical distribution function\n",
            "was calculated based on a mean of 16 units and a standard de-\n",
            "viation of 14 units (derived from a recent study on bleeding man-\n",
            "agement in cardiac surgery)23 and was used to estimate power\n",
            "by performing 10 000 simulations for each of the possible\n",
            "sample sizes. Calculations showed that 1200 patients would pro-\n",
            "vide an empirical power greater than 90% (assuming a 10% drop-\n",
            "out rate and equal mean units transfused per group).\n",
            "\n",
            "The primary analysis set comprised all randomized patients\n",
            "who had undergone cardiac surgery with cardiopulmonary by-\n",
            "pass, received at least 1 (partial or complete) dose of either treat-\n",
            "ment, and for whom informed consent was obtained. The per-\n",
            "protocol analysis excluded patients who did not undergo cardiac\n",
            "surgery with cardiopulmonary bypass, received the incorrect\n",
            "treatment, received less than 80% of the planned dose, or re-\n",
            "ceived the first treatment more than 24 hours after cardiopul-\n",
            "monary bypass. The prespecified subgroups for analysis were\n",
            "elective vs nonelective surgery, simple vs complex surgery, and\n",
            "a subgroup excluding patients who were in critical state before\n",
            "surgery (blinded adjudication based on predefined conditions\n",
            "such as acute aortic dissection or cardiac arrest immediately be-\n",
            "fore surgery). Post hoc subgroups analyzed were patients under-\n",
            "going nonelective surgery and not in critical state before surgery,\n",
            "patients who had a fibrinogen measurement before product ad-\n",
            "ministration, patients with confirmed hypofibrinogenemia\n",
            "(with Clauss method) before product administration, and patients\n",
            "with at least moderate blood loss according to the UDPB.22\n",
            "\n",
            "A 2-sample, 1-sided test of the null hypothesis that the\n",
            "treatment group fibrinogen concentrate to cryoprecipitate ra-\n",
            "tio of the mean number of allogenic blood components was\n",
            "1.2 or greater (ie, 20% noninferiority margin) was used to evalu-\n",
            "ate noninferiority using Poisson regression modeling for count\n",
            "data. Noninferiority would be demonstrated if the upper limit\n",
            "of the model-derived 1-sided 97.5% CI was less than 1.2. If non-\n",
            "inferiority was demonstrated, an analogous test for superior-\n",
            "ity was to be performed, testing the hypothesis that the treat-\n",
            "ment group ratio of the mean number of allogenic blood\n",
            "components was 1.0 or greater against the alternative that\n",
            "it was less than 1.0, at a 1-sided type I error level of α = .025.\n",
            "No α adjustment was made because of the hierarchical order-\n",
            "ing of the tests. This analysis was repeated for the secondary\n",
            "allogeneic blood component transfusion outcomes.\n",
            "\n",
            "There was 1 prespecified interim analysis after approxi-\n",
            "mately 50% of the planned 1200 evaluable patients were en-\n",
            "rolled, which used an adjusted type I error rate of .00258 ac-\n",
            "cording to the O’Brien-Fleming method24 for a noninferiority\n",
            "stop. The trial was also to be stopped for futility if the predic-\n",
            "tive power for the test of noninferiority was less than 0.25.\n",
            "\n",
            "Secondary outcomes were examined using descriptive sta-\n",
            "tistics, the Wilcoxon rank-sum test, point estimates and risk\n",
            "ratios with 2-sided 95% CIs, and the Hodges-Lehmann esti-\n",
            "mator of median differences with 95% CIs, where appropri-\n",
            "ate. Kaplan-Meier estimates for time-to-death distribution were\n",
            "calculated and graphically presented. Comparisons were pre-\n",
            "specified as superiority analyses with α = .05.\n",
            "\n",
            "Several post hoc analyses were performed: (1) noninferi-\n",
            "ority was assessed for the outcome of cumulative allogeneic\n",
            "\n",
            "jama.com\n",
            "\n",
            "(Reprinted) JAMA Published online October 21, 2019\n",
            "\n",
            "E3\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\fResearch Original Investigation\n",
            "\n",
            "Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "\n",
            "Figure 1. Patient Flow in the FIBRES Study of the Effect of Fibrinogen Concentrate vs Cryoprecipitate\n",
            "on Blood Component Transfusion After Cardiac Surgery\n",
            "\n",
            "890 Patients assessed for eligibility\n",
            "\n",
            "63 Excluded\n",
            "\n",
            "27 Physician refusal\n",
            "10 Did not meet inclusion criteria\n",
            "7 Fibrinogen level >3 g/L within 30 min\n",
            "\n",
            "of IMP order\n",
            "\n",
            "3 Enrolled in another trial\n",
            "3 Received either fibrinogen concentrate or\n",
            "cryoprecipitate within 24 h before surgery\n",
            "2 Blood bank technologist unable to randomize\n",
            "\n",
            "because of workload\n",
            "\n",
            "11 Unknown reason\n",
            "\n",
            "827 Randomized\n",
            "\n",
            "415 Randomized to receive fibrinogen concentrate\n",
            "383 Received intervention as randomized\n",
            "32 Did not receive intervention (cessation of bleeding)\n",
            "\n",
            "412 Randomized to receive cryoprecipitate\n",
            "\n",
            "383 Received intervention as randomized\n",
            "29 Did not receive intervention (cessation of bleeding)\n",
            "\n",
            "11 Lost to follow-up\n",
            "\n",
            "20 Lost to follow-up\n",
            "\n",
            "3 Patient refused to provide consent\n",
            "3 Surrogate decision maker refused to provide consent\n",
            "1 Surrogate decision maker and patient did not speak\n",
            "\n",
            "English and no translator available\n",
            "\n",
            "1 Family could not be reached to obtain consent\n",
            "1 Discharged or transferred to another facility\n",
            "\n",
            "before consent obtained\n",
            "\n",
            "1 Patient unable to provide consent (hospital did\n",
            "not allow surrogate decision maker consent)\n",
            "\n",
            "1 Consent not obtained (patient did not meet inclusion\n",
            "\n",
            "criteria [off pump])\n",
            "\n",
            "5 Patient refused to provide consent\n",
            "4 Surrogate decision maker refused to provide consent\n",
            "2 Family could not be reached to obtain consent\n",
            "5 Discharged or transferred to another facility\n",
            "\n",
            "before consent obtained\n",
            "\n",
            "1 Refused (already enrolled in another trial)\n",
            "1 Age <16 y (hospital did not allow surrogate decision\n",
            "\n",
            "maker consent)\n",
            "\n",
            "1 Consent not obtained (patient did not meet inclusion\n",
            "\n",
            "criteria [off pump])\n",
            "\n",
            "1 Unknown reason\n",
            "\n",
            "372 Included in primary analysis\n",
            "364 Included in per-protocol analysis\n",
            "\n",
            "8 Excluded\n",
            "\n",
            "4 Received <80% of planned first dose\n",
            "2 Start of IMP not within 24 h after CPB\n",
            "2 Administered IMP different from assigned IMP\n",
            "\n",
            "363 Included in primary analysis\n",
            "361 Included in per-protocol analysis\n",
            "\n",
            "2 Excluded\n",
            "\n",
            "1 Did not undergo primary cardiac surgery\n",
            "1 Administered IMP different from assigned IMP\n",
            "\n",
            "CPB indicates cardiopulmonary\n",
            "bypass; IMP, investigational\n",
            "medicinal product.\n",
            "\n",
            "blood component units administered from investigational prod-\n",
            "uct administration to 24 hours after cardiopulmonary bypass;\n",
            "(2) treatment × site interaction was accounted for by including\n",
            "site in the model for the primary outcome as a fixed-effect vari-\n",
            "able (as 3 categories based on number of patients enrolled: <40;\n",
            "40-99; >99); and (3) the relationship of critical state before sur-\n",
            "gery was explored by adjusting for it in the comparisons for the\n",
            "primary outcome and mortality. The results of secondary out-\n",
            "comes and post hoc analyses should be interpreted as explor-\n",
            "atory, as no correction for type I error was made.\n",
            "\n",
            "Variables with missing values are noted where applicable\n",
            "and patients with missing values were excluded from the rel-\n",
            "evant analyses. All analyses were performed using SAS ver-\n",
            "sion 9.4 (SAS Institute Inc).\n",
            "\n",
            "Results\n",
            "\n",
            "tee for meeting the criterion for noninferiority at the interim\n",
            "analysis. Of the 15 412 patients who underwent cardiac sur-\n",
            "gery at the 11 participating sites, 827 (5.3%) were screened and\n",
            "randomized (Figure 1). Sixty-one randomized patients were not\n",
            "treated because of cessation of bleeding. Informed consent\n",
            "could not be obtained for 31 treated patients, leaving 735 pa-\n",
            "tients in the primary analysis set (n = 372 for fibrinogen\n",
            "concentrate, n = 363 for cryoprecipitate). After excluding 10\n",
            "patients with major protocol deviations, 725 patients were in-\n",
            "cluded in the per-protocol analysis (Figure 1). No patients\n",
            "in the primary analysis set had missing transfusion or ad-\n",
            "verse event information; thus, they were all included in the\n",
            "relevant analyses.\n",
            "\n",
            "Baseline demographics and surgical characteristics were\n",
            "well balanced except for critical state before surgery (Table 1).\n",
            "Patients received a median of 4 (interquartile range [IQR], 4-4)\n",
            "g of fibrinogen concentrate and 10 (IQR, 10-10) units of cryo-\n",
            "precipitate (Table 2; eTable 1 in Supplement 2).\n",
            "\n",
            "Patient recruitment continued from February 10, 2017, to\n",
            "November 1, 2018, with the final follow-up visit on November\n",
            "28, 2018. The trial was stopped based on the recommenda-\n",
            "tion of the independent data and safety monitoring commit-\n",
            "\n",
            "Transfusions\n",
            "In the primary analysis set, mean allogeneic blood compo-\n",
            "nent units administered were 16.7 (SD, 16.4) units within\n",
            "\n",
            "E4\n",
            "\n",
            "JAMA Published online October 21, 2019 (Reprinted)\n",
            "\n",
            "jama.com\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\fEffect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "\n",
            "Original Investigation Research\n",
            "\n",
            "Table 1. Characteristics of the Study Population at Baseline\n",
            "\n",
            "Table 1. Characteristics of the Study Population at Baseline (continued)\n",
            "\n",
            "Characteristic\n",
            "\n",
            "Age, median (IQR), y\n",
            "\n",
            "Sex\n",
            "\n",
            "Women\n",
            "\n",
            "Men\n",
            "\n",
            "Race\n",
            "\n",
            "White\n",
            "\n",
            "Asian\n",
            "\n",
            "Black\n",
            "\n",
            "Aboriginal\n",
            "\n",
            "Othera\n",
            "\n",
            "Body mass index,\n",
            "median (IQR)b\n",
            "NYHA classc\n",
            "\n",
            "I (least severe)\n",
            "\n",
            "II\n",
            "\n",
            "III\n",
            "\n",
            "IV (most severe)\n",
            "\n",
            "Myocardial infarction, d\n",
            "\n",
            "No.\n",
            "\n",
            "None\n",
            "\n",
            "0-90\n",
            "\n",
            ">90\n",
            "\n",
            "Ejection fraction, %\n",
            "\n",
            "No.\n",
            "\n",
            ">50\n",
            "\n",
            "31-50\n",
            "\n",
            "21-30\n",
            "\n",
            "<21\n",
            "\n",
            "Pulmonary pressure,\n",
            "mm Hg\n",
            "\n",
            "No.\n",
            "\n",
            "≤30\n",
            "\n",
            "31-55\n",
            "\n",
            ">55\n",
            "\n",
            "Hypertension\n",
            "\n",
            "Dyslipidemia\n",
            "\n",
            "Congestive heart\n",
            "failure\n",
            "\n",
            "Atrial fibrillation\n",
            "\n",
            "Diabetes mellitus\n",
            "\n",
            "Chronic lung disease\n",
            "\n",
            "Stroke/TIA\n",
            "\n",
            "Peripheral vascular\n",
            "disease\n",
            "\n",
            "Active endocarditis\n",
            "\n",
            "CCS class IV angina\n",
            "\n",
            "Dialysis (preoperative)\n",
            "\n",
            "Intra-aortic balloon pump\n",
            "\n",
            "VAD/ECMO\n",
            "\n",
            "Critical state before\n",
            "surgeryd\n",
            "\n",
            "No. (%)\n",
            "\n",
            "Fibrinogen\n",
            "Concentrate\n",
            "(n = 372)\n",
            "\n",
            "65 (54-72)\n",
            "\n",
            "113 (30.4)\n",
            "\n",
            "259 (69.6)\n",
            "\n",
            "287 (77.2)\n",
            "\n",
            "51(13.7)\n",
            "\n",
            "3 (0.81)\n",
            "\n",
            "5 (1.3)\n",
            "\n",
            "26 (7.0)\n",
            "\n",
            "22.2\n",
            "(19.6-25.4)\n",
            "\n",
            "104 (27.9)\n",
            "\n",
            "110 (29.6)\n",
            "\n",
            "110 (29.6)\n",
            "\n",
            "48 (12.9)\n",
            "\n",
            "367\n",
            "\n",
            "294 (80.1)\n",
            "\n",
            "39 (10.6)\n",
            "\n",
            "34 (9.3)\n",
            "\n",
            "357\n",
            "\n",
            "256 (71.7)\n",
            "\n",
            "51 (14.3)\n",
            "\n",
            "28 (7.8)\n",
            "\n",
            "22 (6.2)\n",
            "\n",
            "308\n",
            "\n",
            "225 (73.1)\n",
            "\n",
            "58 (18.8)\n",
            "\n",
            "25 (8.1)\n",
            "\n",
            "234 (62.9)\n",
            "\n",
            "185 (49.7)\n",
            "\n",
            "113 (30.4)\n",
            "\n",
            "81 (21.8)\n",
            "\n",
            "80 (21.5)\n",
            "\n",
            "53 (14.3)\n",
            "\n",
            "46 (12.4)\n",
            "\n",
            "37 (10.0)\n",
            "\n",
            "19 (5.1)\n",
            "\n",
            "15 (4.0)\n",
            "\n",
            "9 (2.4)\n",
            "\n",
            "10 (2.7)\n",
            "\n",
            "9 (2.4)\n",
            "\n",
            "Cryoprecipitate\n",
            "(n = 363)\n",
            "\n",
            "64 (53-72)\n",
            "\n",
            "105 (28.9)\n",
            "\n",
            "258 (71.1)\n",
            "\n",
            "273 (75.2)\n",
            "\n",
            "58 (16.0)\n",
            "\n",
            "6 (1.6)\n",
            "\n",
            "2 (0.55)\n",
            "\n",
            "24 (6.6)\n",
            "\n",
            "22.8\n",
            "(19.6-25.6)\n",
            "\n",
            "112 (30.8)\n",
            "\n",
            "108 (29.8)\n",
            "\n",
            "103 (28.4)\n",
            "\n",
            "40 (11.0)\n",
            "\n",
            "358\n",
            "\n",
            "299 (83.5)\n",
            "\n",
            "30 (8.4)\n",
            "\n",
            "29 (8.1)\n",
            "\n",
            "347\n",
            "\n",
            "263 (75.8)\n",
            "\n",
            "57 (16.4)\n",
            "\n",
            "12 (3.5)\n",
            "\n",
            "15 (4.3)\n",
            "\n",
            "303\n",
            "\n",
            "215 (71.0)\n",
            "\n",
            "68 (22.4)\n",
            "\n",
            "20 (6.6)\n",
            "\n",
            "240 (66.1)\n",
            "\n",
            "185 (51.0)\n",
            "\n",
            "91 (25.1)\n",
            "\n",
            "80 (22.0)\n",
            "\n",
            "74 (20.4)\n",
            "\n",
            "37 (10.2)\n",
            "\n",
            "49 (13.5)\n",
            "\n",
            "34 (9.4)\n",
            "\n",
            "18 (5.0)\n",
            "\n",
            "13 (3.6)\n",
            "\n",
            "14 (3.9)\n",
            "\n",
            "3 (0.8)\n",
            "\n",
            "9 (2.5)\n",
            "\n",
            "63 (16.9)\n",
            "\n",
            "38 (10.5)\n",
            "\n",
            "(continued)\n",
            "\n",
            "No. (%)\n",
            "\n",
            "Fibrinogen\n",
            "Concentrate\n",
            "(n = 372)\n",
            "\n",
            "Cryoprecipitate\n",
            "(n = 363)\n",
            "\n",
            "88 (72-107)\n",
            "[n = 359]\n",
            "\n",
            "86 (72-106)\n",
            "[n = 352]\n",
            "\n",
            "13.4 (11.6-14.6)\n",
            "[n = 366]\n",
            "\n",
            "13.5 (11.7-14.8)\n",
            "[n = 356]\n",
            "\n",
            "189 (154-235)\n",
            "[n = 365]\n",
            "\n",
            "185 (152-230)\n",
            "[n = 356]\n",
            "\n",
            "1.02 (0.98-1.20)\n",
            "[n = 335]\n",
            "\n",
            "1.03 (0.98-1.15)\n",
            "[n = 334]\n",
            "\n",
            "Characteristic\n",
            "\n",
            "Preoperative laboratory values,\n",
            "median (IQR)\n",
            "\n",
            "Creatinine, μmol/L\n",
            "\n",
            "Hemoglobin, g/dL\n",
            "\n",
            "Platelet count, ×103/μL\n",
            "\n",
            "International\n",
            "normalized ratio\n",
            "\n",
            "Surgical factors\n",
            "\n",
            "Nonelective surgery\n",
            "\n",
            "Complex surgerye\n",
            "\n",
            "141 (37.9)\n",
            "\n",
            "267 (71.8)\n",
            "\n",
            "Procedure (% of procedures)f\n",
            "\n",
            "653 (100.0)\n",
            "\n",
            "Aortic valve procedure\n",
            "\n",
            "Surgery on aorta\n",
            "\n",
            "CABG surgery\n",
            "\n",
            "Mitral valve procedure\n",
            "\n",
            "Tricuspid valve procedure\n",
            "\n",
            "ASD/VSD repair\n",
            "\n",
            "Heart transplant\n",
            "\n",
            "Complex congenital\n",
            "\n",
            "Otherg\n",
            "\n",
            "165 (25.3)\n",
            "\n",
            "161 (24.7)\n",
            "\n",
            "153 (23.4)\n",
            "\n",
            "68 (10.4)\n",
            "\n",
            "31 (4.7)\n",
            "\n",
            "20 (3.1)\n",
            "\n",
            "18 (2.8)\n",
            "\n",
            "11 (1.7)\n",
            "\n",
            "26 (4.0)\n",
            "\n",
            "128 (35.3)\n",
            "\n",
            "260 (71.6)\n",
            "\n",
            "612 (100.0)\n",
            "\n",
            "146 (23.9)\n",
            "\n",
            "177 (28.9)\n",
            "\n",
            "146 (23.9)\n",
            "\n",
            "70 (11.4)\n",
            "\n",
            "35 (5.7)\n",
            "\n",
            "8 (1.3)\n",
            "\n",
            "10 (1.6)\n",
            "\n",
            "11 (1.8)\n",
            "\n",
            "9 (1.5)\n",
            "\n",
            "Cardiopulmonary bypass\n",
            "duration, median (IQR), min\n",
            "\n",
            "143 (102-209)\n",
            "\n",
            "134 (99-200)\n",
            "\n",
            "Abbreviations: ASD, atrial septal defect; CABG, coronary artery bypass graft;\n",
            "CCS, Canadian Cardiovascular Society; ECMO, extracorporeal membrane\n",
            "oxygenation; IQR, interquartile range; NYHA, New York Heart Association;\n",
            "TIA, transient ischemic attack; VAD, ventricular assist device; VSD, ventricular\n",
            "septal defect.\n",
            "a Other races marked as unknown or not applicable.\n",
            "b Calculated as weight in kilograms divided by height in meters squared.\n",
            "c NYHA functional classification: I = no limitation of physical activity and no\n",
            "\n",
            "symptoms; II = slight limitation of physical activity (ordinary physical activity\n",
            "results in fatigue, palpitation, dyspnea); III = marked limitation of physical\n",
            "activity (less than ordinary activity causes fatigue, palpitation, or dyspnea);\n",
            "IV = unable to carry on any physical activity without discomfort (symptoms of\n",
            "heart failure at rest).\n",
            "\n",
            "d Determined by blinded adjudication for patients who underwent emergency\n",
            "\n",
            "surgery deemed to be in a critical state, based on criteria outlined in\n",
            "Supplement 2.\n",
            "\n",
            "e Procedures other than CABG surgery only, single valve only, or repair of atrial\n",
            "\n",
            "septal defect only.\n",
            "\n",
            "f Totals exceed 100% because some patients underwent more than 1 procedure.\n",
            "g Examples of other procedures included aortic root enlargement, left\n",
            "ventricular aneurysmectomy, and left atrial appendage resection.\n",
            "\n",
            "24 hours after termination of cardiopulmonary bypass and 22.4\n",
            "(SD, 23.1) units from beginning of surgery to postoperative day\n",
            "7. The mean 24-hour postbypass cumulative allogeneic blood\n",
            "component transfusions were 16.3 (95% CI, 14.9 to 17.8) units\n",
            "in the fibrinogen concentrate group and 17.0 (95% CI, 15.6 to\n",
            "18.6) units in the cryoprecipitate group, and the mean ratio was\n",
            "0.96 (1-sided 97.5% CI, −(cid:2) to 1.09; P < .001 for nonferiority;\n",
            "2-sided 95% CI, 0.84 to 1.09; P = .50 for superiority]) (Table 3\n",
            "and Figure 2).\n",
            "\n",
            "jama.com\n",
            "\n",
            "(Reprinted) JAMA Published online October 21, 2019\n",
            "\n",
            "E5\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\fResearch Original Investigation\n",
            "\n",
            "Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "\n",
            "Table 2. Details of Intervention, Perioperative Laboratory Values, Fibrinogen Levels, and Bleeding\n",
            "\n",
            "Variable\n",
            "\n",
            "Dosage of investigational product\n",
            "\n",
            "Mean (SD)\n",
            "\n",
            "Median (IQR)\n",
            "\n",
            "Doses of investigational product, No. (%)\n",
            "\n",
            "1\n",
            "\n",
            "2\n",
            "\n",
            "3\n",
            "\n",
            "≥4\n",
            "\n",
            "Median (IQR)\n",
            "\n",
            "Fibrinogen Concentrate\n",
            "(n = 372)\n",
            "\n",
            "4.8 (2.1) g\n",
            "\n",
            "4 (4-4) g\n",
            "\n",
            "309 (83.1)\n",
            "\n",
            "49 (13.2)\n",
            "\n",
            "10 (2.7)\n",
            "\n",
            "4 (1.1)\n",
            "\n",
            "Time from start of surgery to order of first dose, h\n",
            "\n",
            "5.8 (4.5-7.3)\n",
            "\n",
            "Time from order of first dose to administration, min\n",
            "\n",
            "45 (32-62)\n",
            "\n",
            "97 (52-159)\n",
            "\n",
            "Time from end of CPB to administration\n",
            "of first dose, min\n",
            "\n",
            "Plasma fibrinogen level, g/L\n",
            "\n",
            "Pretransfusion\n",
            "\n",
            "Posttransfusion\n",
            "\n",
            "Cryoprecipitate\n",
            "(n = 363)\n",
            "\n",
            "12.9 (8.5) units\n",
            "\n",
            "10 (10-10) units\n",
            "\n",
            "296 (81.5)\n",
            "\n",
            "49 (13.5)\n",
            "\n",
            "10 (2.8)\n",
            "\n",
            "8 (2.2)\n",
            "\n",
            "5.8 (4.6-7.1)\n",
            "\n",
            "47 (37-60)\n",
            "\n",
            "104 (59-160)\n",
            "\n",
            "1.6 (1.3-1.9) [n = 352]\n",
            "\n",
            "1.6 (1.3-1.9) [n = 346]\n",
            "\n",
            "2.5 (2.1-2.9) [n = 324]\n",
            "\n",
            "2.3 (2.0-2.6) [n = 296]\n",
            "\n",
            "Change from pretransfusion\n",
            "\n",
            "0.90 (0.6-1.2) [n = 306]\n",
            "\n",
            "0.70 (0.5-1.0) [n = 280]\n",
            "\n",
            "Blood components transfused\n",
            "before randomization, mean (SD), units\n",
            "\n",
            "Cell salvage blood, mL\n",
            "\n",
            "4.3 (6.1)\n",
            "\n",
            "373 (0-918)\n",
            "\n",
            "Nadir hematocrit during cardiopulmonary bypass, %\n",
            "\n",
            "26 (23-30)\n",
            "\n",
            "4.5 (6.0)\n",
            "\n",
            "400 (0-876)\n",
            "\n",
            "25 (23-30)\n",
            "\n",
            "Hemoglobin, g/dL\n",
            "\n",
            "Intraoperative post-CPB\n",
            "\n",
            "9.1 (8.3-9.9) [n = 348]\n",
            "\n",
            "8.9 (8.2-9.7) [n = 342]\n",
            "\n",
            "Day of surgery (last recorded value)\n",
            "\n",
            "9.6 (8.6-10.9) [n = 365]\n",
            "\n",
            "9.5 (8.7-10.7) [n = 356]\n",
            "\n",
            "Postoperative day 1 (last recorded value)\n",
            "\n",
            "9.0 (8.3-9.9) [n = 367]\n",
            "\n",
            "9.0 (8.3-10.0) [n = 361]\n",
            "\n",
            "Platelet count, ×103/μL\n",
            "\n",
            "Intraoperative post-CPB\n",
            "\n",
            "107 (84-136) [n = 280]\n",
            "\n",
            "103 (81-129) [n = 278]\n",
            "\n",
            "Day of surgery (last recorded value)\n",
            "\n",
            "132 (107-165) [n = 362]\n",
            "\n",
            "133 (107-163) [n = 353]\n",
            "\n",
            "Postoperative day 1 (last recorded value)\n",
            "\n",
            "117 (91-145) [n = 366]\n",
            "\n",
            "115 (92-143) [n = 359]\n",
            "\n",
            "International normalized ratio\n",
            "\n",
            "Intraoperative post-CPB\n",
            "\n",
            "1.6 (1.4-1.8) [n = 295]\n",
            "\n",
            "1.6 (1.5-1.8) [n = 277]\n",
            "\n",
            "Day of surgery (last recorded value)\n",
            "\n",
            "1.3 (1.2-1.4) [n = 355]\n",
            "\n",
            "1.3 (1.2-1.4) [n = 340]\n",
            "\n",
            "Postoperative day 1 (last recorded value)\n",
            "\n",
            "1.2 (1.1-1.4) [n = 342]\n",
            "\n",
            "1.2 (1.1-1.3) [n = 335]\n",
            "\n",
            "Bleeding categories according to\n",
            "modified UDPB classification, No. (%)a\n",
            "\n",
            "≥2 (moderate to massive)\n",
            "\n",
            "<2 (insignificant to mild)\n",
            "\n",
            "24-h chest tube drainage, mL\n",
            "\n",
            "Reexploration, No. (%)\n",
            "\n",
            "Prothrombin complex concentrate, No. (%)\n",
            "\n",
            "Recombinant factor VII, No. (%)\n",
            "\n",
            "349 (93.8)\n",
            "\n",
            "23 (6.2)\n",
            "\n",
            "347 (95.6)\n",
            "\n",
            "16 (4.4)\n",
            "\n",
            "800 (500-1350)\n",
            "\n",
            "830 (540-1350)\n",
            "\n",
            "53 (14.2)\n",
            "\n",
            "110 (29.6)\n",
            "\n",
            "35 (9.4)\n",
            "\n",
            "44 (12.1)\n",
            "\n",
            "98 (27.0)\n",
            "\n",
            "28 (7.7)\n",
            "\n",
            "Abbreviations: CPB, cardiopulmonary\n",
            "bypass; IQR, interquartile range;\n",
            "UDPB, universal definition of\n",
            "perioperative bleeding.\n",
            "a UDPB determinants used in this\n",
            "\n",
            "study include postoperative chest\n",
            "tube output; units of red blood cells,\n",
            "plasma, and platelets transfused;\n",
            "use of factor concentrates; and\n",
            "surgical reexploration (classification\n",
            "scheme included in the eAppendix\n",
            "in Supplement 2).22 For this study\n",
            "the following components of the\n",
            "UDPB score were not used: delay in\n",
            "chest closure and use of\n",
            "cryoprecipitate or fibrinogen\n",
            "concentrate. One intraoperative\n",
            "death was included in the severe or\n",
            "massive category in the fibrinogen\n",
            "concentrate group.\n",
            "\n",
            "Noninferiority was also observed for the secondary out-\n",
            "comes of individual 24-hour and cumulative 7-day blood com-\n",
            "ponent transfusions (Table 3), as well as in the post hoc out-\n",
            "come of cumulative transfusions measured from product\n",
            "administration to 24 hours after termination of cardiopulmo-\n",
            "nary bypass (mean units, 8.6 [95% CI, 7.5 to 9.9] in the fibrino-\n",
            "gen concentrate group vs 8.9 [95% CI, 7.8 to 10.2] in the cryo-\n",
            "precipitate group; mean ratio, 0.97 [1-sided 97.5% CI, −(cid:2) to 1.18;\n",
            "P = .02 for noninferiority) and after accounting for treat-\n",
            "ment × site interaction (P < .001) (eFigure 1 in Supplement 2)\n",
            "on the primary outcome (mean ratio, 1.00 [1-sided 97.5% CI,\n",
            "\n",
            "−(cid:2) to 1.13; P = .003 for noninferiority). Noninferiority was also\n",
            "observed for all defined subgroups except for the nonelective\n",
            "group, which included all patients in critical state before sur-\n",
            "gery (Figure 2; eTable 2 in Supplement 2).\n",
            "\n",
            "Fibrinogen Levels\n",
            "Timing and number of doses of investigational product were\n",
            "similar between groups. Fibrinogen response was slightly\n",
            "greater in the fibrinogen concentrate group (median in-\n",
            "crease, 0.9 [IQR, 0.6-1.2] g/L vs 0.7 [IQR, 0.5–1.0] g/L; P < .001)\n",
            "(Table 2; eTable 1 in Supplement 2).\n",
            "\n",
            "E6\n",
            "\n",
            "JAMA Published online October 21, 2019 (Reprinted)\n",
            "\n",
            "jama.com\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\fEffect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "\n",
            "Original Investigation Research\n",
            "\n",
            "Table 3. Primary and Secondary Outcomes: Allogeneic Blood Component Transfusions\n",
            "\n",
            "Fibrinogen Concentrate\n",
            "\n",
            "Cryoprecipitate\n",
            "\n",
            "Mean Difference\n",
            "Population\n",
            "(95% CI)\n",
            "Primary Outcome: Cumulative Allogeneic Blood Components Transfused Within 24 h After Cardiopulmonary Bypassa\n",
            "\n",
            "LS Mean\n",
            "(95% CI)\n",
            "\n",
            "LS Mean\n",
            "(95% CI)\n",
            "\n",
            "Median\n",
            "(IQR)\n",
            "\n",
            "Median\n",
            "(IQR)\n",
            "\n",
            "No.\n",
            "\n",
            "No.\n",
            "\n",
            "Unadjusted Ratio\n",
            "of LS Means\n",
            "(1-Sided 97.5% CI)\n",
            "\n",
            "Noninferiority\n",
            "P Value\n",
            "\n",
            "Primary analysis set\n",
            "\n",
            "372\n",
            "\n",
            "12.0\n",
            "(5.5 to 22.0)\n",
            "\n",
            "16.3\n",
            "(14.9 to 17.8)\n",
            "\n",
            "363\n",
            "\n",
            "14.0\n",
            "(7.0 to 23.0)\n",
            "\n",
            "17.0\n",
            "(15.6 to 18.6)\n",
            "\n",
            "−0.73\n",
            "(−3.10 to 1.64)\n",
            "\n",
            "Per-protocol setb\n",
            "\n",
            "364\n",
            "\n",
            "12.0\n",
            "(6.0 to 22.0)\n",
            "\n",
            "16.4\n",
            "(15.0 to 18.0)\n",
            "\n",
            "361\n",
            "\n",
            "14.0\n",
            "(7.0 to 22.0)\n",
            "\n",
            "16.9\n",
            "(15.5 to 18.5)\n",
            "\n",
            "−0.50\n",
            "(−2.90 to 1.89)\n",
            "\n",
            "Unadjusted 0.96\n",
            "(−(cid:2) to 1.09)\n",
            "Adjusted 0.91\n",
            "(−(cid:2) to 1.03)c\n",
            "Unadjusted 0.97\n",
            "(−(cid:2) to 1.10)\n",
            "Adjusted 0.92\n",
            "(−(cid:2) to 1.05)c\n",
            "\n",
            "Secondary Outcome: Red Blood Cell Transfusions Within 24 h After Cardiopulmonary Bypass\n",
            "\n",
            "Primary analysis set\n",
            "\n",
            "372\n",
            "\n",
            "Per-protocol set\n",
            "\n",
            "364\n",
            "\n",
            "2.0\n",
            "(0.0 to 5.0)\n",
            "\n",
            "2.0\n",
            "(0.0 to 5.0)\n",
            "\n",
            "3.3\n",
            "(3.0 to 3.7)\n",
            "\n",
            "3.3\n",
            "(3.0 to 3.7)\n",
            "\n",
            "363\n",
            "\n",
            "361\n",
            "\n",
            "2.0\n",
            "(1.0 to 5.0)\n",
            "\n",
            "2.0\n",
            "(1.0 to 5.0)\n",
            "\n",
            "3.3\n",
            "(2.9 to 3.7)\n",
            "\n",
            "3.3\n",
            "(2.9 to 3.7)\n",
            "\n",
            "0.23\n",
            "(−0.55 to 1.00)\n",
            "\n",
            "0.25\n",
            "(−0.53 to 1.03)\n",
            "\n",
            "1.00\n",
            "(0 to 1.18)\n",
            "\n",
            "1.01\n",
            "(0 to 1.18)\n",
            "\n",
            "Secondary Outcome: Platelet Transfusions Within 24 h After Cardiopulmonary Bypass\n",
            "\n",
            "Primary analysis set\n",
            "\n",
            "372\n",
            "\n",
            "Per-protocol set\n",
            "\n",
            "364\n",
            "\n",
            "8.0\n",
            "(4.0 to 12.0)\n",
            "\n",
            "8.0\n",
            "(4.0 to 12.0)\n",
            "\n",
            "9.1\n",
            "(8.3 to 9.9)\n",
            "\n",
            "9.1\n",
            "(8.3 to 10.0)\n",
            "\n",
            "363\n",
            "\n",
            "361\n",
            "\n",
            "8.0\n",
            "(4.0 to 12.0)\n",
            "\n",
            "8.0\n",
            "(4.0 to 12.0)\n",
            "\n",
            "9.7\n",
            "(8.9 to 10.5)\n",
            "\n",
            "9.6\n",
            "(8.8 to 10.5)\n",
            "\n",
            "−0.46\n",
            "(−1.70 to 0.78)\n",
            "\n",
            "−0.31\n",
            "(−1.56 to 0.93)\n",
            "\n",
            "0.94\n",
            "(−(cid:2) to 1.06)\n",
            "0.95\n",
            "(−(cid:2) to 1.08)\n",
            "\n",
            "Secondary Outcome: Plasma Transfusions Within 24 h After Cardiopulmonary Bypass\n",
            "\n",
            "Primary analysis set\n",
            "\n",
            "372\n",
            "\n",
            "Per-protocol set\n",
            "\n",
            "364\n",
            "\n",
            "2.0\n",
            "(0.0 to 6.0)\n",
            "\n",
            "2.0\n",
            "(0.0 to 6.0)\n",
            "\n",
            "3.9\n",
            "(3.5 to 4.4)\n",
            "\n",
            "4.0\n",
            "(3.5 to 4.5)\n",
            "\n",
            "363\n",
            "\n",
            "361\n",
            "\n",
            "3.0\n",
            "(0.0 to 6.0)\n",
            "\n",
            "3.0\n",
            "(0.0 to 6.0)\n",
            "\n",
            "4.1\n",
            "(3.6 to 4.6)\n",
            "\n",
            "4.0\n",
            "(3.6 to 4.6)\n",
            "\n",
            "−0.04\n",
            "(−0.97 to 0.89)\n",
            "\n",
            "0.04\n",
            "(−0.91 to 0.98)\n",
            "\n",
            "0.96\n",
            "(−(cid:2) to 1.15)\n",
            "0.98\n",
            "(−(cid:2) to 1.17)\n",
            "\n",
            "Secondary Outcome: Cumulative Allogeneic Blood Components Transfused Within 7 d After Start of Surgery\n",
            "\n",
            "Primary analysis set\n",
            "\n",
            "372\n",
            "\n",
            "15.5\n",
            "(6.0 to 29.5)\n",
            "\n",
            "22.5\n",
            "(20.5 to 24.7)\n",
            "\n",
            "363\n",
            "\n",
            "17.0\n",
            "(9.0 to 28.0)\n",
            "\n",
            "22.3\n",
            "(20.3 to 24.5)\n",
            "\n",
            "0.21\n",
            "(−3.14 to 3.55)\n",
            "\n",
            "Per-protocol set\n",
            "\n",
            "364\n",
            "\n",
            "15.5\n",
            "(6.0 to 29.0)\n",
            "\n",
            "22.5\n",
            "(20.5 to 24.8)\n",
            "\n",
            "361\n",
            "\n",
            "17.0\n",
            "(9.0 to 28.0)\n",
            "\n",
            "22.2\n",
            "(20.2 to 24.5)\n",
            "\n",
            "0.31\n",
            "(−3.07 to 3.70)\n",
            "\n",
            "Unadjusted 1.01\n",
            "(0 to 1.15)\n",
            "\n",
            "Adjusted 0.96\n",
            "(−(cid:2) to 1.09)c\n",
            "Unadjusted 1.01\n",
            "(0 to 1.16)\n",
            "\n",
            "Adjusted 0.96\n",
            "(−(cid:2) to 1.09)c\n",
            "\n",
            "<.001\n",
            "\n",
            "<.001\n",
            "\n",
            "<.001\n",
            "\n",
            "<.001\n",
            "\n",
            ".02\n",
            "\n",
            ".02\n",
            "\n",
            "<.001\n",
            "\n",
            "<.001\n",
            "\n",
            ".008\n",
            "\n",
            ".01\n",
            "\n",
            ".005\n",
            "\n",
            "<.001\n",
            "\n",
            ".007\n",
            "\n",
            "<.001\n",
            "\n",
            "Abbreviation: LS, least-squares.\n",
            "a Units of allogenic blood components counted as follows: each red blood cell\n",
            "unit = 1 unit, each 250-mL plasma unit = 1 unit, each 500-mL plasma unit = 2\n",
            "units, each platelet dose = 4 units.\n",
            "\n",
            "b Per-protocol set excluded patients who did not undergo cardiac surgery with\n",
            "\n",
            "cardiopulmonary bypass, received the incorrect treatment, received less than\n",
            "80% of the planned dose, or received the first treatment more than 24 hours\n",
            "after cardiopulmonary bypass.\n",
            "\n",
            "c Adjusted for critical state before surgery (post hoc analysis).\n",
            "\n",
            "Adverse Events and Other Outcomes\n",
            "Treatment-emergent adverse event profiles were similar\n",
            "(Table 4; eTable 3 in Supplement 2), as were the duration of\n",
            "intubation, intensive care unit stay, and hospital stay (Table 4).\n",
            "There were 35 deaths (9.4%) in the fibrinogen concentrate\n",
            "group and 27 (7.4%) in the cryoprecipitate group (unadjusted\n",
            "hazard ratio, 1.28 [95% CI, 0.77 to 2.12]; P = .35) (Kaplan-\n",
            "Meier curves shown in eFigures 2 and 3 in Supplement 2). Death\n",
            "rates were also not significantly different when stratified by\n",
            "critical state before surgery (fibrinogen concentrate vs cryo-\n",
            "precipitate: 19/63 [30.2%] vs 12/38 [31.6%] in critical state pa-\n",
            "tients; 16/309 [5.2%] vs 15/325 [4.6%] in remaining patients)\n",
            "and after risk adjustment for critical state (post hoc analysis\n",
            "hazard ratio, 1.03 [95% CI, 0.62 to 1.70]; P = .92) (results from\n",
            "post hoc analyses reported in eTables 4 and 5 in Supple-\n",
            "ment 2). Thromboembolic adverse events were observed in 26\n",
            "patients (7.0%) in the fibrinogen group and 35 patients (9.6%)\n",
            "in the cryoprecipitate group (unadjusted odds ratio, 0.70 [95%\n",
            "CI, 0.42 to 1.20]) (Table 4).\n",
            "\n",
            "Discussion\n",
            "\n",
            "In this study of patients who experienced bleeding after car-\n",
            "diac surgery and required fibrinogen replacement as part of rou-\n",
            "tine clinical practice, the primary finding was that fibrinogen\n",
            "concentrate was noninferior to cryoprecipitate as measured by\n",
            "the number of blood components transfused.\n",
            "\n",
            "The study protocol, which did not modify clinical prac-\n",
            "tice and used a delayed (postintervention) consent process,\n",
            "successfully randomized the small proportion of patients\n",
            "with bleeding who were ordered fibrinogen replacement\n",
            "(comprising approximately 5% of patients who underwent\n",
            "cardiac surgery at participating centers during the study\n",
            "period). The groups were well balanced for baseline vari-\n",
            "ables except for critical state before surgery, an important\n",
            "prognostic variable that was more prevalent in the fibrino-\n",
            "gen concentrate group. The occurrence of adverse events\n",
            "was comparable between the groups, although there was\n",
            "\n",
            "jama.com\n",
            "\n",
            "(Reprinted) JAMA Published online October 21, 2019\n",
            "\n",
            "E7\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\fResearch Original Investigation\n",
            "\n",
            "Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "\n",
            "Figure 2. Ratio of Mean Number of Allogeneic Blood Components Transfused in the 24 Hours\n",
            "After Cardiopulmonary Bypass for the Primary Analysis Set, Per-Protocol Analysis Set,\n",
            "and A Priori–Defined Subgroups\n",
            "\n",
            "Favors\n",
            "Fibrinogen\n",
            "Concentrate\n",
            "\n",
            "Favors\n",
            "Cryoprecipitate\n",
            "\n",
            "Group/Subgroup\n",
            "Primary analysis set\n",
            "\n",
            "Per-protocol analysis set\n",
            "\n",
            "Excluding patients in critical state\n",
            "\n",
            "Elective surgery\n",
            "\n",
            "Nonelective surgery\n",
            "\n",
            "Complex surgery\n",
            "\n",
            "Noncomplex surgery\n",
            "\n",
            "Ratio (97.5% CI)\n",
            "0.96 (–∞ to 1.09)\n",
            "\n",
            "0.97 (–∞ to 1.10)\n",
            "\n",
            "0.84 (–∞ to 0.96)\n",
            "\n",
            "0.81 (–∞ to 0.96)\n",
            "\n",
            "1.09 (0 to 1.31)\n",
            "\n",
            "0.98 (–∞ to 1.13)\n",
            "\n",
            "0.86 (–∞ to 1.12)\n",
            "\n",
            "0.7\n",
            "\n",
            "1.2\n",
            "Ratio of Mean No. of Units (97.5% CI)\n",
            "\n",
            "1\n",
            "\n",
            "2\n",
            "\n",
            "All patients in critical state were in the\n",
            "nonelective subgroup. Blue dashed\n",
            "line at x = 1.2 indicates the\n",
            "noninferiority margin.\n",
            "\n",
            "Table 4. Treatment-Emergent Adverse Events and Other Measured Outcomes at 28-Day Follow-up\n",
            "\n",
            "Outcome\n",
            "\n",
            "Any adverse event\n",
            "\n",
            "No. of events\n",
            "\n",
            "Any serious adverse event\n",
            "\n",
            "No. of events\n",
            "\n",
            "Thromboembolic adverse eventsa\n",
            "\n",
            "No. of events\n",
            "\n",
            "Stroke/TIA\n",
            "\n",
            "DVT/PE\n",
            "\n",
            "Myocardial infarction\n",
            "\n",
            "Other vessel thrombosis\n",
            "\n",
            "Amaurosis fugax\n",
            "\n",
            "Disseminated intravascular coagulation\n",
            "\n",
            "Thrombophlebitis\n",
            "\n",
            "Acute kidney injuryb\n",
            "\n",
            "Hepatobiliary disordersc\n",
            "\n",
            "Duration of mechanical ventilation,\n",
            "median (IQR), d\n",
            "\n",
            "Duration of intensive care unit stay,\n",
            "median (IQR), d\n",
            "\n",
            "Duration of hospitalization,\n",
            "median (IQR), d\n",
            "\n",
            "No. (%)\n",
            "\n",
            "Fibrinogen Concentrate\n",
            "(n = 372)\n",
            "\n",
            "248 (66.7)\n",
            "\n",
            "623\n",
            "\n",
            "117 (31.5)\n",
            "\n",
            "224\n",
            "\n",
            "26 (7.0)\n",
            "\n",
            "27\n",
            "\n",
            "17 (4.6)\n",
            "\n",
            "5 (1.3)\n",
            "\n",
            "3 (0.8)\n",
            "\n",
            "0\n",
            "\n",
            "0\n",
            "\n",
            "1 (0.3)\n",
            "\n",
            "1 (0.3)\n",
            "\n",
            "48 (12.9)\n",
            "\n",
            "32 (8.6)\n",
            "\n",
            "Cryoprecipitate\n",
            "(n = 363)\n",
            "\n",
            "264 (72.7)\n",
            "\n",
            "673\n",
            "\n",
            "126 (34.7)\n",
            "\n",
            "264\n",
            "\n",
            "35 (9.6)\n",
            "\n",
            "39\n",
            "\n",
            "18 (5.0)\n",
            "\n",
            "9 (2.5)\n",
            "\n",
            "4 (1.1)\n",
            "\n",
            "7 (1.9)\n",
            "\n",
            "1 (0.3)\n",
            "\n",
            "0\n",
            "\n",
            "0\n",
            "\n",
            "48 (13.2)\n",
            "\n",
            "37 (10.2)\n",
            "\n",
            "1.3 (0.7-5.0) [n = 337]\n",
            "\n",
            "1.3 (0.7-4.2) [n = 342]\n",
            "\n",
            "2.9 (1.4-5.7) [n = 352]\n",
            "\n",
            "2.8 (1.2-5.6) [n = 345]\n",
            "\n",
            "8.2 (6.3-13.0) [n = 314]\n",
            "\n",
            "9.0 (6.3-13.3) [n = 308]\n",
            "\n",
            "Abbreviations: DVT, deep vein\n",
            "thrombosis; PE, pulmonary\n",
            "embolism; TIA, transient ischemic\n",
            "attack.\n",
            "a Patients who experienced more\n",
            "\n",
            "than 1 event are counted only once\n",
            "in the total.\n",
            "\n",
            "b Acute kidney injury was defined\n",
            "as greater than a 2-fold increase\n",
            "in creatinine or kidney failure\n",
            "requiring hemodialysis within\n",
            "28 days of surgery.\n",
            "\n",
            "c Hepatobiliary disorders were\n",
            "\n",
            "defined by the Medical Dictionary\n",
            "for Regulatory Activities (version\n",
            "21.1) system of nomenclature.\n",
            "\n",
            "a nonsignificant difference of 2.0% in mortality. This\n",
            "seemed to be related to the between-group imbalance in the\n",
            "number of patients in critical state before surgery.\n",
            "\n",
            "The study objective was to compare the 2 currently rec-\n",
            "ommended therapies for fibrinogen replacement4,5 under\n",
            "usual conditions of clinical care. Thus, it did not include a\n",
            "placebo group to determine the efficacy of fibrinogen\n",
            "replacement per se, nor did it attempt to identify the appro-\n",
            "priate threshold for fibrinogen replacement.16 A recent sys-\n",
            "tematic review comparing fibrinogen concentrates with\n",
            "cryoprecipitate in patients with bleeding10 identified 1 ran-\n",
            "domized trial (with high risk for bias)19 and 3 observational\n",
            "studies25-27 and concluded that there was insufficient evi-\n",
            "dence to recommend one product over the other. Another\n",
            "\n",
            "review of trauma, obstetric, and gastrointestinal bleeding\n",
            "populations reached similar conclusions.9 This study pro-\n",
            "vides further data regarding the comparative efficacy and\n",
            "adverse event profile of these 2 products.\n",
            "\n",
            "The noninferiority finding can inform the choice of cryo-\n",
            "precipitate or fibrinogen concentrate for treatment of bleed-\n",
            "ing related to acquired hypofibrinogenemia. A core tenet and\n",
            "major regulatory driver in transfusion medicine is the pre-\n",
            "cautionary principle that requires risk-mitigation strategies\n",
            "to be instituted even if there is only a theoretical risk of\n",
            "harm.28 Consistent with this principle, the US Food and Drug\n",
            "Administration blood safety strategy recommends the use of\n",
            "pathogen-reduced blood products when feasible.28 Cur-\n",
            "rently, there are no known impending infectious threats for\n",
            "\n",
            "E8\n",
            "\n",
            "JAMA Published online October 21, 2019 (Reprinted)\n",
            "\n",
            "jama.com\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\fEffect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "\n",
            "Original Investigation Research\n",
            "\n",
            "recipients of cryoprecipitate; however, the history of blood\n",
            "pathogens suggests that plasma-derived products have\n",
            "transmitted pathogens in the past and may do so in the\n",
            "future.29 In addition, mathematical models of emerging\n",
            "pathogens suggest that the association of plasma-derived\n",
            "products (such as cryoprecipitate) with outcomes and costs\n",
            "may be substantial.30 In this regard, fibrinogen concentrate\n",
            "may be preferred to cryoprecipitate because it is pathogen-\n",
            "reduced. Another advantage of fibrinogen concentrate is\n",
            "that in most situations it can be logistically simpler to deliver\n",
            "to the bedside of a patient with bleeding. One important\n",
            "consideration is the cost differential that currently favors\n",
            "cryoprecipitate, but this varies across regions, and the most\n",
            "recent economic analysis failed to include the costs of future\n",
            "emerging pathogens and did not include comprehensive\n",
            "activity-based costing.31\n",
            "\n",
            "Limitations\n",
            "This study has several limitations. First, since the aim was to\n",
            "compare the 2 products when used under usual conditions of\n",
            "care, it was not logistically possible to institute a standard-\n",
            "ized transfusion protocol across the sites or to blind clini-\n",
            "cians to treatment assignment. Although a post hoc analysis\n",
            "showed that there were treatment × site interactions, account-\n",
            "ing for the interactions did not have a material effect on the\n",
            "primary outcome. Moreover, postoperative hemoglobin, plate-\n",
            "let count, and coagulation measures were similar between\n",
            "groups (Table 2), suggesting that transfusion practice was\n",
            "consistent in both groups. In addition, the results were con-\n",
            "sistent when transfusions were measured from beginning of\n",
            "surgery to postoperative day 7 (a priori analysis) or after ad-\n",
            "ministration of investigational product (post hoc analysis),\n",
            "which suggests that lack of blinding did not influence the tim-\n",
            "ing of transfusions relative to product administration. Of note,\n",
            "to ensure that all transfusions and adverse events were col-\n",
            "lected without bias, patients and outcome assessors were\n",
            "blinded to treatment allocation and independent monitors re-\n",
            "\n",
            "viewed all transfusion and adverse events. Second, while the\n",
            "study had few exclusion criteria, it included only patients un-\n",
            "dergoing cardiac surgery with bleeding, and its findings may\n",
            "therefore not be generalizable to other settings where fibrino-\n",
            "gen replacement is required. This would primarily be other\n",
            "types of surgery, trauma, and postpartum hemorrhage,32 but\n",
            "most evidence suggests that the role of fibrinogen is similar\n",
            "in these settings.33,34 Third, because of the pragmatic design\n",
            "of the study, strict timing of laboratory assessments could not\n",
            "be enforced. However, only less than 5% of patients had no\n",
            "measured fibrinogen levels before product administration. Re-\n",
            "lated to this, a small proportion of patients had fibrinogen val-\n",
            "ues above recommended thresholds when treatment order was\n",
            "received. However, this is consistent with recent experience\n",
            "in major bleeding,32 and ongoing bleeding from sample col-\n",
            "lection to therapy means that actual fibrinogen levels at the\n",
            "time of therapy were likely lower than measured values.\n",
            "Fourth, fibrinogen content is standardized in fibrinogen con-\n",
            "centrate but is highly variable in cryoprecipitate. As a result,\n",
            "some patients in the cryoprecipitate group likely received much\n",
            "less or much more than 4 g of fibrinogen. While this is one of\n",
            "the inherent limitations of cryoprecipitate, observed differ-\n",
            "ences in pretreatment and posttreatment fibrinogen levels sug-\n",
            "gest that on average both groups received clinically similar\n",
            "amounts of fibrinogen.\n",
            "\n",
            "Conclusions\n",
            "\n",
            "In patients undergoing cardiac surgery who develop clini-\n",
            "cally significant bleeding and hypofibrinogenemia after car-\n",
            "diopulmonary bypass, fibrinogen concentrate is noninferior\n",
            "to cryoprecipitate with regard to number of blood compo-\n",
            "nents transfused in a 24-hour period post bypass. Use of fi-\n",
            "brinogen concentrate may be considered for management of\n",
            "bleeding in patients with acquired hypofibrinogenemia in car-\n",
            "diac surgery.\n",
            "\n",
            "ARTICLE INFORMATION\n",
            "\n",
            "Accepted for Publication: October 2, 2019.\n",
            "\n",
            "Published Online: October 21, 2019.\n",
            "doi:10.1001/jama.2019.17312\n",
            "\n",
            "Author Affiliations: Department of Laboratory\n",
            "Medicine and Molecular Diagnostics, Sunnybrook\n",
            "Health Sciences Centre, Toronto, Ontario, Canada\n",
            "(Callum); Laboratory Medicine Program, University\n",
            "Health Network, Toronto, Ontario, Canada\n",
            "(Callum); Department of Laboratory Medicine and\n",
            "Pathobiology, University of Toronto, Toronto,\n",
            "Ontario, Canada (Callum); Peter Munk Cardiac\n",
            "Centre, University Health Network, Toronto,\n",
            "Ontario, Canada (Farkouh, Rao, Carroll, Grewal,\n",
            "Karkouti); Heart and Stroke Richard Lewar Centre,\n",
            "University of Toronto, Toronto, Ontario, Canada\n",
            "(Farkouh); Interdepartmental Division of Critical\n",
            "Care, Department of Medicine, University of\n",
            "Toronto, Toronto, Ontario, Canada (Scales,\n",
            "Karkouti); Sunnybrook Research Institute,\n",
            "Department of Critical Care Medicine, Sunnybrook\n",
            "Health Sciences Centre, Toronto, Ontario, Canada\n",
            "(Scales); Faculty of Health Sciences, McMaster\n",
            "\n",
            "University, Hamilton, Ontario, Canada (Heddle);\n",
            "Department of Medicine, McMaster University,\n",
            "Hamilton, Ontario, Canada (Heddle, Crowther);\n",
            "University Health Network, Division of\n",
            "Cardiovascular Surgery, Toronto General Hospital,\n",
            "Toronto, Ontario, Canada (Rao); University of\n",
            "Toronto, Toronto, Ontario, Canada (Rao, Carroll,\n",
            "Grewal); Department of Biostatistics, ERGOMED\n",
            "CDS GmbH, Cologne, Germany (Hucke);\n",
            "Department of Anesthesia and Pain Management,\n",
            "Sinai Health System, Women’s College Hospital,\n",
            "University Health Network, Toronto, Ontario,\n",
            "Canada (Carroll, Grewal, Karkouti); Department of\n",
            "Anesthesiology, Pharmacology and Therapeutics;\n",
            "University of British Columbia, Vancouver, Canada\n",
            "(Brar); Royal Columbian Hospital, Vancouver, British\n",
            "Columbia, Canada (Brar); Anesthesiology\n",
            "Department, Institut universitaire de cardiologie et\n",
            "de pneumologie de Québec-Université Laval,\n",
            "Québec City, Québec, Canada (Bussières);\n",
            "Departments of Anesthesiology, Perioperative and\n",
            "Pain Medicine, and Surgery, University of Manitoba,\n",
            "Winnipeg, Canada (Grocott); Department of\n",
            "Anesthesia and Perioperative Medicine, Western\n",
            "\n",
            "University, London, Ontario, Canada (Harle);\n",
            "St Michael’s Hospital, Division of Transfusion\n",
            "Medicine, Department of Laboratory Medicine and\n",
            "Pathobiology, University of Toronto, Toronto,\n",
            "Ontario, Canada (Pavenski); Department of\n",
            "Anesthesiology, Montréal Heart Institute,\n",
            "Université de Montréal, Montréal, Québec, Canada\n",
            "(Rochon); Department of Anesthesiology and\n",
            "Perioperative Medicine; Kingston General Hospital,\n",
            "Queen’s University, Kingston, Ontario, Canada\n",
            "(Saha); Department of Pathology and Molecular\n",
            "Medicine, Kingston Health Science Center, Queen’s\n",
            "University, Kingston, Ontario, Canada (Shepherd);\n",
            "Department of Anesthesiology; Hamilton Health\n",
            "Sciences Corporation, McMaster University,\n",
            "Hamilton, Ontario, Canada (Syed); University of\n",
            "Ottawa Heart Institute, Division of Cardiac\n",
            "Anesthesiology and Critical Care, Department of\n",
            "Anesthesia and Pain Medicine, University of Ottawa\n",
            "School of Epidemiology and Public Health, Ottawa,\n",
            "Ontario, Canada (Tran); Cardiac Surgery, Royal\n",
            "Columbian Hospital, University of British Columbia,\n",
            "Vancouver, Canada (Wong); McMaster Centre for\n",
            "Transfusion Research, Department of Medicine,\n",
            "\n",
            "jama.com\n",
            "\n",
            "(Reprinted) JAMA Published online October 21, 2019\n",
            "\n",
            "E9\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\fResearch Original Investigation\n",
            "\n",
            "Effect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "\n",
            "McMaster University, Hamilton, Ontario, Canada\n",
            "(Zeller); Department of Anesthesia and Institute of\n",
            "Health Policy, Management, and Evaluation,\n",
            "University of Toronto, Toronto, Ontario, Canada\n",
            "(Karkouti).\n",
            "\n",
            "Author Contributions: Drs Hucke and Karkouti had\n",
            "full access to all of the data in the study and take\n",
            "responsibility for the integrity of the data and the\n",
            "accuracy of the data analysis.\n",
            "Concept and design: Callum, Farkouh, Scales,\n",
            "Heddle, Crowther, Rao, Hucke, Grocott, Karkouti.\n",
            "Acquisition, analysis, or interpretation of data:\n",
            "Callum, Farkouh, Scales, Heddle, Rao, Hucke,\n",
            "Carroll, Grewal, Brar, Bussières, Grocott, Harle,\n",
            "Pavenski, Rochon, Saha, Shepherd, Syed, Tran,\n",
            "Wong, Zeller, Karkouti.\n",
            "Drafting of the manuscript: Callum, Grocott, Tran,\n",
            "Karkouti.\n",
            "Critical revision of the manuscript for important\n",
            "intellectual content: All authors.\n",
            "Statistical analysis: Callum, Hucke, Karkouti.\n",
            "Obtained funding: Karkouti.\n",
            "Administrative, technical, or material support:\n",
            "Callum, Farkouh, Crowther, Rao, Carroll, Grewal,\n",
            "Brar, Grocott, Harle, Pavenski, Rochon, Saha,\n",
            "Shepherd, Syed, Tran, Wong, Karkouti.\n",
            "Supervision: Callum, Carroll, Brar, Bussières,\n",
            "Grocott, Harle, Pavenski, Rochon, Saha, Shepherd,\n",
            "Tran, Wong, Zeller, Karkouti.\n",
            "\n",
            "Conflict of Interest Disclosures: Dr Callum\n",
            "reported receiving grants from Canadian Blood\n",
            "Services, Octapharma, and CSL Behring during the\n",
            "conduct of the study. Dr Farkouh reported receiving\n",
            "grants from Amgen and Novo Nordisk. Dr Scales\n",
            "reported receiving grants from Canadian Institute\n",
            "for Health Research. Dr Heddle reported receiving\n",
            "nonfinancial support from Octapharma during the\n",
            "conduct of the study and receiving grants from\n",
            "Canadian Blood Services. Dr Crowther reported\n",
            "receiving grants or personal fees from Bayer, Pfizer,\n",
            "BMS Canada, CSL Behring, Servier Canada, and\n",
            "Diagnostica Stago. Dr Rao reported receiving grants\n",
            "from Octapharma during the conduct of the study\n",
            "and receiving personal fees from Medtronic and\n",
            "Abbott. Dr Hucke reported receiving grants from\n",
            "Octapharma during the conduct of the study.\n",
            "Dr Pavenski reported serving as a member of the\n",
            "National Advisory Committee on Blood and Blood\n",
            "Products (Canada) and the Ontario Blood Advisory\n",
            "Committee (Ontario). Dr Tran reported receiving\n",
            "grants from Octapharma during the conduct of the\n",
            "study. Dr Zeller reported receiving grants from\n",
            "Canadian Blood Services and receiving personal\n",
            "fees from Pfizer. Dr Karkouti reported receiving\n",
            "grants and personal fees from Octapharma and\n",
            "Instrumentation Laboratory during the conduct of\n",
            "the study. No other disclosures were reported.\n",
            "\n",
            "Funding/Support: The trial was supported by an\n",
            "unrestricted grant from Octapharma AG (Lachen,\n",
            "Switzerland), which also provided the fibrinogen\n",
            "concentrate. Cryoprecipitate was provided by the\n",
            "Canadian Blood Services (Ottawa, Ontario) and\n",
            "Héma-Québec (Ville de Québec, Québec, Canada).\n",
            "\n",
            "Role of the Funders/Sponsors: Octapharma,\n",
            "Canadian Blood Services, and Héma-Québec had no\n",
            "role in the design and conduct of the study;\n",
            "collection, management, analysis, and\n",
            "interpretation of the data; preparation, review, or\n",
            "approval of the manuscript; and decision to submit\n",
            "the manuscript for publication.\n",
            "\n",
            "Meeting Presentation: Presented at the\n",
            "AABB Annual Meeting; October 21, 2019;\n",
            "San Antonio, Texas.\n",
            "\n",
            "Data Sharing Statement: See Supplement 3.\n",
            "\n",
            "Additional Contributions: We thank all the\n",
            "patients and clinicians who participated in this\n",
            "study, all members of the study teams at the\n",
            "participating centers, members of study\n",
            "committees and monitoring team, the Octapharma\n",
            "team (Sri Adapa, MBA [Octapharma Canada Inc];\n",
            "Oliver Hegener, PhD, Sigurd Knaub, PhD, and\n",
            "Cristina Solomon, MD [Octapharma AG,\n",
            "Switzerland]; and Bruce Schwartz, PhD\n",
            "[Octapharma USA Inc]), and Dr Kathryn Webert,\n",
            "MD (Canadian Blood Services) for their support.\n",
            "None of these individuals received compensation\n",
            "for their roles in the study; however, the\n",
            "Octapharma team members were employees of\n",
            "Octapharma at time of study. Editorial assistance\n",
            "for revisions of the manuscript was provided by\n",
            "Abigail Baines, PhD, of Portland Medical\n",
            "Communications (Manchester, United Kingdom),\n",
            "who received compensation for her contributions.\n",
            "\n",
            "REFERENCES\n",
            "\n",
            "1. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI,\n",
            "Culliford L, Angelini GD. Increased mortality,\n",
            "postoperative morbidity, and cost after red blood\n",
            "cell transfusion in patients having cardiac surgery.\n",
            "Circulation. 2007;116(22):2544-2552. doi:10.1161/\n",
            "CIRCULATIONAHA.107.698977\n",
            "\n",
            "2. Faraoni D, Willems A, Savan V, Demanet H,\n",
            "De Ville A, Van der Linden P. Plasma fibrinogen\n",
            "concentration is correlated with postoperative\n",
            "blood loss in children undergoing cardiac surgery:\n",
            "a retrospective review. Eur J Anaesthesiol. 2014;31\n",
            "(6):317-326. doi:10.1097/EJA.\n",
            "0000000000000043\n",
            "\n",
            "3. Karkouti K, Callum J, Crowther MA, et al. The\n",
            "relationship between fibrinogen levels after\n",
            "cardiopulmonary bypass and large volume red cell\n",
            "transfusion in cardiac surgery: an observational\n",
            "study. Anesth Analg. 2013;117(1):14-22. doi:10.1213/\n",
            "ANE.0b013e318292efa4\n",
            "\n",
            "4. Spahn DR, Bouillon B, Cerny V, et al. The\n",
            "European guideline on management of major\n",
            "bleeding and coagulopathy following trauma: fifth\n",
            "edition. Crit Care. 2019;23(1):98. doi:10.1186/\n",
            "s13054-019-2347-3\n",
            "\n",
            "5. Boer C, Meesters MI, Milojevic M, et al; Task\n",
            "Force on Patient Blood Management for Adult\n",
            "Cardiac Surgery of the European Association for\n",
            "Cardio-Thoracic Surgery (EACTS) and the European\n",
            "Association of Cardiothoracic Anaesthesiology\n",
            "(EACTA). 2017 EACTS/EACTA Guidelines on patient\n",
            "blood management for adult cardiac surgery.\n",
            "J Cardiothorac Vasc Anesth. 2018;32(1):88-120. doi:\n",
            "10.1053/j.jvca.2017.06.026\n",
            "\n",
            "6. Callum JL, Karkouti K, Lin Y. Cryoprecipitate:\n",
            "the current state of knowledge. Transfus Med Rev.\n",
            "2009;23(3):177-188. doi:10.1016/j.tmrv.2009.03.001\n",
            "\n",
            "7. Dunbar NM, Olson NJ, Szczepiorkowski ZM,\n",
            "et al. Blood component transfusion and wastage\n",
            "rates in the setting of massive transfusion in three\n",
            "regional trauma centers. Transfusion. 2017;57(1):45-\n",
            "52. doi:10.1111/trf.13880\n",
            "\n",
            "8. Yazer MH, Dunbar NM, Cohn C, et al; Biomedical\n",
            "Excellence for Safer Transfusion (BEST)\n",
            "Collaborative. Blood product transfusion and\n",
            "\n",
            "wastage rates in obstetric hemorrhage. Transfusion.\n",
            "2018;58(6):1408-1413. doi:10.1111/trf.14571\n",
            "\n",
            "9. Novak A, Stanworth SJ, Curry N. Do we still need\n",
            "cryoprecipitate? cryoprecipitate and fibrinogen\n",
            "concentrate as treatments for major\n",
            "hemorrhage—how do they compare? Expert Rev\n",
            "Hematol. 2018;11(5):351-360. doi:10.1080/17474086.\n",
            "2018.1458610\n",
            "\n",
            "10. Jensen NH, Stensballe J, Afshari A. Comparing\n",
            "efficacy and safety of fibrinogen concentrate to\n",
            "cryoprecipitate in bleeding patients: a systematic\n",
            "review. Acta Anaesthesiol Scand. 2016;60(8):1033-\n",
            "1042. doi:10.1111/aas.12734\n",
            "\n",
            "11. Li JY, Gong J, Zhu F, et al. Fibrinogen\n",
            "concentrate in cardiovascular surgery:\n",
            "a meta-analysis of randomized controlled trials.\n",
            "Anesth Analg. 2018;127(3):612-621. doi:10.1213/\n",
            "ANE.0000000000003508\n",
            "\n",
            "12. Karkouti K, Callum J, Rao V, et al. Protocol for\n",
            "a phase III, non-inferiority, randomised comparison\n",
            "of a new fibrinogen concentrate versus\n",
            "cryoprecipitate for treating acquired\n",
            "hypofibrinogenaemia in bleeding cardiac surgical\n",
            "patients: the FIBRES trial. BMJ Open. 2018;8(4):\n",
            "e020741. doi:10.1136/bmjopen-2017-020741\n",
            "\n",
            "13. Canadian Institutes of Health Research.\n",
            "Introducing TCPS 2 (2018)—Tri-Council Policy\n",
            "Statement: Ethical Conduct for Research Involving\n",
            "Humans. Government of Canada website.\n",
            "http://www.pre.ethics.gc.ca/eng/nr-cp_2019-06-\n",
            "05.html. Published August 15, 2019. Accessed\n",
            "October 8, 2019.\n",
            "\n",
            "14. Erdoes G, Gerster G, Colucci G, Kaiser H, Alberio\n",
            "L, Eberle B. Prediction of post-weaning fibrinogen\n",
            "status during cardiopulmonary bypass: an\n",
            "observational study in 110 patients. PLoS One. 2015;\n",
            "10(5):e0126692. doi:10.1371/journal.pone.0126692\n",
            "\n",
            "15. Mace H, Lightfoot N, McCluskey S, et al. Validity\n",
            "of thromboelastometry for rapid assessment of\n",
            "fibrinogen levels in heparinized samples during\n",
            "cardiac surgery: a retrospective, single-center,\n",
            "observational study. J Cardiothorac Vasc Anesth.\n",
            "2016;30(1):90-95. doi:10.1053/j.jvca.2015.04.030\n",
            "\n",
            "16. Bilecen S, de Groot JA, Kalkman CJ, et al. Effect\n",
            "of fibrinogen concentrate on intraoperative blood\n",
            "loss among patients with intraoperative bleeding\n",
            "during high-risk cardiac surgery: a randomized\n",
            "clinical trial. JAMA. 2017;317(7):738-747. doi:10.\n",
            "1001/jama.2016.21037\n",
            "\n",
            "17. Nascimento B, Callum J, Tien H, et al.\n",
            "Fibrinogen in the initial Resuscitation of Severe\n",
            "Trauma (FiiRST): a randomized feasibility trial. Br J\n",
            "Anaesth. 2016;117(6):775-782. doi:10.1093/bja/\n",
            "aew343\n",
            "\n",
            "18. Winearls J, Wullschleger M, Wake E, et al.\n",
            "Fibrinogen Early In Severe Trauma studY (FEISTY):\n",
            "study protocol for a randomised controlled trial. Trials.\n",
            "2017;18(1):241. doi:10.1186/s13063-017-1980-x\n",
            "\n",
            "19. Galas FR, de Almeida JP, Fukushima JT, et al.\n",
            "Hemostatic effects of fibrinogen concentrate\n",
            "compared with cryoprecipitate in children after\n",
            "cardiac surgery: a randomized pilot trial. J Thorac\n",
            "Cardiovasc Surg. 2014;148(4):1647-1655. doi:10.\n",
            "1016/j.jtcvs.2014.04.029\n",
            "\n",
            "20. Green L, Bolton-Maggs P, Beattie C, et al.\n",
            "British Society of Haematology Guidelines on the\n",
            "spectrum of fresh frozen plasma and\n",
            "cryoprecipitate products: their handling and use in\n",
            "various patient groups in the absence of major\n",
            "\n",
            "E10\n",
            "\n",
            "JAMA Published online October 21, 2019 (Reprinted)\n",
            "\n",
            "jama.com\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\fEffect of Fibrinogen Concentrate vs Cryoprecipitate on Transfusion Volume After Cardiac Surgery\n",
            "\n",
            "Original Investigation Research\n",
            "\n",
            "bleeding. Br J Haematol. 2018;181(1):54-67. doi:10.\n",
            "1111/bjh.15167\n",
            "\n",
            "2012;22(5):344-349. doi:10.1111/j.1365-3148.2012.\n",
            "01178.x\n",
            "\n",
            "21. Callum JL, Pinkerton PH, Lima A, et al. Bloody\n",
            "Easy 4: Blood Transfusions, Blood Alternatives and\n",
            "Transfusion Reaction. 4th ed. Toronto, Ontario,\n",
            "Canada: Ontario Regional Blood Coordinating\n",
            "Network; 2016.\n",
            "\n",
            "26. Theodoulou A, Berryman J, Nathwani A, Scully\n",
            "M. Comparison of cryoprecipitate with fibrinogen\n",
            "concentrate for acquired hypofibrinogenaemia.\n",
            "Transfus Apher Sci. 2012;46(2):159-162. doi:10.\n",
            "1016/j.transci.2011.11.005\n",
            "\n",
            "22. Dyke C, Aronson S, Dietrich W, et al. Universal\n",
            "definition of perioperative bleeding in adult cardiac\n",
            "surgery. J Thorac Cardiovasc Surg. 2014;147(5):\n",
            "1458-1463. doi:10.1016/j.jtcvs.2013.10.070\n",
            "\n",
            "23. Karkouti K, Callum J, Wijeysundera DN, et al;\n",
            "TACS Investigators. Point-of-care hemostatic\n",
            "testing in cardiac surgery: a stepped-wedge\n",
            "clustered randomized controlled trial. Circulation.\n",
            "2016;134(16):1152-1162. doi:10.1161/\n",
            "CIRCULATIONAHA.116.023956\n",
            "\n",
            "24. Fleming TR, Harrington DP, O’Brien PC. Designs\n",
            "for group sequential tests. Control Clin Trials. 1984;\n",
            "5(4):348-361. doi:10.1016/S0197-2456(84)80014-8\n",
            "\n",
            "25. Ahmed S, Harrity C, Johnson S, et al.\n",
            "The efficacy of fibrinogen concentrate compared\n",
            "with cryoprecipitate in major obstetric\n",
            "haemorrhage—an observational study. Transfus Med.\n",
            "\n",
            "27. Yang L, Vuylsteke A, Gerrard C, Besser M,\n",
            "Baglin T. Postoperative fibrinogen level is\n",
            "associated with postoperative bleeding following\n",
            "cardiothoracic surgery and the effect of fibrinogen\n",
            "replacement therapy remains uncertain. J Thromb\n",
            "Haemost. 2013;11(8):1519-1526. doi:10.1111/jth.12304\n",
            "\n",
            "28. Leach Bennett J, Blajchman MA, Delage G,\n",
            "Fearon M, Devine D. Proceedings of a consensus\n",
            "conference: risk-based decision making for blood\n",
            "safety. Transfus Med Rev. 2011;25(4):267-292. doi:\n",
            "10.1016/j.tmrv.2011.05.002\n",
            "\n",
            "29. Stramer SL, Hollinger FB, Katz LM, et al.\n",
            "Emerging infectious disease agents and their\n",
            "potential threat to transfusion safety. Transfusion.\n",
            "2009;49(suppl 2):1S-29S. doi:10.1111/j.1537-2995.\n",
            "2009.02279.x\n",
            "\n",
            "30. Kleinman S, Cameron C, Custer B, et al.\n",
            "Modeling the risk of an emerging pathogen\n",
            "\n",
            "entering the Canadian blood supply. Transfusion.\n",
            "2010;50(12):2592-2606. doi:10.1111/j.1537-2995.2010.\n",
            "02724.x\n",
            "\n",
            "31. Okerberg CK, Williams LA III, Kilgore ML, et al.\n",
            "Cryoprecipitate AHF vs. fibrinogen concentrates for\n",
            "fibrinogen replacement in acquired bleeding\n",
            "patients—an economic evaluation. Vox Sang. 2016;\n",
            "111(3):292-298. doi:10.1111/vox.12417\n",
            "\n",
            "32. McQuilten ZK, Bailey M, Cameron PA, et al.\n",
            "Fibrinogen concentration and use of fibrinogen\n",
            "supplementation with cryoprecipitate in patients\n",
            "with critical bleeding receiving massive transfusion:\n",
            "a bi-national cohort study. Br J Haematol. 2017;179\n",
            "(1):131-141. doi:10.1111/bjh.14804\n",
            "\n",
            "33. McQuilten ZK, Wood EM, Bailey M, Cameron\n",
            "PA, Cooper DJ. Fibrinogen is an independent\n",
            "predictor of mortality in major trauma patients:\n",
            "a five-year statewide cohort study. Injury. 2017;48\n",
            "(5):1074-1081. doi:10.1016/j.injury.2016.11.021\n",
            "\n",
            "34. Gillissen A, van den Akker T, Caram-Deelder C,\n",
            "et al; TeMpOH-1 Study Group. Coagulation\n",
            "parameters during the course of severe postpartum\n",
            "hemorrhage: a nationwide retrospective cohort\n",
            "study. Blood Adv. 2018;2(19):2433-2442.\n",
            "\n",
            "jama.com\n",
            "\n",
            "(Reprinted) JAMA Published online October 21, 2019\n",
            "\n",
            "E11\n",
            "\n",
            "© 2019 American Medical Association. All rights reserved.\n",
            "\n",
            "Downloaded From: https://jamanetwork.com/ on 10/22/2019\f\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## ☝ now THAT looks good"
      ],
      "metadata": {
        "id": "_7dTazC_OaRt"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "but what you need to decide is what the basic data form will be, is it a variable?\n",
        "\n",
        "So...\n",
        "\n",
        "+ as you parse the PDF to txt, do you save the full text version\n",
        "+ What do you store the full text version or do you just run the 'summarizer on that, inline in the summarizer (and don't store it at all)?\n",
        "+ When you have summarized, what elements of the summary do you write to Google Sheets?\n",
        "+ Or would it be just as good to write the summary to Google Docs, with a larger 'header' for each filename, instead of a dedicated worksheet?"
      ],
      "metadata": {
        "id": "tueS3aD8SuvS"
      }
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "fX6otqeKNpKo"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}